

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

IMPERATIVE CARE, INC.,

Petitioner

VS.

INARI MEDICAL, INC.,

Patent Owner

Case No. IRP2025-00289

U.S. Patent No. 11,554,005

VIDEOTAPED DEPOSITION of PAUL ZALESKY, Ph.D.

Friday, November 7, 2025
9:01 a.m.

Held at: Hilton Boston Airport
One Hotel Drive
Boston, Massachusetts

----- Megan M. Castro, RPR, Court Reporter -----

1 APPEARANCES:

2

3 KNOBBE MARTENS OLSON & BEAR LLP
4 Brian Barnes, Esquire
5 2040 Main Street
6 14th Floor
7 Irvine, California 92614
8 949-760-0404
9 brian.barnes@knobbe.com
10 on behalf of the Petitioner
11

12 PERKINS COIE
13 James Miller, Esquire
14 1301 Second Avenue
15 Suite 4200
16 Seattle, Washington 98101
17 206-359-8000
18 jmliller@perkinscoie.com
19 on behalf of the Patent Owner
20

21

22 ALSO PRESENT:

23 Bob Giannini, videographer
24

1	I N D E X		Page 3
2	Witness		Page
3	PAUL ZALESKY, Ph.D.		
4	Examination by Attorney Barnes	5, 137	
5	Examination by Attorney Miller	129	
6			
7			
8			
9	E X H I B I T S		
10	No exhibits were marked.		
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			

1 P R O C E E D I N G S

2 - - -

3 THE VIDEOGRAPHER: Good morning. We
4 are on the record.

5 This is the videographer speaking,
6 Bob Giannini. I am with court reporter Megan
7 Castro with Digital Evidence Group. Today's
8 date is November 7, 2025, and the time is
9 9:01 a.m.

10 We are currently at the Hilton Boston
11 Logan Airport which is located in Boston,
12 Massachusetts, to take the video deposition of
13 Paul Zalesky in the matter of Imperative Care,
14 Inc., versus Inari Medical, Inc.

15 Will counsel please introduce
16 themselves for the record.

17 ATTORNEY BARNES: This is Brian Barnes
18 of Knobbe Martens on behalf of the petitioner,
19 Imperative Care.

20 ATTORNEY MILLER: James Miller of
21 Perkins Coie on behalf of Inari Medical.

22 THE VIDEOGRAPHER: Thank you.

23 Will the court reporter please swear in
24 the witness.

1 - - -

2 PAUL ZALESKY, PH.D., first having been
3 satisfactorily identified by the production of
4 his driver's license and duly sworn by the
5 Notary Public, testified under oath as follows
6 in answer to examination by ATTORNEY BARNES.

7 - - -

8 Q. Good morning, Dr. Zalesky.

9 A. Good morning.

10 Q. Welcome back.

11 A. Thanks.

12 Q. Can you please state your full name and
13 home address for the record?

14 A. Paul John Zalesky, 124 Gilbert Stuart
15 Drive, East Greenwich, Rhode Island.

16 Q. You are been retained to serve as an
17 expert witness on behalf of the patent owner,
18 Inari Medical, in this inter partes review
19 proceeding. Is that correct?

20 A. Yes.

21 Q. And you understand today's deposition
22 concerns an IPR filed by Imperative Care
23 relating to U.S. Patent Number 11,554,005?

24 A. Yes.

1 Q. Can we agree to refer to the patent at
2 issue today as the '005 patent for shorthand?

3 A. Sure.

4 Q. And similarly, for inter partes review,
5 if I refer to them as an "IPR," will you
6 understand what I am talking about?

7 A. Yes.

8 Q. And I understand you have been
9 previously deposed in two prior IPRs that were
10 filed by Imperative Care that relate to today's
11 IPR. Is that correct?

12 A. Yes.

13 Q. I believe your most recent deposition
14 in a related IPR was in August of this year.
15 Does that sound right?

16 A. In L.A., yes.

17 Q. After that August deposition, did you
18 have a chance to review the transcript from
19 that deposition?

20 A. I did very briefly.

21 Q. I understand that you prepared an
22 errata sheet that identified certain errors
23 transcript of that deposition. Is that
24 correct?

1 ATTORNEY MILLER: Objection. Scope.

2 A. Yes.

3 BY ATTORNEY BARNES:

4 Q. Other than the errors that you
5 identified in that errata sheet, are you aware
6 of any other errors in your testimony from your
7 prior deposition?

8 ATTORNEY MILLER: Objection. Scope.

9 A. None that I recall, no.

10 BY ATTORNEY BARNES:

11 Q. Do you stand by your testimony in your
12 prior depositions related to the IPRs filed by
13 Imperative Care?

14 ATTORNEY MILLER: Objection. Scope.

15 A. I believe so, yes.

16 BY ATTORNEY BARNES:

17 Q. Since that August deposition, have you
18 been deposed in any other cases?

19 A. Yes. One other case.

20 Q. Was that a patent case?

21 A. Yes.

22 Q. Was that an IPR or a district court
23 case. Do you know?

24 A. It is a complex case that included an

1 IPR and a district case.

2 Q. Do you know whether your deposition
3 related to the IPR specifically?

4 A. It encompassed the IPR.

5 Q. Do you recall when that deposition was?

6 A. I do. It is kind of a date to forget.
7 September 11.

8 Q. What type of technology is at issue in
9 that case?

10 A. It was a cardiovascular device.

11 Q. What type of cardiovascular device?

12 A. Something called a guide extension
13 catheter, which is effectively a small version
14 of a guide catheter used in interventional
15 procedures.

16 Q. Are the guide extension catheters at
17 issue in that case used in any blood clot
18 aspiration procedures?

19 ATTORNEY MILLER: Objection. Scope.

20 A. Not that I am aware.

21 BY ATTORNEY BARNES:

22 Q. Does that case involves hemostasis
23 valves at all?

24 A. Sorry. Involve what?

1 Q. Hemostasis valves?

2 ATTORNEY MILLER: Objection.

3 A. Yes, a Tuohy-Borst valve is
4 traditionally used in almost all of these
5 procedures.

6 Q. Since your August deposition, have you
7 given testimony at any trial or court hearing?

8 A. No.

9 Q. And I know that we personally have gone
10 through lot of these instructions before. But
11 I think it is always helpful to have a
12 refresher and to have it on the record. So we
13 will just go over the ground rules for today to
14 make sure everything goes smoothly.

15 So do you understand that you are under
16 oath just as if you were in court, and you are
17 obligated to testify truthfully?

18 A. Yes.

19 Q. Do you understand that all of your
20 answers need to be verbal so that the court
21 reporter can take down an accurate record of
22 today's deposition?

23 A. Yes.

24 Q. Just like last time, I ask that you do

1 your best to wait until I finish a question
2 before you start your answer. And I, of
3 course, will do my best to wait until you
4 finish your answer to ask my next question. Is
5 that fair?

6 A. Yes.

7 Q. And, again, like last time, please let
8 me know if you don't understand one of my
9 questions. If you do not tell me that you
10 don't understand, I will assume that you have
11 understood the question. Is that fair?

12 A. Yes.

13 Q. Your counsel may make short objections
14 from time to time during today's deposition.
15 But if -- however, you will need to answer my
16 question unless your counsel specifically
17 instructs you not to. Do you understand?

18 A. I understand.

19 Q. And like our last deposition, I will
20 try to go roughly an hour and we will take
21 several breaks throughout the day. If at any
22 point you need a break, please let me know and
23 I can go off the record. The only thing I ask
24 is that, if we are in the middle of an answer

1 to a question, we finish that question and
2 answer before we take a break. Is that fair?

3 A. Yes.

4 Q. Is there any reason you can't provide
5 truthful and accurate testimony today?

6 A. No.

7 Q. Have you had any food, drink, or
8 medication that would inhibit your ability to
9 testify truthfully?

10 A. No.

11 Q. Since your August deposition, have you
12 performed any work for Inari, other than work
13 that is related to the IPRs that are been filed
14 by Imperative Care?

15 ATTORNEY MILLER: Objection. Scope.

16 A. No.

17 BY ATTORNEY BARNES:

18 Q. Have you acquired any stock in Inari
19 since your last deposition?

20 A. No.

21 Q. Have you spoken to anyone at Inari
22 about this IPR?

23 A. No.

24 Q. Have you spoken to anyone at Inari

1 about any of the IPRs that have been filed by
2 Imperative Care?

3 A. No.

4 Q. Has your billing rate changed for your
5 work on these IPRs, changed since your last --

6 ATTORNEY BARNES: Let me rephrase the
7 question.

8 BY ATTORNEY BARNES:

9 Q. Has your billing rate for your work on
10 these IPRs changed since your August
11 deposition?

12 A. No.

13 Q. Do you know how many total hours that
14 you have billed Inari for this specific IPR
15 involving the '005 patent?

16 ATTORNEY MILLER: Objection. Scope.

17 A. I would estimate less than 20.

18 BY ATTORNEY BARNES:

19 Q. Do you know how many total hours you
20 have billed Inari for all of the IPRs that have
21 been filed by Imperative Care?

22 ATTORNEY MILLER: Objection. Scope.

23 A. Likely 40 and change total hours.

24 BY ATTORNEY BARNES:

1 Q. Since your August deposition, have you
2 perform any work for Inari related to the
3 district court litigation involving Inari and
4 Imperative Care?

5 ATTORNEY MILLER: Objection. Scope.

6 A. No.

7 BY ATTORNEY BARNES:

8 Q. Other than your work on these IPRs,
9 have you performed any work for Stryker since
10 your August deposition?

11 ATTORNEY MILLER: Objection. Scope.
12 And to the extent it requires confidential
13 information.

14 You are not required to disclose the
15 client's information, but if you can talk about
16 it generally, that is fine.

17 A. No.

18 BY ATTORNEY BARNES:

19 Q. Have you acquired any stock in Stryker
20 since your last deposition?

21 A. No.

22 Q. Have you spoken to anyone at Stryker
23 about this IPR?

24 A. No.

1 Q. Have you spoken to anyone at Stryker
2 about any of the IPRs that have been filed by
3 Imperative Care?

4 A. No.

5 Q. In your August deposition, you
6 testified that you had not had the opportunity
7 to physically inspect Inari's ClotTrievers or
8 FlowTrievers device. Do you recall that?

9 ATTORNEY MILLER: Objection. Scope.

10 A. I do recall that.

11 BY ATTORNEY BARNES:

12 Q. Have you had the opportunity to
13 physically inspect either the ClotTrievers or
14 the FlowTrievers devices since your August
15 deposition?

16 ATTORNEY MILLER: Objection. Scope.

17 A. No.

18 BY ATTORNEY BARNES:

19 Q. Have you virtually inspected either the
20 ClotTrievers or the FlowTrievers devices since
21 your August deposition?

22 ATTORNEY MILLER: Objection. Scope.

23 A. Very briefly via websites for either.

24 BY ATTORNEY BARNES:

1 Q. Do you recall when that was?

2 A. Probably six months ago.

3 Q. So that was before your August
4 deposition. Is that right?

5 A. Yes.

6 Q. Have you virtually inspected either the
7 ClotTrieve or FlowTrieve device again since
8 that initial visit to the website?

9 ATTORNEY MILLER: Objection. Scope.

10 A. No.

11 BY ATTORNEY BARNES:

12 Q. Have you physically inspected any of
13 Imperative Care's products since your August
14 deposition?

15 ATTORNEY MILLER: Objection. Scope.

16 A. No.

17 BY ATTORNEY BARNES:

18 Q. Have you virtually inspected any of
19 Imperative Care's products since your last
20 deposition?

21 ATTORNEY MILLER: Objection. Scope.

22 A. No.

23 BY ATTORNEY BARNES:

24 Q. Did you do anything to prepare for

1 today's deposition?

2 A. I did a brief review of my supplemental
3 response.

4 Q. Did you meet with anyone to prepare for
5 today's deposition?

6 A. I meet with counsel for
7 approximately -- very brief time, an hour and a
8 half.

9 Q. And when you refer to counsel, are you
10 referring to Mr. Miller?

11 A. Yes.

12 Q. Was that meeting in person?

13 A. Yes.

14 Q. Where did that meeting take place?

15 A. An interesting restaurant known as
16 Sonsie here in Boston.

17 Q. Did you just have the one meeting with
18 Mr. Miller to prepare for today's deposition?

19 A. Yes, we had breakfast, but that was
20 just eating.

21 Q. In total, how long did you spend
22 preparing for today's deposition?

23 A. Probably four or five hours.

24 Q. Did you review any documents as part of

1 your preparation for today's deposition, other
2 than your supplemental declaration?

3 ATTORNEY MILLER: Objection to the
4 extent it calls for privileged information.

5 To the extent you answer with a yes or
6 no, that is fine.

7 A. I briefly reviewed a few figures from
8 some of the relevant prior art patents.

9 BY ATTORNEY BARNES:

10 Q. Do you recall which prior art patents
11 you reviewed?

12 ATTORNEY MILLER: Objection to the
13 extent it called for privileged information.

14 To the extent you can answer without
15 revealing conversations with counsel, you can.

16 A. Schaffer and Hartley.

17 BY ATTORNEY BARNES:

18 Q. Did you review the Garrison prior art
19 reference in preparation for today's
20 deposition?

21 ATTORNEY MILLER: Same objection.

22 A. No.

23 BY ATTORNEY BARNES:

24 Q. Did you review the Eller prior art

1 reference in preparation for today's
2 deposition?

3 ATTORNEY MILLER: Same objection.

4 A. No.

5 BY ATTORNEY BARNES:

6 Q. Other than your supplemental
7 declaration and the two prior art references
8 you reviewed, did you review any other
9 documents to prepare for today's deposition?

10 ATTORNEY MILLER: Objection to the
11 extent it calls for privileged information.

12 A. No.

13 BY ATTORNEY BARNES:

14 Q. You have prepared two declarations for
15 the '005 patent IPR. Is that correct?

16 A. I believe so. I have lost track over
17 documents and supplements, but I believe so.

18 Q. Understood. That is fair.

19 I am going to hand you a document that
20 has been marked as Exhibit 2001 in this IPR.

21 (Handing document to the witness.)

22 BY ATTORNEY BARNES:

23 Q. Dr. Zalesky, do you recognize
24 Exhibit 2001?

1 A. Yes.

2 Q. What is Exhibit 2001?

3 A. It is my declaration regarding the
4 Imperative versus Inari case.

5 Q. And this is your declaration regarding
6 the '005 patent. Correct?

7 A. Yes.

8 Q. If you could turn to page 132 at the
9 end of or towards the end of Exhibit 2001.

10 Is that your signature on page 132?

11 A. Yes.

12 Q. Did you sign Exhibit 2001 on March 31,
13 2025?

14 A. I did.

15 Q. Do you recall where you signed this
16 document at?

17 A. My home office in Rhode Island.

18 Q. And when you signed this declaration,
19 you declared that you believed all of the
20 statements in the declaration were true. Was
21 that an accurate statement when you signed the
22 declaration?

23 A. Yes.

24 Q. Do you still believe all of the

1 statements in the declaration are true?

2 A. Yes.

3 Q. Are you aware of any errors or
4 misstatements in Exhibit 2001?

5 A. I don't think so.

6 Q. Did you personally draft Exhibit 2001?

7 A. It was a collaborative effort with
8 patent counsel.

9 Q. Do you recall who that counsel was?

10 A. Joe Hamilton and Matt, whose last name
11 is escaping me, from the Seattle office.

12 Q. Is it Matt Williams?

13 A. Yes, Matt Williams.

14 Q. What role did you play in the drafting
15 process of Exhibit 2001?

16 ATTORNEY MILLER: Objection to the
17 extent it calls for communications, drafts, or
18 anything between counsel and yourself. To
19 extent you can answer without revealing any of
20 that, you can.

21 A. Outline, composition of certain
22 specific segments, and then back-and-forth with
23 red-lines.

24 BY ATTORNEY BARNES:

1 Q. Do you recall which specific sections
2 of Exhibit 2001 that you composed?

3 ATTORNEY MILLER: Objection to the
4 extent the question calls for privileged
5 information.

6 I instruct you not to answer.

7 A. So no.

8 BY ATTORNEY BARNES:

9 Q. To clarify, are you refusing to answer
10 my question based on your counsel's instruction
11 or do you not recall which portions of the
12 declaration you personally drafted?

13 A. I am following a counsel objection.

14 Q. Do you recall how many drafts of the
15 declaration you reviewed before you signed it?

16 ATTORNEY MILLER: Objection to the
17 extent it calls for communications or drafts
18 between counsel and yourself.

19 A. Several. Probably four or five.

20 BY ATTORNEY BARNES:

21 Q. Do you recall how much time you spent
22 drafting Exhibit 2001 before you signed it?

23 ATTORNEY MILLER: Objection. Vague.

24 A. This goes back several months to the

1 early part of this year. So I am guesstimating

2 15 to 20 hours.

3 BY ATTORNEY BARNES:

4 Q. Other than Mr. Hamilton and
5 Mr. Williams, did you work with anyone else in
6 the preparation of Exhibit 2001?

7 ATTORNEY MILLER: Objection to the
8 extent it calls for communications with
9 counsel.

10 To the extent you can answer without
11 revealing those.

12 A. No.

13 BY ATTORNEY BARNES:

14 Q. Other than Mr. Hamilton and
15 Mr. Williams, did you speak to anyone about
16 Exhibit 2001?

17 ATTORNEY MILLER: Same objection.

18 A. No.

19 BY ATTORNEY BARNES:

20 Q. I am now going to hand you what has
21 been marked as Exhibit 2026 in this IPR.

22 (Handing document to the witness.)

23 Q. Do you recognize Exhibit 2026?

24 A. Yes.

1 Q. What is Exhibit 2026?

2 A. It is my supplemental declaration
3 regarding the IPR case on the '005 patent.

4 Q. If we turn to page 144 at the end of
5 Exhibit 2006. Is that your signature on
6 page 144?

7 A. Yes.

8 Q. Did you sign your supplemental
9 declaration on September 9, 2025?

10 A. Yes.

11 Q. Do you recall where you were when you
12 signed Exhibit 2026?

13 A. The same home office in East Greenwich,
14 Rhode Island.

15 Q. When you signed Exhibit 2026, you
16 declared that you believed all of the
17 statements in the declaration were true. Was
18 that an accurate statement when you signed the
19 declaration?

20 A. Yes.

21 Q. Do you still believe all of the
22 statements in 2026 are true?

23 A. Yes.

24 Q. Are you aware of any errors or

1 misstatements in Exhibit 2026?

2 A. No.

3 Q. Had your opinions regarding any of the
4 issues in this IPR changed between your first
5 declaration, Exhibit 2001, and your
6 supplemental declaration, Exhibit 2026?

7 ATTORNEY MILLER: Objection. Vague.

8 A. No.

9 BY ATTORNEY BARNES:

10 Q. Why did you prepare a supplemental
11 declaration for this IPR?

12 ATTORNEY MILLER: Objection to the
13 extent it calls for privileged communications.

14 To the extent you can answer without
15 revealing conversations with counsel, you may.

16 A. Requested by counsel.

17 BY ATTORNEY BARNES:

18 Q. Did you not fully set forth your
19 opinions regarding this IPR in your first
20 declaration?

21 ATTORNEY MILLER: Objection. Vague.

22 A. I think there is only minor additions.

23 BY ATTORNEY BARNES:

24 Q. Did you develop any new opinions about

1 this IPR after signing your first declaration?

2 ATTORNEY MILLER: Objection. Asked and
3 answered. Vague.

4 A. No.

5 BY ATTORNEY BARNES:

6 Q. Did you personally draft Exhibit 2026?

7 A. Again, a collaboration with patent
8 counsel.

9 Q. Was that counsel Mr. Hamilton and
10 Mr. Williams?

11 A. Yes.

12 Q. Anyone else?

13 A. No.

14 Q. Did you draft any specific portions of
15 Exhibit 2026?

16 ATTORNEY MILLER: Objection.

17 To the extent it calls for a
18 communications or drafts between counsel and
19 yourself, I instruct you not to answer.

20 A. I will follow counsel advice.

21 BY ATTORNEY BARNES:

22 Q. Do you recall how many drafts of
23 Exhibit 2026 you reviewed before you signed it?

24 ATTORNEY MILLER: Objection to the

1 extent it calls for communications or drafts
2 between counsel.

3 To the extent you can answer without
4 revealing that.

5 A. Only two or three.

6 BY ATTORNEY BARNES:

7 Q. Do you recall roughly how much time you
8 spent preparing Exhibit 2026 before you signed
9 it?

10 A. I guesstimate 15 hours or so.

11 Q. Other than Mr. Williams --

12 ATTORNEY BARNES: Or let me rephrase.

13 BY ATTORNEY BARNES:

14 Q. Other than legal counsel, did you
15 discuss Exhibit 2026 with anyone?

16 A. No.

17 Q. Are all of the opinions that you have
18 regarding this IPR set forth in your
19 supplemental declaration?

20 ATTORNEY MILLER: Objection. Vague.

21 A. I think all of my relevant opinions
22 are, yes.

23 BY ATTORNEY BARNES:

24 Q. Does your supplemental declaration

1 supersede your first declaration?

2 ATTORNEY MILLER: Objection. Vague.

3 A. In my opinion, it largely confirm.

4 BY ATTORNEY BARNES:

5 Q. Can you turn to paragraph 5 of your
6 supplemental declaration, which is on page 2.
7 Bottom of page 2.

8 A. I am there.

9 Q. In paragraph 5, you state, "My analysis
10 of the materials produced in this matter are
11 ongoing and I will continue any new material as
12 it is provided. This declaration represents
13 only those opinions I have formed to date. I
14 reserve the right to revise, supplement, and/or
15 amend my opinions stated herein based on new
16 information and on my continuing analysis of
17 the materials already provided."

18 Did I read that correctly?

19 A. Yes.

20 Q. Have you reviewed any materials since
21 signing your supplemental declaration that have
22 impacted any of your opinions?

23 ATTORNEY MILLER: Objection. Vague.

24 A. No.

1 BY ATTORNEY BARNES:

2 Q. Have any of your opinions that you set
3 forth in your supplemental declaration changed
4 since you signed it?

5 A. No.

6 Q. If you look higher up on page 2, and
7 this will be at the end of paragraph 2 of your
8 supplemental declaration, you stated, "I have
9 been asked by counsel for Inari Medical, Inc.,
10 ('Inari' or 'patent owner') to opine on the
11 patentability of the claims of the '005 patent
12 and, in particular, the patentability of
13 independent claims 1 and 10 with respect to
14 grounds 1 through 4."

15 Did I read that correctly?

16 A. Yes.

17 Q. Why did you focus your opinions on
18 independent claims 1 and 10?

19 ATTORNEY MILLER: Objection to the
20 extent it called for privileges information.

21 To the extent you can answer without
22 revealing that information, you may proceed.

23 A. Primarily because of the importance of
24 independent claims.

1 BY ATTORNEY BARNES:

2 Q. You do you present any opinions
3 specific to any of the dependent claims of the
4 '005 patent in your supplemental declaration.
5 Correct?

6 ATTORNEY MILLER: Objection. Vague.

7 A. I would have to look through it. I
8 don't think so, but I would have to look
9 through it.

10 BY ATTORNEY BARNES:

11 Q. Can you turn to paragraph 65 of your
12 supplemental declaration, which is on page 35.

13 A. I am there.

14 Q. In paragraph 65 of your supplemental
15 declaration, you state, "Petitioner has cited
16 three different references, Schaffer, Hartley,
17 and Eller, in its petition challenging the
18 patentability of the claims of the '005
19 patent."

20 Did I read that correctly?

21 A. Yes.

22 Q. Why did you reference a petition
23 challenging the '012 patent in paragraph 65 of
24 your supplemental declaration?

1 A. Would you repeat the question?

2 Q. Sure.

3 Why did you reference a petition
4 challenging '012 patent in paragraph 65?

5 ATTORNEY MILLER: Objection to the
6 extent it calls for privileged information.

7 To the extent you can answer without
8 revealing that information, you may answer.

9 ATTORNEY BARNES: Counsel, are you
10 suggesting that Dr. Zalesky cannot testify
11 about the material in his declaration because
12 it is privileged?

13 ATTORNEY MILLER: No. You asked him a
14 "why" question. And to the extent it involves
15 conversations with counsel and he needs to
16 reveal those or wants to reveal those, I am
17 telling him not to.

18 ATTORNEY BARNES: So is patent owner
19 attempting to prevent Dr. Zalesky from
20 testifying about why he put statements in his
21 own declaration because patent owner believes
22 those reasons are privileged?

23 ATTORNEY MILLER: Well, if those
24 reasons involve him describing conversations

1 with counsel, yes, those are privileged. But
2 to the extent that he can answer technically
3 why it is in there, yes, he can say that.

4 ATTORNEY BARNES: For the record,
5 petitioner disagrees with patent owner's
6 characterizations and reserves the right to
7 potentially seek an additional deposition of
8 Dr. Zalesky if patent owner is preventing him
9 from testifying as to the contents or reasoning
10 of the opinions set forth in this declaration.

11 ATTORNEY MILLER: Patent owner
12 disagrees with that characterization.

13 BY ATTORNEY BARNES:

14 Q. Would you like me to repeat it
15 question, Dr. Zalesky?

16 A. No, I recall the question.

17 I was asked to review prior art and
18 opine on '005 independent claims with respect
19 to prior art.

20 Q. And this paragraph refers to the claims
21 of the '012 patent. Correct?

22 A. Sorry. Yes, '012.

23 Q. So why were you referencing the claims
24 of the '012 patent in paragraph 65?

1 A. It is my understanding that going back
2 to the 2018 application that culminated in '012
3 issue was inherited, if that is the right word,
4 by the '005 patent.

5 Q. So is it your understanding that the
6 claims of the '005 patent incorporate the
7 claims of the '012 patent?

8 ATTORNEY MILLER: Objection. Misstates
9 testimony.

10 A. I wouldn't put it precisely like that.
11 It is certainly -- the written description and
12 the claims do, in fact, integrate the material
13 from the '012.

14 BY ATTORNEY BARNES:

15 Q. Is your reference to the '012 patent in
16 paragraph 65 a typo?

17 A. It is possible.

18 Q. Did you use your declaration that you
19 submitted for the '012 patent IPR as a template
20 for your supplemental declaration for the '005
21 patent?

22 ATTORNEY MILLER: Objection to the
23 extent it calls for confidential information
24 regarding drafts or communications with

1 counsel.

2 If you can answer without revealing
3 that information, you may.

4 A. More as background than template.

5 BY ATTORNEY BARNES:

6 Q. And you would agree that petitioner is
7 not only relying on Schaffer, Hartley, and
8 Eller in its petition challenging the
9 patentability of the '005 patent. Correct?

10 A. That is my understanding, yes.

11 Q. Further down on page 35, in
12 paragraph 67, you state, "The sealing mechanism
13 present in the hemostasis valve of the '012
14 patent is different from the sealing mechanism
15 employed in Schaffer."

16 Did I read that correctly?

17 A. Yes.

18 Q. Again, why were you referencing the
19 hemostasis valve of the '012 patent in
20 paragraph 67?

21 ATTORNEY MILLER: Same objection with
22 regards to privilege.

23 You may answer.

24 A. The written description and the claims

1 of '005 incorporate the material disclosed in
2 the '012.

3 BY ATTORNEY BARNES:

4 Q. If you turn to page 143, at the end of
5 your supplemental declaration, and specifically
6 looking at paragraph 210.

7 In paragraph 210, you state, "I have
8 not rendered any opinions on secondary
9 considerations of nonobviousness at this time
10 but reserve the right to analyze evidence of
11 secondary considerations at a later stage if
12 asked to do so."

13 Did I read that correctly?

14 A. Yes.

15 Q. Have you analyzed any evidence of
16 secondary considerations since signing your
17 supplemental declaration?

18 A. No.

19 Q. Other than legal counsel for Inari, did
20 you discuss the '005 patent IPR with anyone?

21 A. No.

22 Q. If you could turn to paragraph 3 at the
23 beginning of your supplemental declaration.
24 The second sentence of paragraph 3 states, "The

1 materials that I evaluated in support of this
2 declaration include all exhibits cited in this
3 declaration and in the petition." Correct?

4 A. Yes.

5 Q. And is that an accurate statement?

6 A. I believe so.

7 Q. Did you consider the board's decision
8 granting institution of the '005 patent IPR in
9 forming any of the opinions in your
10 supplemental declaration?

11 A. Very briefly.

12 Q. And when you say you considered them
13 very briefly, can you explain what you mean by
14 that?

15 A. I am aware of conclusions without
16 analyzing any content.

17 Q. If you could turn to paragraph 143 of
18 your supplemental declaration, which is on
19 page 86.

20 A. Okay.

21 Q. And at the beginning of paragraph 143,
22 you state, "I understand that in the
23 Institution decision the board stated that
24 Schaffer's disclosure of the, quote, use of

1 certain materials for portions of a seal module
2 that provide a nearly fluid/gas tight seal and
3 exhibit a self-closing nature concern only some
4 embodiments using optional features and that
5 the valve of Schaffer's figures 30 through 34
6 does not require a seal module that includes
7 the above described optional third seal member
8 with an extremely compliant, soft, gelatinous,
9 self-closing material."

10 Did I read that correctly?

11 A. Yes.

12 Q. Do you disagree with the board's
13 conclusion that the valve in Schaffer's
14 figures 30 through 34 does not require a seal
15 module with an extremely compliant, soft,
16 gelatinous, self-closing material?

17 ATTORNEY MILLER: Objection. Vague.

18 A. I would have to remind myself of the
19 specific figures.

20 BY ATTORNEY BARNES:

21 Q. So sitting here right now, you don't
22 recall whether you agree or disagree with the
23 board's conclusion?

24 A. I don't, yes. Without looking at the

1 figures.

2 Q. If you could turn to paragraph 168 of
3 your supplemental declaration. And that is on
4 page 107. Okay. Are you there?

5 A. Yes.

6 Q. And the first sentence of paragraph 168
7 states, "I understand that the board contends
8 that Schaffer's two actuating members apply
9 constricting force to the valve seal module
10 when pulled by opposing spring-actuated buttons
11 and that replacing those members with a single
12 string or wire would provide substantially the
13 same function."

14 Did I read that correctly?

15 A. Yes.

16 Q. Do you disagree with the board's
17 conclusion that replacing Schaffer's actuating
18 members with a single string or wire would
19 provide substantially the same function as the
20 actuating members?

21 ATTORNEY MILLER: Objection. Vague.

22 A. Yes, I disagree.

23 BY ATTORNEY BARNES:

24 Q. So you think the board got it wrong

1 when it found that replacing Schaffer's
2 actuating members with a single string or wire
3 would provide substantially the same function
4 as the actuating members?

5 A. I believe they are incorrect.

6 Q. How would the function differ if the
7 actuating members were replaced by a string or
8 wire?

9 A. The valve operation or mechanism is
10 dramatically different for a filament such as a
11 string compared to two opposing blades or
12 actuator elements in the Schaffer
13 configuration.

14 Q. Is the valve operation dramatically
15 different for a string --

16 ATTORNEY BARNES: Let me rephrase.

17 BY ATTORNEY BARNES:

18 Q. Is the valve operation dramatically
19 different for a single string as compared to
20 two bites?

21 A. I wouldn't say dramatically different,
22 no.

23 Q. Is it substantially the same?

24 A. I believe both of those configurations

1 operate with circumferential constriction.

2 Q. If you could turn to paragraph 26 of
3 your supplemental declaration.

4 A. Okay.

5 Q. And the first sentence of paragraph 26,
6 you state, "I understand that my opinions
7 regarding patentability are from the viewpoint
8 of a person having ordinary skill in the field
9 of the technology of the patent as of the time
10 of the invention."

11 Did I read that correctly?

12 A. Yes.

13 Q. What is the field of the technology of
14 the '005 patent?

15 A. Broadly, medical devices that
16 incorporate mechanical components.

17 Q. I am going to hand you what has been
18 marked as Exhibit 1001 in this IPR.

19 (Handing document to the witness.)

20 Q. Do you recognize Exhibit 1001,
21 Dr. Zalesky?

22 A. Yes.

23 Q. What is Exhibit 1001?

24 A. It the referenced '005 patent.

1 Q. If you could turn to -- sorry to switch
2 gears on you a little bit. But if you could
3 turn back to your supplemental declaration and
4 paragraph 35, which is on page 13.

5 A. Okay.

6 Q. The first sentence of paragraph 35
7 states, "The '005 patent is directed to vacuum
8 aspiration systems for rapidly aspirating clot
9 material from a patient's blood vessel that
10 offers significant benefits over such
11 conventional treatments."

12 Did I read that correctly?

13 A. Yes.

14 Q. What are the conventional treatments
15 that you are referring to in paragraph 35?

16 A. In general, a simple single lumen
17 catheter or tube, and a connected syringe.

18 Q. How would --

19 ATTORNEY BARNES: Let me rephrase.

20 BY ATTORNEY BARNES:

21 Q. How were the simple single lumen
22 catheters and a connected syringe used to treat
23 blood clots prior to the '005 patent?

24 A. Simply manual withdrawal for

1 aspiration.

2 Q. What are the significant benefits over
3 those conventional treatments that you were
4 referring to in paragraph 35?

5 A. I think there is two perspectives.

6 One is an integrated system which
7 involves multiple components for aspiration and
8 control of the aspiration. And integrated into
9 that system are particular elements are
10 components such as hemostasis valve that
11 provide incremental benefits.

12 Q. So focusing on the first perspective
13 you identified, what are the significant
14 benefits that are provided by the integrated
15 system?

16 A. It is a combination of elements that
17 provide controlled aspiration with various
18 assemblies of syringes, manifolds, stopcocks,
19 and fluid pathways, as well as filter and
20 collection devices.

21 Q. How do those --

22 ATTORNEY BARNES: Let me rephrase.

23 BY ATTORNEY BARNES:

24 Q. How does that combination of elements

1 provide the controlled aspiration that you are
2 referring to?

3 A. Compared to previous procedures and
4 assemblies that were jerry-rigged, this is an
5 integrated approach that includes stopcock
6 control of fluid flows and application of
7 aspiration pressures.

8 Q. Prior to 2018, were there no integrated
9 blood clot aspiration systems that were used or
10 available?

11 ATTORNEY MILLER: Objection. Vague.

12 A. I am not sure.

13 BY ATTORNEY BARNES:

14 Q. Are you familiar with the AngioVac
15 blood clot aspiration system?

16 A. Not especially, no.

17 Q. Are you familiar with the blood clot
18 aspiration system developed by Penumbra?

19 A. I am aware of it. I am not familiar
20 with it.

21 Q. You would agree with me that aspirating
22 blood clots with a catheter and a syringe was
23 not new in 2018. Right?

24 ATTORNEY MILLER: Objection. Vague.

1 A. Generally, yes, that is true.

2 BY ATTORNEY BARNES:

3 Q. You would also agree with me that using
4 a stopcock in a blood clot aspiration system
5 that included a catheter and a syringe was not
6 new in 2018. Right?

7 ATTORNEY MILLER: Objection. Vague.

8 A. I am not sure how commonly a stopcock
9 was used in those previous procedures.

10 BY ATTORNEY BARNES:

11 Q. Do you know whether it was used?

12 A. I believe so, but, again, I don't have
13 particular examples.

14 Q. So if we turn back to the '005 patent
15 and if you could go to claim 1 at the end of
16 the patent.

17 Are there any components that are
18 recited in claim 1 of the '005 patent that
19 provide the significance benefits that you were
20 referring to in paragraph 35?

21 ATTORNEY MILLER: Objection. Vague.

22 A. I think the housing, which includes
23 several components, integrated. And the
24 constricting mechanism used for hemostasis are

1 part of those benefits.

2 BY ATTORNEY BARNES:

3 Q. How does the housing provide
4 significant benefits over the conventional
5 treatments that were available in 2018?

6 ATTORNEY MILLER: Objection. Scope.

7 A. It integrates discreet components.

8 BY ATTORNEY BARNES:

9 Q. How does that provide a benefit?

10 A. Primarily convenience to the operator.

11 Q. If you look back at paragraph 35 of
12 your supplemental declaration. In
13 paragraph 35, you discuss or --

14 ATTORNEY BARNES: Let me rephrase.

15 BY ATTORNEY BARNES:

16 Q. In paragraph 35, you refer to the
17 aspiration of PE or DVT. Correct?

18 A. Yes.

19 Q. And if you look at paragraphs 32
20 through 34, in those paragraphs, you also
21 discuss the treatment of PE and DVT. Correct?

22 A. Yes.

23 Q. Why did you focus on PE and DVT in your
24 discussion in paragraphs 32 through 35?

1 ATTORNEY MILLER: Objection to the
2 extent it calls for privileged information and
3 communications with counsel.

4 To the extent you can answer without
5 revealing those communications, you may.

6 A. It is my understanding that the
7 pulmonary and deep vein thrombosis scenarios
8 are the most common and most challenging.

9 BY ATTORNEY BARNES:

10 Q. I probably should have done this before
11 this whole line of questioning.

12 But when you refer to "PE" in your
13 supplemental declaration, does that refer to
14 pulmonary embolism?

15 A. Yes.

16 Q. When you refer to "DVT" in your
17 supplemental declaration, does that refer to
18 deep vein thrombosis?

19 A. Yes.

20 Q. Is it your opinion that the claims of
21 the '005 patent are limited to aspiration
22 systems that are used to treat PE or DVT?

23 A. No.

24 Q. So the claims of the '005 patent

1 encompass aspiration systems used to treat
2 other types of blood clots. Correct?

3 A. I believe so, yes.

4 Q. What other types of blood clots would
5 the claims of the '005 patent encompass?

6 A. Potentially, heart-related, as in
7 coronaries. Certainly, gastrointestinal
8 vessels in proximity to key organs. And also
9 peripheral arteries.

10 Q. What about neurovascular blood clots?
11 Would the claims of the '005 patent encompass
12 systems used to treat neurovascular blood
13 clots?

14 A. I should have included that, yes.

15 Q. Can you turn to paragraph 36, which is
16 on page 13 of your supplemental declaration.
17 And in paragraph 36, you state, "Figure 1 of
18 the '005 patent shows a vacuum aspiration
19 system with a flow path extending through a
20 housing, a valve 126 in the flow path, (e.g.,
21 an on-off control), and a first catheter 102 in
22 fluid communication with a pressure source 140
23 via a connector 108."

24 Did I read that correctly?

1 A. Yes.

2 Q. And after that statement, you provide
3 an annotated version of figure 1 from the '005
4 patent. Correct?

5 A. Yes.

6 Q. In the annotated version of figure 1 on
7 page 14 of your supplemental declaration, you
8 added a blue line to illustrate the flow path
9 extending through a housing. Correct?

10 A. Yes.

11 Q. In your annotated version of figure 1,
12 you identified the component labeled with
13 number 126 as an on-off control. Correct?

14 A. Yes.

15 Q. You stated that the component 126 is an
16 on-off control that is in the flow path, in
17 paragraph 36. Correct?

18 A. Yes.

19 Q. Can you explain why you believe that
20 the valve 126 is in the flow path that extends
21 through a housing in figure 1?

22 A. It is the path between the negative
23 pressure source and the target.

24 Q. And how is the valve 126 in that flow

1 path?

2 A. I don't understand the question.

3 Q. What don't you understand about it?

4 A. You are saying "how." I am not sure
5 what you mean by "how."

6 Q. Why do you believe that the valve 126
7 is in the flow path?

8 A. The patent describes that
9 configuration.

10 Q. In your annotated figure on page 14,
11 you did not identify the housing that you
12 referred to earlier in that paragraph.
13 Correct?

14 A. I don't cite it specifically.

15 Q. Can you identify where in figure 1 the
16 housing that you are referring to is?

17 A. It is in the vicinity of 106.

18 Q. Does that housing in 106 include a
19 hemostasis valve?

20 A. As shown, the hemostasis valve is to
21 the right of the housing, but could be
22 incorporated as well.

23 Q. You would agree with me that in
24 figure 1 of the '005 patent, the valve 126 is

1 not in the housing 106. Correct?

2 A. That appears to be the case.

3 Q. The valve 126 is connected to the
4 housing 106 by tubing. Correct?

5 ATTORNEY MILLER: Objection. Vague.

6 A. Yes.

7 BY ATTORNEY BARNES:

8 Q. Despite that configures, it is your
9 opinion that in figure 1, the valve 126 is in
10 the flow path that extends through the housing
11 106. Correct?

12 ATTORNEY MILLER: Objection. Misstates
13 testimony.

14 A. Would you repeat that?

15 BY ATTORNEY BARNES:

16 Q. Sure.

17 It is your opinion that in figure 1,
18 the valve 126 is in the flow path that extends
19 through the housing 106. Correct?

20 ATTORNEY MILLER: Objection. Misstates
21 testimony.

22 A. The control 126, yes.

23 BY ATTORNEY BARNES:

24 Q. In your annotated version of figure 1

1 on page 14, you identify the reference
2 number 108 as a connector. Correct?

3 A. Yes.

4 Q. And if you pull up the '005 patent and
5 specifically turn to column 5. If you look to
6 lines 43 through 47, you would agree with me
7 that the '005 patent describes the reference
8 number 108 as a branch or side port on the
9 valve 106. Correct?

10 A. Yes.

11 Q. Why do you believe that the branch or
12 side port 108 is a connector in figure 1?

13 A. The diagram suggests that.

14 Q. How does the diagram suggest that the
15 side port 108 is a connector?

16 ATTORNEY MILLER: Objection. Vague.

17 A. It is a discrete component attached to
18 the catheter body.

19 BY ATTORNEY BARNES:

20 Q. What is the purpose of the side
21 port 108 in figure 1?

22 A. The application of negative pressure
23 for aspiration.

24 Q. Does the side port 108 place the

1 pressure source in communication with the flow
2 path that you identified in your annotated
3 version of figure 1?

4 A. Yes.

5 Q. How does it do that?

6 ATTORNEY MILLER: Objection. Vague.

7 A. It is part of the specification.

8 BY ATTORNEY BARNES:

9 Q. When you refer to the specification in
10 your last answer, are you referring to the
11 specification of the '005 patent?

12 A. Yes.

13 Q. How does being part of the
14 specification of the '005 patent enable the
15 side port to place the pressure source in
16 communication with the flow path?

17 ATTORNEY MILLER: Objection. Vague.

18 A. A written description walks through the
19 process.

20 BY ATTORNEY BARNES:

21 Q. What is the process that is described
22 in the written description?

23 A. The application using a pressure source
24 with various components between the pressure

1 source and the target thrombus. The wash
2 through the components and the process of
3 aspiration.

4 Q. Does the side port 108 in figure 1 need
5 to have any specific type of structure?

6 ATTORNEY MILLER: Objection. Vague.

7 A. Not sure how to answer that. It
8 certainly has to have certain geometry, certain
9 dimensions, and certain materials.

10 Q. Could the side port be a barbed
11 connector?

12 A. I don't believe so.

13 Q. Why not?

14 A. That wouldn't satisfy the aspiration
15 requirement.

16 Q. Why would having a barbed connector as
17 the side port not satisfy the aspiration?

18 A. It would interfere, is my
19 understanding, with the pressure transfer.

20 Q. How would a barbed connector interfere
21 with the transfer of the pressure?

22 A. An additional pressure gradient
23 creation.

24 Q. What type of connector would the side

1 port 108 need to be in order to not interfere
2 with the pressure transfer?

3 A. A relatively simple luer comes to mind
4 as an example.

5 Q. Any other type of connector?

6 A. I am sure there are, but nothing on my
7 plate right now.

8 Q. But it can't be a barbed connector. Is
9 that right?

10 A. That is my understanding.

11 ATTORNEY BARNES: We have been going
12 for a little over an hour. Would you like to
13 take a break?

14 THE WITNESS: Sure.

15 ATTORNEY BARNES: We can go off the
16 record.

17 THE VIDEOGRAPHER: The time is 10:04.
18 We are off the record.

19 (Recess taken at 10:04 a.m.)

20 (Recess ended at 10:19 a.m.)

21 THE VIDEOGRAPHER: Time is 10:19. We
22 are back on the record.

23 BY ATTORNEY BARNES:

24 Q. Welcome back, Dr. Zalesky. Did you

1 speak to anyone about the substance of your
2 testimony during the break?

3 A. No.

4 Q. Did you review any documents during the
5 break?

6 A. No.

7 Q. If you could turn back to page 14 of
8 your supplemental declaration. In the
9 annotated version of figure 1 on page 14, there
10 is a box labeled pressure source 140. Correct?

11 A. Yes.

12 Q. What is the pressure source 140 in the
13 system that is shown in figure 1?

14 A. The is a means of creating and exerting
15 negative pressure.

16 Q. Is it a syringe?

17 A. That is one option, yes.

18 Q. What are the other options for the
19 pressure source 140?

20 A. The options include ganged syringes and
21 motors of various configurations that create
22 negative pressure.

23 Q. When you refer to ganged syringes, can
24 you explain what you mean by that?

1 A. Two or more syringes arranged typically
2 in parallel.

3 Q. Could the pressure source 140 be an
4 aspiration pump?

5 A. Yes.

6 Q. What kind of aspiration pump could the
7 pressure source 140 be?

8 ATTORNEY MILLER: Objection. Scope.
9 Objection. Vague.

10 A. Really what I refer to as the motors or
11 engines that create negative pressures so a
12 pretty wide description.

13 BY ATTORNEY BARNES:

14 Q. Could it be a centrifugal pump?

15 A. Yes.

16 Q. Could it be a peristaltic pump?

17 A. Yes.

18 Q. Are there any other types of aspiration
19 pumps that were known in 2018 that it could be?

20 ATTORNEY MILLER: Objection. Scope.
21 Objection. Vague.

22 A. Roller pump would be one option.

23 BY ATTORNEY BARNES:

24 Q. Any others?

1 A. Not that come to mind.

2 Q. Before -- or let me rephrase.

3 Earlier, you testified that the
4 pressure source is a means of creating and
5 exerting negative pressure.

6 How does the pressure source create and
7 exert negative pressure in the system?

8 ATTORNEY MILLER: Objection. Vague.
9 Scope.

10 A. The simplest description is to consider
11 a syringe where the pullback of the -- the one
12 component creates a negative pressure in the
13 connected chamber.

14 BY ATTORNEY BARNES:

15 Q. How about the example wheres the
16 pressure source is an aspiration pump? How
17 would the aspiration pump create negative
18 pressure in the system?

19 ATTORNEY MILLER: Objection. Vague.
20 Objection. Scope.

21 A. The physics is pretty much the same as
22 with a syringe, just created with an
23 energy-driven device versus manual.

24 BY ATTORNEY BARNES:

1 Q. In the aspiration pumps, is there a
2 chamber like there is for the syringe where the
3 negative pressure is generated in?

4 ATTORNEY MILLER: Objection. Vague and
5 scope.

6 A. There can be but not necessarily.

7 BY ATTORNEY BARNES:

8 Q. If you turn to the next page of your
9 supplemental declaration, page 15. On page 15,
10 and I believe this is part of paragraph 37, you
11 state, "Figure 19 of the '005 patent shows
12 another example of the pressure source
13 comprising a clot canister 1940 that is fluidly
14 coupled to the fluid path and the source of
15 aspiration 460 shown in figures 4A through 4C."

16 Did I read that correct?

17 A. Yes.

18 Q. Do you have an understanding of how the
19 pressure source with a clot canister that is
20 shown in figure 19 works?

21 A. Yes, in general.

22 Q. How does the pressure source with the
23 clot canister shown in figure 19 work?

24 A. This seems to indicate a syringe that

1 would be used via withdrawal of the piston to
2 create a negative pressure, which would be the
3 source of the aspiration.

4 Q. How does the arrangement in figure 19
5 apply the negative pressure to the system?

6 ATTORNEY MILLER: Objection. Vague.
7 Scope.

8 A. It is controllably connected to the
9 flow path.

10 BY ATTORNEY BARNES:

11 Q. Is it correct that in figure 19,
12 aspirated blood and clot material would enter
13 the clot canister along the flow path that you
14 have illustrated on page 16?

15 A. Yes.

16 Q. Does the blood get aspirated into the
17 source of aspiration 460?

18 A. It is possible but minimally.

19 Q. What happens to the aspirated blood and
20 the clot material once it is drawn into the
21 clot canister?

22 ATTORNEY MILLER: Objection. Vague.
23 Scope.

24 A. It is collected and either filtered for

1 clot material versus plasma or otherwise
2 discarded.

3 BY ATTORNEY BARNES:

4 Q. How would it be filtered for clot
5 material versus plasma?

6 A. I believe other figures demonstrate the
7 integration of a filter that would trap the
8 clot material.

9 Q. In figure 19, it shows a filter 1942 in
10 the clot canister. Is that correct?

11 A. Yes.

12 Q. How does the filter 1942 work to filter
13 the clot versus plasma?

14 A. It is simply a passive filter, the
15 equivalent of a screen that traps solid
16 material and lets liquid flow through it.

17 Q. Does the clot canister need to include
18 a filter in order to work?

19 A. I wouldn't say needs to, no.

20 Q. How would the clot canister function
21 without a filter?

22 A. It would simply collect the
23 conglomerate thrombus and blood materials.

24 Q. Are there any advantages to the

1 arrangement of components in the clot canister
2 and source of aspiration shown in figure 19 on
3 page 16 of your supplemental declaration?

4 A. One could argue it is convenient
5 integration of components and simplifies the
6 procedure.

7 Q. How does it simplify the procedure?

8 A. It is a ready-to-use apparatus.

9 Q. Are there any advantages to the
10 arrangement of the filter and the clot canister
11 that is shown on figure 19?

12 ATTORNEY MILLER: Objection. Vague.
13 Scope.

14 A. The filter segregation of thrombus
15 material enables the capture of thrombus --
16 essentially thrombus-free blood that can then
17 be returned to the patient.

18 BY ATTORNEY BARNES:

19 Q. Is there any advantage to placing the
20 filter closer to the outflow port versus the
21 in-flow port in figure 19?

22 ATTORNEY MILLER: Objection. Vague.
23 Scope.

24 A. Potentially in that it thereby

1 encompasses the entire volume of blood and
2 material in the canister.

3 BY ATTORNEY BARNES:

4 Q. Looking at the bottom of page 16 of
5 your supplemental declaration, in paragraph 38,
6 you state, "Figure 1 of the '005 patent shows a
7 hemostasis valve 106 (i.e., a valve that
8 inhibits or prevents blood from flowing through
9 the valve) attached to a proximal end of the
10 first catheter 102."

11 Did I read that right?

12 A. Yes.

13 Q. On the next page, on page 17, you
14 provide another annotated version of figure 1.
15 Correct?

16 A. Yes.

17 Q. In the annotated version on page 17,
18 you identified the reference number 106 as a
19 hemostasis valve. Correct?

20 A. That is what is cited here, yes.

21 Q. On the next page of your supplemental
22 declaration, you provide an annotated version
23 of figure 11 from the '005 patent. Correct?

24 A. Yes.

1 Q. In the annotated version of figure 11,
2 you identified three components, the first
3 catheter 1002, a hemostasis valve 1006, and a
4 second catheter 1102. Correct?

5 A. Yes.

6 Q. Does figure 11 of the '005 patent
7 disclose a housing with a hemostasis valve in
8 the housing?

9 A. It doesn't specify it but it appears to
10 show it in the configuration.

11 Q. Can you identify the housing that is
12 shown in figure 11?

13 A. I believe 1007A.

14 Q. Does figure 11 disclose a connector?

15 A. I see what could be construed as a
16 connector just below 1007A.

17 Q. So the side port attached to the
18 housing 1007A would be a connector?

19 A. It could well be, yes.

20 Q. Does figure 11 disclose a flow path
21 extending through the housing?

22 A. Yes.

23 Q. Can you identify where the flow path
24 extending through housing would be in

1 figure 11?

2 A. From left to right in the figure.

3 Q. Would there be a flow path that extends
4 through the side port of the housing in the
5 direction of component 1026?

6 ATTORNEY MILLER: Objection. Vague.

7 A. Yes. This is a dual pressure source
8 configuration. So both of the side arms, if
9 you will, are connected to separate pressure
10 sources or the same pressure source,
11 conceivably.

12 BY ATTORNEY BARNES:

13 Q. One of the pressure sources that is
14 identified in figure 11 is the pressure
15 source 1040. Correct?

16 A. Yes.

17 Q. Is that pressure source 1040 in fluid
18 communication with the first catheter 1002?

19 A. Yes.

20 Q. Does figure 11 disclose an on-off
21 control that is in the flow path?

22 A. Yes.

23 Q. Can you identify where in figure 11 the
24 on-off control is?

1 A. Labeled as 1026 and 1126.

2 Q. You would agree that in figure 11, the
3 on-off control 1026 is not located in the
4 housing of the hemostasis valve. Correct?

5 A. In this particular figure, no, it is
6 not in the housing.

7 Q. If you could turn to the '005 patent,
8 which is Exhibit 1001, and specifically if you
9 could turn to figure 3D.

10 A. Sorry. Which figure?

11 Q. 3D.

12 A. Okay.

13 Q. Can you explain what is shown in figure
14 3D?

15 A. From bottom right, you have a syringe,
16 which is a pressure source, connected to a
17 tubing that goes through an on-off switch, if
18 you will, which, in turn, is connected via side
19 arm to the housing, and the housing is distal
20 to the hemostasis valve with an aspiration
21 catheter exiting the housing and going to the
22 target clot.

23 Q. Does the system shown in figure 3D
24 include a flow path that extends through the

1 housing?

2 ATTORNEY MILLER: Objection. Vague.

3 A. I am not sure "through the housing" is
4 correct. It involves the housing.

5 BY ATTORNEY BARNES:

6 Q. Why would there not be a flow path that
7 extends through the housing in figure 3D?

8 A. "Through" suggests an axial path from
9 left to right as opposed to a side arm path.

10 Q. Well, if you turn back to page 14 of
11 your supplemental declaration, on page 14 of
12 your declaration, you illustrated a flow path
13 that extends through the side port of the
14 housing. Correct?

15 A. It extends through the side port of the
16 housing, yes.

17 Q. And in paragraph 36, you described that
18 flow path as "a flow path extending through a
19 housing." Correct?

20 A. I did. But in retrospect, I would
21 probably choose a slightly different term than
22 "through."

23 Q. So is your description in paragraph 36
24 inaccurate?

1 ATTORNEY MILLER: Objection. Vague.

2 Misstates testimony.

3 A. It is not inaccurate but it is not
4 precise.

5 BY ATTORNEY BARNES:

6 Q. So as you described it in paragraph 36
7 of your supplemental declaration, wouldn't
8 figure 3D of the '005 patent include the same
9 flow path extending through the housing?

10 ATTORNEY MILLER: Objection. Vague.

11 A. Yes.

12 BY ATTORNEY BARNES:

13 Q. Figure 3D also includes an on-off
14 control in that flow path. Correct?

15 A. Yes.

16 Q. You would agree that in figure 3D of
17 the '005 patent, the on-off control is not
18 located in the housing of the hemostasis valve.
19 Correct?

20 A. In this particular configuration,
21 correct.

22 Q. Can you turn to figures 9A through 9C
23 of the '005 patent.

24 A. Okay.

1 Q. Can you explain what is shown in
2 figures 9A through 9C?

3 A. My interpretation is equivalent
4 aspiration flow paths using a syringe for
5 pressure creation and control with the piston
6 in different positions from A to B and C. And
7 showing different on-off control configurations
8 labeled as 126.

9 Q. Would you agree that the figures 9A,
10 9B, and 9C illustrate the same system, just at
11 different points during the aspiration
12 procedure?

13 ATTORNEY MILLER: Objection. Vague.

14 A. That is part of what they depict, yes.
15 That is not the whole -- that wouldn't be my
16 entire description, but they do depict that.

17 BY ATTORNEY BARNES:

18 Q. Would you agree that figures 9A and 9B
19 and 9C show generally the same configuration of
20 components?

21 A. Generally the same, yes.

22 Q. If we look first to figure 9A, does
23 figure 9A include a housing with a hemostasis
24 valve within it?

1 A. It appears to, yes.

2 Q. And it looks like that is generally the
3 same housing that is shown in figure 1 of the
4 '005 patent. Would you agree with that?

5 A. I think they are consistent. Without
6 going to the written description, it is hard to
7 evaluate whether it is integrated in the
8 housing or connected to the housing via tubing.

9 Q. I believe you stated that figure 9A
10 includes an on-off control which is identified
11 as reference number 126. Is that right?

12 A. Yes.

13 Q. Would you agree with me that in
14 figure 9A, the on-off control is not located in
15 the housing of the hemostasis valve?

16 A. The drawn 126 element in this figure is
17 not part of the housing.

18 Q. Would you agree that that is also the
19 case for figure 9B?

20 A. Yes.

21 Q. Would you agree that that is also the
22 case for figure 9C?

23 A. Yes.

24 Q. Can you turn to figures 20C through E.

1 A. 20, which letters?

2 Q. C through E.

3 A. Okay.

4 Q. Can you explain what is shown in
5 figures 20C through E?

6 ATTORNEY MILLER: Objection. Vague.

7 A. My understanding is they are depicting
8 different steps in the aspiration process.

9 BY ATTORNEY BARNES:

10 Q. If we start with figure 20C, does
11 figure 20C include a housing within that --

12 ATTORNEY BARNES: Let me rephrase.

13 BY ATTORNEY BARNES:

14 Q. Does figure 20C include a housing with
15 a hemostasis valve in the housing?

16 A. I guess to answer this question I need
17 to clarify my previous answer, that the figures
18 are not terribly well done in terms of defining
19 the integration of the hemostasis valve with
20 the housing. So hence, my commenting that it
21 could be either, based on just the figures by
22 themselves.

23 Q. When you say "could be either," what
24 are the options you are referring to by

1 "either"?

2 A. One option is indeed the hemostasis
3 valve integral with the housing. But the other
4 option would be discreet from the housing.

5 Q. Would you agree that figure 20C
6 includes an on-off control identified with
7 reference number 126?

8 A. Yes.

9 Q. Would you agree that the on-off control
10 in figure 20C is not located in a housing with
11 the hemostasis valve?

12 A. As I answered previously, in this
13 particular embodiment, it is separate from the
14 housing.

15 Q. If you turn to figure 20D. Would you
16 agree that in figure 20D, it also shows that
17 the on-off control 126 is not located in a
18 housing that also includes the hemostasis
19 valve?

20 A. Yes. The same answer to the previous
21 question. It doesn't rule out an embodiment
22 where it is part or there is an additional
23 on-off valve.

24 Q. But that is not shown in figure 20D.

1 Correct?

2 A. That's correct.

3 Q. In figure 20E, would you also agree
4 that in that figure, the on-off control 126 is
5 not located in the housing that includes the
6 hemostasis valve?

7 A. This is either a poorly drawn figure or
8 for some reason 126 appears different than in
9 figures C and D of that same number.

10 It's presumably been rotated to enable
11 flow to the right, from left to right, but that
12 is not clearly depicted in the figure.

13 Q. Would you agree that the on-off
14 control 126 is not located in the housing that
15 includes the hemostasis valve?

16 ATTORNEY MILLER: Objection. Vague.

17 A. The same answer to the previous two in
18 that regard.

19 BY ATTORNEY BARNES:

20 Q. Can you turn to figure 24 of the '005
21 patent.

22 A. Okay.

23 Q. Does figure 24 include an on-off
24 control?

1 A. It doesn't spell it out, but it appears
2 to be between elements 128 and 120.

3 Q. Does figure 24 include a housing that
4 includes a hemostasis valve?

5 A. As I mentioned earlier, that is one of
6 the two interpretations of these depictions,
7 yes.

8 Q. You would agree that in figure 24, the
9 on-off control is not located in the housing
10 that includes the hemostasis valve. Correct?

11 A. This figure depicts only one on-off
12 control that is not integrated into the
13 housing, but it doesn't rule out there being a
14 parallel on-off control in the housing.

15 Q. You would agree with me that none of
16 the figures in the '005 patent disclose an
17 on-off control located in the same housing as a
18 hemostasis valve. Correct?

19 A. All of the figures that we have just
20 reviewed clearly show an on-off valve by itself
21 that is not integrated, and they don't indicate
22 that there is not another or is another on-off
23 valve within the housing.

24 Q. I am going to repeat my question.

1 You would agree that none of the
2 figures in the '005 patent disclose an on-off
3 control located in the same housing as a
4 hemostasis valve. Correct?

5 A. I would have to look at all of the
6 other figures we didn't address this morning.

7 Q. Please do so.

8 (Pause.)

9 A. I am not seeing any figures that
10 clearly depict an on-off control switch within
11 the housing.

12 Q. Why did you qualify your answer with,
13 "clearly depict"?

14 A. There is no detail regarding the
15 housing in the figures. Or I should say there
16 is minimal dealing.

17 Q. You would agree that the '005 patent,
18 including the written description, does not
19 disclose any examples of an aspiration system
20 with a single housing that includes both a
21 hemostasis valve and an on-off control within
22 it. Correct?

23 ATTORNEY MILLER: Objection. Vague.
24 Misstates the document and his testimony.

1 A. I would, frankly, have to go back
2 through the text of the written description.

3 BY ATTORNEY BARNES:

4 Q. Did you consider whether the '005
5 patent discloses any examples of a single
6 housing that includes both a hemostasis valve
7 and an on-off control when forming your
8 opinions presented in your supplemental
9 declaration?

10 A. It has been a while since I reviewed
11 the details of the written description. But
12 certainly only selected embodiments are
13 described, not all-inclusive.

14 Q. So for the embodiments that are
15 actually described in the '005 patent, you
16 would agree with me that none of those
17 embodiments are described as having a single
18 housing that includes both a hemostasis valve
19 and an on-off control. Correct?

20 ATTORNEY MILLER: Objection. Misstates
21 testimony. Misstates document.

22 A. I don't recall. As I said, I would
23 have to go back through this specific
24 embodiment citation.

1 But as I said earlier, these are just
2 example embodiments, not all-inclusive.

3 BY ATTORNEY BARNES:

4 Q. Did you identify any embodiment
5 disclosed in the '005 patent that includes a
6 single housing with both a hemostasis valve and
7 an on-off control in your supplemental
8 declaration?

9 A. I honestly don't recall.

10 Q. Was that something you considered when
11 forming the opinions you presented in your
12 supplemental declaration?

13 ATTORNEY MILLER: Objection. Asked and
14 answered.

15 A. I looked at claim 1 in particular and
16 certainly reviewed the written description and,
17 frankly, looked at it from a high altitude
18 perspective without going into minute detail of
19 the housing.

20 BY ATTORNEY BARNES:

21 Q. If you turn to paragraph 93 of your
22 supplemental declaration.

23 A. Okay.

24 Q. In the last sentence of paragraph 93,

1 you state, "The '005 patent description
2 reflects this difference as well, drawing a
3 distinction between embodiments in which a
4 fluid control device is fluidly coupled to a
5 valve housing (e.g., via tubing) and
6 embodiments in which the fluid control device
7 is part of the valve housing."

8 Did I read that correctly?

9 A. Yes.

10 Q. Then in the citation after that
11 sentence, you compared column 6, 3 through 11,
12 in figure 1 of the '005 patent with column 6,
13 lines 45 through 49. Correct?

14 A. That is what it says there, yes.

15 Q. Would you agree with me that none of
16 the sections of the '005 patent that you cite
17 here in figure 93 disclose an embodiment that
18 includes a single housing with both a
19 hemostasis valve and an on-off control in it?

20 ATTORNEY MILLER: Objection. Vague.
21 Misstates the document.

22 A. I am rereading column 3, lines 3 to
23 11 -- or column 6. Sorry.

24 (Pause.)

1 A. My interpretation of the citation
2 column 6 does not exclude an integrated control
3 within the housing.

4 Q. Would you agree that it does not
5 describe an on-off control within the same
6 housing as a hemostasis valve?

7 ATTORNEY MILLER: Objection. Vague.
8 Can you specify which section of column 6 you
9 are talking about?

10 A. It is not that specific, no.

11 BY ATTORNEY BARNES:

12 Q. And specifically you would agree that
13 column 6, lines 3 through 11, of the '005
14 patent does not describe an on-off control
15 within the same housing as a hemostasis valve.
16 Correct?

17 A. It describes a stopcock that is fluidly
18 coupled which doesn't specify where exactly it
19 is located in the fluid path.

20 Q. While in column 6, lines 3 through 11,
21 it describes that, "The fluid control
22 device 126 is a stopcock that is fluidly
23 coupled to (I) the side port 108 of the valve
24 106 via the first tubing section 124A."

1 Correct?

2 A. Yes, that is one specific embodiment.

3 Q. That is the only embodiment that is
4 described in that cited portion of the '005
5 patent. Correct?

6 A. Yes.

7 Q. If we go down further in column 6, in
8 the other portion of the '005 patent you cited,
9 at lines 45 through 49, you would agree that
10 lines 45 through 49 also don't disclose a
11 single housing that includes both the
12 hemostasis valve and an on-off control.
13 Correct?

14 ATTORNEY MILLER: Objection. Misstates
15 the document. Vague.

16 A. I interpret this to be broader than you
17 just suggested. In particular, the phrase
18 "integrally formed" in line 49, which suggests
19 an integration of components such as would be a
20 control device within the housing.

21 BY ATTORNEY BARNES:

22 Q. So beginning at line 45 of column 6 --

23 ATTORNEY BARNES: Let me rephrase.

24 BY ATTORNEY BARNES:

1 Q. You would agree with me that lines 45
2 through 49 of column 6 are describing
3 configurations of the tubing subsystem 120.
4 Correct?

5 ATTORNEY MILLER: Objection. Vague.
6 Misstates the document.

7 A. Yes.

8 BY ATTORNEY BARNES:

9 Q. And the on-off control is part of the
10 tubing subsystem 120. Correct?

11 ATTORNEY MILLER: Objection. Vague.
12 Misstates document.

13 A. The key word is, "can have."

14 BY ATTORNEY BARNES:

15 Q. If you look to column 5, lines 27
16 through 29, you would agree with me that the
17 '005 patent states that the valve 106 is part
18 of the catheter subsystem 100, not the tubing
19 subsystem 120. Correct?

20 A. That is how this reads, yes.

21 Q. So looking back to column 6 at lines 45
22 through 49, is it your interpretation of the
23 statement, "In some embodiments, one or more of
24 the components can be permanently connected

1 and/or integrally formed" that "integrally
2 formed" is referring to every single component
3 of the aspiration system?

4 ATTORNEY MILLER: Objection. Vague.

5 A. I think there is at least two
6 interpretations of that line, "integrally
7 formed." One is the point you just made about
8 describing the conglomerate, if you will, of
9 individual components. The other is the
10 integration of select components into a
11 subassembly, in particular, potentially a
12 housing.

13 And I just want to point out, again,
14 these are selected embodiments, not
15 all-inclusive.

16 BY ATTORNEY BARNES:

17 Q. Earlier I believe you agreed that this
18 portion of the specification in lines 45
19 through 49 is referring to configurations of
20 the tubing subsystem 120. Correct?

21 ATTORNEY MILLER: Objection. Misstates
22 testimony.

23 A. Yes.

24 BY ATTORNEY BARNES:

1 Q. So doesn't that statement regarding
2 integrally formed components refer to
3 components of the tubing subsystem 120?

4 ATTORNEY MILLER: Objection. Misstates
5 testimony. Vague.

6 A. I don't interpret it to be that
7 restrictive, no.

8 BY ATTORNEY BARNES:

9 Q. How are you interpreting it?

10 A. I just pointed out, it could go -- it
11 could be interpreted at least two different
12 ways, one of which is selected components
13 integrated into a subassembly.

14 Q. Which components?

15 A. It could be a filter, it could be an
16 on-off control device. It could be a
17 connector.

18 Q. This statement doesn't reference any of
19 those components. Right?

20 ATTORNEY MILLER: Objection. Vague.
21 Misstates testimony. Misstates document.

22 A. No. But there is another key line in
23 here, "can have other suitable configurations."

24 BY ATTORNEY BARNES:

1 Q. Is it your interpretation that that
2 statement means any possible configuration is
3 encompassed by that statement?

4 A. I am not sure I would say "any."

5 ATTORNEY MILLER: Objection. Vague.

6 A. But it has to be functionally
7 consistent with the intended use of the device.

8 BY ATTORNEY BARNES:

9 Q. How would a person of skill in the art
10 go about determining if a configuration is
11 within this statement, under your
12 interpretation?

13 A. It is a combination of the intended
14 use, which is aspiration of clot material, with
15 a reasonable combination of negative pressure
16 application to a fluid path.

17 Q. In this portion of your supplemental
18 declaration, which I believe is section VI.A,
19 you are opining that the combination of
20 Garrison and Schaffer does not disclose the
21 housing of claims 1 and 10. Correct?

22 A. Sorry. Where are you?

23 Q. If you look at page 54 of your
24 supplemental declaration. In this section,

1 which is section 6A, you are providing an
2 opinion that the combination of Garrison and
3 Schaffer does not disclose the housing of
4 claims 1 and 10. Correct?

5 A. Correct.

6 Q. And it is your opinion that Garrison
7 does not disclose an on-off control in the flow
8 path as recited in claim 1 because Garrison's
9 valve 3325 is not located in the same housing
10 as the hemostasis valve. Correct?

11 ATTORNEY MILLER: Objection. Misstates
12 the document.

13 A. You are going to have to repeat that.
14 Sorry.

15 BY ATTORNEY BARNES:

16 Q. Sure.

17 It is your opinion that Garrison does
18 not disclose an on-off control in the flow path
19 as recited in claim 1 because Garrison's valve
20 3325 is not located in the same housing as the
21 hemostasis valve. Correct?

22 A. Yes, that is what I am stating.

23 Q. So you are construing claim 1 to
24 require that the housing --

1 ATTORNEY BARNES: Let me rephrase.

2 BY ATTORNEY BARNES:

3 Q. You are construing claim 1 to require
4 that the on-off control is in the housing.
5 Correct?

6 A. No. That is one option. It is not
7 constrained to that.

8 Q. What are the other options?

9 A. In the flow path but not in the
10 housing.

11 Q. So it is your opinion that the on-off
12 control recited in claim 1 does not need to be
13 in the housing. Is that right?

14 A. I am allowing for the two options, in
15 or not in the housing.

16 Q. So then why do you believe that
17 Garrison's valve 3325 is not in the flow path
18 as recited in claim 1?

19 A. It is, frankly, a confusing figure
20 because of the dashed reds.

21 Q. So it is your opinion that Garrison
22 does not disclose that valve 3325 is in the
23 flow path because it is a confusing
24 figure because of the dashed red line -- dots?

1 A. That is part of my observation, yes.

2 Q. Did you do any personal analysis of
3 whether Garrison's figure 34 without the dashed
4 red dots includes an on-off control that is in
5 the flow path extending through housing?

6 ATTORNEY MILLER: Objection. Vague.

7 A. No. I simply looked at his depicted
8 figures.

9 BY ATTORNEY BARNES:

10 Q. In paragraph 92, in the second
11 sentence, you say, "First, the red dashed line
12 that petitioner uses to denote the purported
13 flow path extends well beyond either end of the
14 alleged housing and thus tracks more than just
15 'the flow path' 'extending through the
16 housing.' A POSITA would understand that the
17 proper illustration of the flow path extending
18 through the housing would be from one end of
19 the proximal adapter to the other."

20 Did I read that correctly?

21 A. Yes.

22 Q. If we turn back to page 13 of your
23 supplemental declaration -- or page 14, rather.

24 You would agree with me that, in the

1 annotated version of figure 1 that you
2 prepared, you illustrated a flow path that
3 extends through the housing that extends well
4 beyond the proximal and distal ends of the
5 housing. Correct?

6 A. No, that is not exactly what I said.

7 Q. Why is that wrong?

8 A. Your descriptor suggests axial flow
9 throughout the entire assembly.

10 Q. What descriptor?

11 A. The phrase that you just used for my
12 interpretation.

13 Q. So in your own phrasing in paragraph 36
14 than is on page 13, you said, "Figure 1 of the
15 '005 patent shows a vacuum aspiration system
16 with a flow path extending through a housing."

17 Did I read that right?

18 A. Yes, we addressed this earlier. The
19 key word here is "through." And "through"
20 connotes completely through as opposed to
21 partially through.

22 Q. That is words that you used in your
23 declaration. Right?

24 A. Those are the words. And as I said

1 earlier, in retrospect, I should have been more
2 precise.

3 Q. So your figure -- your annotated
4 version of figure 1, it is your testimony that
5 that figure is wrong. Is that right?

6 A. No.

7 Q. So does figure one accurately show a
8 flow path --

9 ATTORNEY BARNES: Let me rephrase.

10 BY ATTORNEY BARNES:

11 Q. Does the annotated version of figure 1
12 that you prepared on page 14 accurately show a
13 flow path extending through the housing as you
14 have shown it with the blue lines?

15 A. Again, in retrospect, I would have been
16 more precise. It shows a flow path through
17 part of the housing.

18 Q. Is it your interpretation of claim 1 of
19 the '005 patent that the flow path must extend
20 through the entirety of the housing?

21 ATTORNEY MILLER: Objection. Vague.

22 A. No, that is not my interpretation.

23 BY ATTORNEY BARNES:

24 Q. So as it is recited in claim 1, the

1 blue flow path you illustrated on page 14 of
2 your supplemental declaration is a flow path
3 extending through the housing. Correct?

4 A. Yes, I will try this one more time.

5 "Through" can be interpreted different
6 ways by different POSITAs. One interpretation
7 is an axial flow through the entire length of
8 the housing. Another interpretation is it goes
9 through a part of the housing and certainly is
10 still through, but a different flow path
11 configuration.

12 Q. Which is the interpretation that
13 applies to claim 1 of the '005 patent?

14 A. My interpretation is it covers both.

15 Q. So if we turn back to page 55 of your
16 supplemental declaration, you would agree with
17 me that the fact that Garrison's valve 3325 is
18 not located within the same housing as the
19 hemostasis valve is not relevant for purposes
20 of claim 1 of the '005 patent?

21 A. That is not exactly correct. It is not
22 that it is not relevant; it is not precise.

23 Q. What is not precise?

24 A. The control device is clearly not

1 integrated with the hemostasis valve in this
2 configuration.

3 Q. Right.

4 A. That is one of the option that I
5 interpreted in the '005 patent.

6 Q. But the integration of a hemostasis
7 valve and the on-off control is not required by
8 claim 1 of the '005 patent. Correct?

9 ATTORNEY MILLER: Objection. Misstates
10 the document. Calls for a legal conclusion.

11 A. It is not required but it is included.

12 BY ATTORNEY BARNES:

13 Q. So because the claim 1 does not require
14 the hemostasis valve and the on-off control to
15 be integrated, the fact that Garrison's on-off
16 control valve is not integrated with the
17 hemostasis valve does not matter for purposes
18 of invalidity. Correct?

19 ATTORNEY MILLER: Objection. Calls for
20 a legal conclusion. Misstates the testimony.

21 A. He is not specifying optional
22 configurations, he is specifying a very
23 specific configuration where the on-off control
24 is segregated from the hemostasis valve.

1 BY ATTORNEY BARNES:

2 Q. And that configuration is one of the
3 configurations that is encompassed by claim 1
4 of the '005 patent. Correct?

5 A. The segregation aspect is, yes.

6 ATTORNEY BARNES: We have been going
7 for another hour. Would you like to take a
8 break?

9 ATTORNEY MILLER: Let's do that.

10 ATTORNEY BARNES: Sure.

11 THE VIDEOGRAPHER: The time is 11:16.
12 We are off the record.

13 (Recess taken at 11:16 a.m.)

14 (Recess ended at 11:29 a.m.)

15 THE VIDEOGRAPHER: The time is 11:29.
16 We are back on the record.

17 BY ATTORNEY BARNES:

18 Q. Welcome back, Dr. Zalesky. Did you
19 discuss the substance of your testimony with
20 anyone during the break?

21 A. No.

22 Q. Did you review any documents during the
23 break?

24 A. No.

1 Q. Does claim 1 of the '005 patent cover
2 the system that is shown in figure 1 of the
3 '005 patent?

4 ATTORNEY MILLER: Objection. Calls for
5 a legal conclusion.

6 A. I believe so.

7 BY ATTORNEY BARNES:

8 Q. If you could turn to paragraph 39 of
9 your supplemental declaration, which is on
10 page 17.

11 Or, actually, it is on page 18.

12 A. Okay.

13 Q. In paragraph 39, you state, "The '005
14 patent incorporates by reference all the
15 subject matter of U.S. Patent Application
16 Number 16-117519." Correct?

17 A. Yes.

18 Q. And you refer to that application by
19 the shorthand "the '519 application." Correct?

20 A. Yes.

21 Q. What is your understanding of what it
22 means for the '005 patent to incorporate by
23 reference the subject matter of the '519
24 application?

1 A. My interpretation is that the '005
2 invention includes the inventive description in
3 the 519.

4 Q. Did that understanding impact any of
5 the opinions that you presented in your
6 supplemental declaration?

7 A. No.

8 Q. I am going to hand you what has been
9 marked as Exhibit 1017 in this IPR.

10 (Handing document to the witness.)

11 Q. Do you recognize Exhibit 1017?

12 A. I don't believe I have ever seen this,
13 at least the front page.

14 Sorry, it looks like it is excerpted, I
15 guess.

16 Q. Does Exhibit 1017 appear to be a copy
17 of the '519 application that you referred to in
18 your declaration?

19 A. That is what I was trying to verify by
20 paging through. I believe so.

21 Q. At the bottom of page 18 of your
22 supplemental declaration, or -- you can finish
23 your review.

24 A. That is okay. Page 18?

1 Q. Correct. And in paragraph 40, the
2 first sentence of paragraph 40, you state, "The
3 '005 patent, via its incorporation of the '519
4 application, explains that, while traditional
5 hemostasis valves are greatly beneficial for
6 intravascular access, they have some
7 drawbacks." Is that correct?

8 A. Yes.

9 Q. Do you have an understanding of what
10 types of hemostasis valves the '519 patent --

11 ATTORNEY BARNES: Let me restate.

12 BY ATTORNEY BARNES:

13 Q. Did I have an understanding of what
14 types of hemostasis valves the '519 application
15 was referring to when it references traditional
16 hemostasis valves?

17 ATTORNEY MILLER: Objection. Vague.

18 A. In general, the Tuohy-Borst family, and
19 there are variations to Tuohy-Borst, but
20 essentially the same closing principle in the
21 Tuohy-Borst family.

22 BY ATTORNEY BARNES:

23 Q. Can you explain what you mean when you
24 refer to the Tuohy-Borst family of hemostasis

1 valves?

2 A. So it is an axial-configured valve with
3 silicone valves or flutters or whatever you
4 want to call them that, upon a screwing
5 rotation aspect of the device, creates a
6 sealing around the enclosed catheter or tube or
7 other device.

8 Q. Were passive hemostasis valves included
9 within the traditional hemostasis valves that
10 the '519 application is referring to?

11 A. I would think so, yes.

12 Q. Do you agree with the '519 application
13 statement that traditional hemostasis valves
14 had some drawbacks?

15 A. Yes.

16 Q. What are the drawbacks that traditional
17 hemostasis valves had?

18 A. Those traditional valves don't seal
19 well on large devices or complex configuration
20 devices thought are not circular. They
21 sometimes struggle with high pressure scenarios
22 and require two hands to operate.

23 Q. Any other drawbacks that you can think
24 of?

1 A. Just pressure gradient as well as
2 pressure itself.

3 Q. Can you identify any examples of the
4 complex configuration devices that you were
5 referring to in your previous answer?

6 A. There are different therapeutic tools
7 used for procedures -- interventional
8 procedures, such as atherectomy devices,
9 different stent configurations around balloons,
10 and others that I could come up with if I had
11 enough time that present either a complex
12 geometry or a complex enclosure.

13 Q. If you turn to paragraph 57 of your
14 supplemental declaration. That is going to
15 start at the bottom of page 31.

16 A. Okay.

17 Q. And the first sentence of paragraph 57,
18 you state, "The easy one-handed operation and
19 strong seal of the garrote valve is
20 particularly useful in vacuum aspiration
21 systems such as those disclosed and claimed in
22 the '005 patent." Is that correct?

23 A. Yes.

24 Q. How does the valve that is claimed in

1 the '005 patent provide for easy one-handed
2 operation?

3 A. The opposing actuators can be easily
4 compressed with the digits of one hand.

5 Q. Are there any other components of the
6 valve that is claimed in the '005 patent that
7 enable it to provide the easy one-handed
8 operation?

9 A. That is the most important, the one I
10 just described.

11 Q. Does the biasing system contribute to
12 the easy one-handed operation?

13 A. The biasing system enables tactile
14 control by the operator. I am not sure that is
15 the same as easy one-handed operation.

16 Q. How does the hemostasis valve that is
17 claimed in the '005 patent provide a strong
18 seal?

19 A. I think the word "garrote" best
20 describes the mechanism of sealing where there
21 is a circumferential choking of the enclosed
22 structure.

23 Q. So if we look at claim 1 of the '005
24 patent, can you identify the component or

1 components that are recited in claim 1 that
2 help create the strong seal that you refer to
3 in your declaration?

4 ATTORNEY MILLER: Objection. Vague.

5 A. I think the middle of the top paragraph
6 on column 36 where the filament
7 circumferentially constricts the lumen to
8 create a seal, as supported by the written
9 description, talks about a garrote seal which
10 is quite robust.

11 BY ATTORNEY BARNES:

12 Q. How does the filament that is recited
13 in claim 1 of the '005 patent create a strong
14 seal?

15 A. The actuators are spring-loaded, if you
16 will, to pull the filament in opposing
17 directions, creating a circumferential
18 constriction.

19 Q. What are the features of the filament
20 that makes it particularly useful for creating
21 a strong seal?

22 A. Its inherent flexibility and geometry.

23 Q. Can you explain what you mean when you
24 refer to geometry?

1 A. Size matters. And you can't rule out
2 hexagons, pentagons, and so forth, but circular
3 would probably be the most preferred.

4 Q. With respect to size, what about the
5 size of the filament helps it create a strong
6 seal?

7 A. A smaller diameter filament is going to
8 have a concentrated force at a reduced area.
9 So pressure, being force divided by area, gives
10 you a higher pressure at a focal point.

11 Q. Besides the filament, do any of the
12 other components that are recited in claim 1
13 help to create the strong seal?

14 A. The force of the actuators of course
15 are critical to that.

16 Q. And that force is provided by the
17 biasing system. Correct?

18 A. Partially. As I said earlier,
19 spring-loaded force.

20 Q. Any other components listed in claim 1
21 that contribute to the strong seal?

22 A. I mean, those are clearly the drivers,
23 the filament and the actuators.

24 Q. In paragraph 58 of your supplemental

1 declaration, in that last sentence of
2 paragraph 58, you state, "Thus, a POSITA would
3 understand, for example, the garrote valve to
4 be particularly useful in thrombectomy
5 procedures using large-bore catheters to apply
6 significant vacuum pressure such as
7 thrombectomy procedures used to treat pulmonary
8 embolism or deep vein thrombosis."

9 Did I read that right?

10 A. Yes.

11 Q. Would that understanding that the
12 POSITA would have had --

13 ATTORNEY BARNES: Let me rephrase.

14 BY ATTORNEY BARNES:

15 Q. Would the POSITA have had this
16 understanding that you are referring to prior
17 to 2018?

18 ATTORNEY MILLER: Objection.

19 A. Would you repeat that?

20 BY ATTORNEY BARNES:

21 Q. Sure.

22 Would a POSITA have had this
23 understanding that you are referring to in
24 paragraph 58 prior to 2018?

1 A. I think the reason I am hesitating is I
2 am not sure how many large thrombectomy
3 procedures were common prior to 2018. It
4 became more common late in that decade, into
5 the following decade.

6 Q. Is it your opinion that the garrote
7 valve would only be useful for thrombectomy
8 procedures to treat pulmonary embolism or deep
9 vein thrombosis?

10 ATTORNEY MILLER: Objection. Vague.

11 A. No, it could be used in procedures we
12 described earlier in this process, including
13 peripheral, coronary, cerebral.

14 BY ATTORNEY BARNES:

15 Q. Would it be useful in procedures that
16 involved smaller bore catheters?

17 ATTORNEY MILLER: Objection. Vague.

18 A. I don't think it would be any worse. I
19 don't know how much incrementally better it
20 would be in a smaller, whereas it is
21 significantly more effective in larger.

22 BY ATTORNEY BARNES:

23 Q. Would it provide any benefit over
24 traditional hemostasis valves in systems that

1 used catheters with sizes that were less than
2 20 French?

3 ATTORNEY MILLER: Objection. Vague.
4 Scope.

5 A. Conceivably, sure, in particular where
6 there is a large pressure gradient supplied or
7 sudden bursts of pressure to dislodge a tough
8 thrombus, and that could occur in small vessels
9 as well as large vessels.

10 BY ATTORNEY BARNES:

11 Q. In that sentence in paragraph 58, you
12 refer to significant vacuum pressure.

13 Do you see that?

14 A. Yes.

15 Q. Can you explain what you meant by
16 significant vacuum pressure?

17 A. It applies to the question we just
18 addressed in terms of small versus large.
19 Because of the volume involved in a larger
20 catheter body, a larger total vacuum pressure
21 would need to be generated.

22 Q. Are significant vacuum pressures used
23 during thrombectomy procedures for clots other
24 than pulmonary embolisms or deep vein

1 thrombosis?

2 ATTORNEY MILLER: Objection. Vague.

3 A. They could well be, as I said with a
4 difficult thrombus or a mature or older
5 thrombus which tends to be harder and tougher
6 to dislodge.

7 BY ATTORNEY BARNES:

8 Q. If you turn to next page, page 33 of
9 your supplemental declaration.

10 Towards the center of paragraph 59, you
11 state, "A robust seal and quick self-closing
12 valve are critical to reduce patient blood loss
13 during procedures, which can be significant
14 through a large catheter. Traditional rotating
15 hemostasis valves take many turns to seal the
16 large-bore catheters used in such procedures.
17 The incorporation of bias features and springs
18 ensures that the actuator can quickly and
19 easily function effectively."

20 Did I read that right?

21 A. Yes.

22 Q. Would the fact that traditional
23 rotating hemostasis valves take many turns to
24 seal larger bore catheters have been one of the

1 drawbacks that those valves were known to have
2 prior to 2018?

3 A. Yes.

4 Q. How do the bias features and springs of
5 the '005 patent's hemostasis valve ensure that
6 the actuator can quickly and easily function
7 effectively?

8 ATTORNEY MILLER: Objection. Vague.

9 A. The spring-loaded mechanism means that,
10 almost instantly upon release, there is
11 closure.

12 BY ATTORNEY BARNES:

13 Q. Why is that a useful benefit?

14 A. Among other things, the time factor.
15 Taking an extra 10, 15 seconds with a
16 Tuohy-Borst traditional means that during that
17 10 or 15 seconds you could -- results with some
18 significant blood loss, whereas with almost
19 instant closure, you are preventing or
20 minimizing blood loss.

21 Q. If you turn to paragraph 48 of your
22 supplemental declaration.

23 You would agree that the filament 150
24 that is described in the '519 application can

1 comprise multiple filaments. Correct?

2 A. Yes.

3 Q. And you would agree that the '519
4 application describes the filament 150 in the
5 singular being comprised of multiple filaments.
6 Correct?

7 A. Not sure I understood the question.

8 Q. Maybe it will be more helpful to just
9 turn to the '519 application.

10 A. Okay.

11 Q. If you look at paragraph 65, which is
12 on page 17. And the first sentence of
13 paragraph 65 says, "In some embodiments the
14 filament 150 can comprise multiple filaments."
15 Correct?

16 A. Yes.

17 Q. In that statement, it is referring to
18 the filament 150 in the singular. Correct?

19 A. Yes.

20 Q. And that singular component 150 can
21 comprise multiple filaments. Correct?

22 A. Yes.

23 Q. You would agree with me that
24 paragraph 65 of the '519 application defines

1 the reference number 700 as the first end?

2 A. Yes.

3 Q. You would also agree that the '519
4 application defined reference number 702 as the
5 second end of the filament. Correct?

6 A. Yes.

7 Q. It is your opinion that figures 8 and 9
8 of the '519 application contain typographical
9 errors. Is that right?

10 ATTORNEY MILLER: Objection. Vague.

11 A. Yes.

12 BY ATTORNEY BARNES:

13 Q. Do you believe that there are any other
14 errors in the '519 application, besides those
15 alleged errors that you identified in figures 8
16 and 9?

17 A. Not that I recall.

18 Q. How did you determine that figures 8
19 and 9 contained typographical errors?

20 ATTORNEY MILLER: Objection. Vague.

21 And to the extent it calls for privileged
22 information or communications with counsel.

23 A. Based on the written description.

24 BY ATTORNEY BARNES:

1 Q. What about the written description?

2 A. It includes the mechanism of garroting.
3 In other words, the circumferential
4 constricting mechanism and how that occurs with
5 one end and the other end of a filament.

6 Q. Can you identify what portion of the
7 written description you relied on in
8 determining that figures 8 and 9 contain
9 typographical errors?

10 A. I would have to go back through it, but
11 I believe it is in multiple portions of the
12 written description.

13 And, again, I make reference to the
14 garrote closing dynamic.

15 Q. Are you aware that a patentee can seek
16 to correct errors in its patents with the
17 patent office?

18 ATTORNEY MILLER: Objection. Scope.

19 A. I think generally, yes.

20 BY ATTORNEY BARNES:

21 Q. Do you know whether Inari has attempted
22 to correct the alleged error in the '519
23 application or any of the related patents?

24 ATTORNEY MILLER: Objection. Scope.

1 A. I honestly have no idea.

2 BY ATTORNEY BARNES:

3 Q. Is that something you considered in
4 forming your opinions?

5 A. No.

6 Q. If you turn to paragraph 54 of your
7 supplemental declaration.

8 A. Okay.

9 Q. Towards the middle of paragraph 54, you
10 state, "As expressly set forth in the
11 specification, each of those individual
12 filaments 150A and 150B has a first end and a
13 second end."

14 Did I read that right?

15 A. Yes.

16 Q. And you are not quoting any disclosure
17 from the '519 application in that sentence.
18 Correct?

19 A. I am citing the specification, I don't
20 see what particular reference I made here. It
21 talks about the '005. But by reference, the
22 '519 was incorporated. So I think it probably
23 encompasses both.

24 Q. Are you aware at the '519 application

1 never uses the term "individual filaments"?

2 ATTORNEY MILLER: Objection. Vague.

3 A. I would have to review it again.

4 BY ATTORNEY BARNES:

5 Q. If we look up to paragraph 53 of your
6 supplemental declaration, the actual quote from
7 the '519 application that you provide states,
8 "In embodiments in which the filament 150
9 comprises multiple filaments, each of the
10 multiple filaments can have a first end 700 and
11 a second end 702."

12 Did I read that right?

13 A. Yes.

14 Q. That statement doesn't refer to the
15 phrase "individual filaments." Correct?

16 A. That refers to embodiments that include
17 multiple filaments.

18 Q. And this quoted statement in
19 paragraph 53 does not state that each
20 individual filament has a first end 700 and a
21 second end 702. Correct?

22 A. Maybe I misheard that.

23 It says each individual filament has a
24 first end and a second end as follows.

1 Q. So I am specifically looking at the
2 quoted language that is the quote from the '519
3 application.

4 A. Okay.

5 Q. So the quoted language from the '519
6 application does not state that each individual
7 filament has a first end 700 and a second end
8 702. Right?

9 A. It says each of the multiple filaments
10 has a first end and a second end.

11 Q. And it does not refer to each
12 individual filament. Correct?

13 A. It doesn't use that word, but it says
14 "each," which indicates an individual filament.

15 Q. So the '519 application does not
16 expressly say that each individual filament has
17 a first end and a second end. Correct? That
18 is just your interpretation of the patent.
19 Correct?

20 ATTORNEY MILLER: Objection. Vague.
21 Asked and answered.

22 A. I would have to review the precise
23 language to answer that.

24 I wanted to add a sentence to that last

1 answer, which is: In the '519 application, if
2 you look at selected figures, they depict an
3 individual filament, which is part of the
4 specification.

5 BY ATTORNEY BARNES:

6 Q. Would you agree that there are figures
7 that also depict multiple filaments?

8 A. Yes.

9 Q. Would you agree that figures 8 and 9,
10 which are the figures you believe include a
11 typographical error, depict multiple filaments?

12 ATTORNEY MILLER: Objection. Vague.

13 A. Yes.

14 BY ATTORNEY BARNES:

15 Q. I am going to hand you what has been
16 marked as Exhibit 1011 in this IPR.

17 (Handing document to the witness.)

18 Q. Do you recognize Exhibit 1011?

19 A. It appears to be the Garrison patent.

20 Q. Is Exhibit 1011 one of the prior art
21 references that are relied on in the petition?

22 A. That is my understanding, yes.

23 Q. Did you review the Garrison patent in
24 preparing the opinions that you set forth in

1 your supplemental declaration?

2 A. I had reviewed the Garrison patent in
3 my original declaration earlier in the year and
4 didn't rereview in detail the Garrison patent
5 as I found it largely irrelevant.

6 Q. Why did you find the Garrison patent
7 largely irrelevant?

8 A. The Garrison patent is very specific to
9 a cerebrovascular, what is called a
10 transcarotid procedure -- transcarotid
11 procedure -- which is in the neck area of the
12 body, that utilizes very small devices and
13 catheters because of the small vasculature in
14 the brain.

15 Q. Why does that make Garrison largely
16 irrelevant?

17 A. Because of its specificity as opposed
18 to generality for hemostasis.

19 It is very specific to intracerebral
20 neurovascular interventional devices, which are
21 typically less than 6 French in size and very
22 specific to navigating a very short length of
23 vessel between the carotid insertion point and
24 the location of the thrombus in the

1 mid-cerebral artery.

2 Q. So is it your opinion that prior art
3 references that relate to treating
4 intravascular blood clots are irrelevant to the
5 '005 patent?

6 ATTORNEY MILLER: Objection. Misstates
7 testimony. Vague.

8 A. I wouldn't say "completely irrelevant."
9 But they are very limiting. And using Garrison
10 in particular, he provides no description of
11 any inventive aspect related to a hemostasis
12 valve.

13 BY ATTORNEY BARNES:

14 Q. When was the last time that you
15 reviewed Garrison?

16 A. I reviewed it very briefly, probably
17 last week, not in detail, as I mentioned
18 earlier. The detailed review I did prior to
19 June of this year.

20 Q. The first page of the Garrison
21 reference lists two individuals as inventors.
22 Correct?

23 A. Yes.

24 Q. Are you personally familiar with either

1 of those individuals?

2 A. I don't know Mr. Garrison. I know a
3 person with the name Tony Chow, but I am not
4 sure of the spelling and I can't imagine it is
5 the same person because he was a finance
6 person.

7 Q. Understood.

8 The Garrison reference identifies Silk
9 Road Medical, Inc., as the applicant. Correct?

10 A. Yes.

11 Q. Are you familiar with that company?

12 A. Only third-hand references. No
13 specifics, no details.

14 Q. Can you turn to figure 34 of the
15 Garrison reference.

16 A. Okay.

17 Q. Do you have an understanding of what is
18 shown in figure 34 of Garrison?

19 A. Yes.

20 Q. What is that understanding?

21 A. He has his version of an aspiration
22 system on the bottom connected via tubing or
23 small catheter inserted into the CCA, which is
24 the common carotid artery, then advanced into

1 the internal carotid artery with a small
2 catheter inside the catheter then advanced to
3 the MCA, the mid-cerebral artery.

4 Q. Do you agree that the system shown in
5 figure 34 of Garrison is a vacuum aspiration
6 system?

7 A. That is my understanding, yes.

8 Q. Do you agree that the system in
9 figure 34 of Garrison includes an aspiration
10 source?

11 A. Yes.

12 Q. The aspiration source in figure 34 is
13 identified by reference number 3430. Correct?

14 A. Yes.

15 Q. Do you agree that the aspiration source
16 in figure 34 could be an aspiration pump?

17 A. I think it wouldn't commonly be but it
18 could be.

19 Q. Do you agree that the aspiration source
20 in figure 34 could be a syringe?

21 A. Yes.

22 Q. Do you agree that the aspiration source
23 in figure 34 could be a locking syringe?

24 A. Yes.

1 Q. Do you agree that the aspiration source
2 in figure 34 could be a centrifugal aspiration
3 pump?

4 A. Yes.

5 Q. Do you agree that the aspiration source
6 in figure 34 could be a peristaltic aspiration
7 pump?

8 A. Yes.

9 But I want to modify my answer. I am
10 saying could be. In terms of physically
11 possible, yes. Practically useable, unlikely,
12 because of the very restrictive anatomy in the
13 neck area of a patient.

14 This is something that I think I show
15 in one of my declarations that a POSITA needs
16 to have some exposure to the use of medical
17 devices in procedures like this to understand
18 both the requirements and the limitations
19 associated with anatomy and pathology.

20 Q. So the restrictive anatomy in the neck
21 area of a patient would make it difficult to
22 use a peristaltic pump as the aspiration
23 source? Am I understand your testimony
24 correctly?

1 A. Yes. I think it would make it
2 difficult to use almost any energized pump
3 because of the restrictive space.

4 Q. What about the restrictive space makes
5 it difficult to use an aspiration pump?

6 A. The doc has to get his arms -- or his
7 hands, sorry, his gloved hands into the neck
8 procedure to navigate, advance, withdraw,
9 advance, withdraw, aspirate, close, and so
10 forth.

11 If you have got a significantly sized
12 apparatus in that same space, it would
13 require -- it would be positioned further away,
14 which would mean a longer length of tubing,
15 which complicates the geometry of treating the
16 patient.

17 There is just not enough physical space
18 in that area of the body.

19 Q. Are you aware of any prior art
20 aspiration systems that used aspiration pumps
21 to treat neurovascular blood clots?

22 A. I am not familiar with them, no.

23 Q. Are you familiar with the Penumbra
24 aspiration pump?

1 A. As commented earlier, I know of it. I
2 haven't looked at it in great detail.

3 Q. And I believe earlier you testified
4 that you are not familiar with the AngioVac
5 aspiration pump. Is that correct?

6 A. Correct.

7 Q. So you don't know whether either of
8 those pumps had been used in procedures to
9 treat neurovascular clots. Is that right?

10 A. I don't know that they have or have not
11 been used. But just to augment what I said
12 earlier, many of these patients have a mask on,
13 an oxygen mask or oxygen tubing. In addition
14 to everything else going on, they may have an
15 IV tube. So there is a lot going on in this
16 area, this anatomical area.

17 Q. How close does the aspiration source in
18 Garrison's system need to be to, for example,
19 the check valve 3419?

20 A. I don't have an exact number but
21 relatively close so that it could be
22 controlled.

23 Q. Can you give a ballpark distance?

24 A. Inches.

1 Q. Would a foot be too far away?

2 A. That is right on the edge of
3 practicality, I would say.

4 Q. So looking again at figure 34, do you
5 agree that figure 34 discloses an aspiration
6 catheter that is identified by reference number
7 2030?

8 A. Yes.

9 Q. Do you agree that in figure 34, the
10 aspiration catheter 2030 is fluidly coupled to
11 the aspiration source by a connector?

12 A. It appears to be.

13 Q. Did you agree that in figure 34, is a
14 flow path that runs from the aspiration source
15 to the aspiration catheter 2030?

16 A. Yes.

17 Q. Do you agree that that flow path would
18 run through the tubing that is identified as
19 reference number 2045?

20 A. In this figure, yes.

21 Q. Would you agree that that flow path
22 would extend through the proximal adaptor
23 housing that is shown in figure 34?

24 A. Which citation is that?

1 Q. Let me actually have you turn to
2 paragraph 91 of your declaration --
3 supplemental declaration. This is on page 55.

4 A. Okay.

5 Q. On page 55 of your supplemental
6 declaration, you reproduced an annotated
7 version of figure 34 of Garrison that was
8 included in the petition. Correct?

9 A. Yes.

10 Q. And in this annotated version of
11 figure 34, there is a portion of the system
12 circled in yellow.

13 Do you see that?

14 A. Yes.

15 Q. Do you agree that the portion of
16 Garrison's system circled in yellow includes a
17 hemostasis valve within a proximal adapter?

18 A. Yes. To use his written description,
19 that would be either a Tuohy-Borst or a passive
20 seal valve.

21 Q. So going back to my prior question,
22 with reference to that flow path that extends
23 from the aspiration source to the aspiration
24 catheter 2030, would you agree with me that

1 that flow path extends through the housing
2 identified in the yellow circle in this
3 annotated version of the figure?

4 A. I don't believe that is a housing, at
5 least not in the same terminology that is used
6 in '005.

7 Q. Why don't you believe that is a
8 housing?

9 A. It doesn't appear to be any integration
10 of any components, other than, as you pointed
11 out, a flow path and a connector.

12 Q. Did you present any opinions on whether
13 that portion of Garrison's figure 34 is a
14 housing in your supplemental declaration?

15 A. I have to read through paragraph 92
16 because I think I make reference to housing.
17 It is, frankly, confusing because it is labeled
18 as housing and, yet, it is not depicted as what
19 I would describe as a housing.

20 Q. So do you not understand figure 34 of
21 Garrison?

22 A. As I said much earlier, it is a
23 confusing figure.

24 Q. Were there any other portions of

1 Garrison that you could not understand when you
2 reviewed it?

3 ATTORNEY MILLER: Objection. Vague.
4 Misstates testimony.

5 A. Not that I recall.

6 BY ATTORNEY BARNES:

7 Q. So just figure 34?

8 A. In particular, yes.

9 Q. Would you agree that Garrison's
10 figure 34 includes an on-off control valve that
11 is identified as reference number 3325?

12 A. Yes, that is what is depicted.

13 Q. And you would agree that Garrison
14 describes that the valve 3325 can control
15 whether aspiration is applied to the catheter
16 2030. Correct?

17 A. Yes.

18 Q. Do you agree that the system in
19 figure 34 includes a filter that is identified
20 by reference number 3418?

21 A. That appears to be the case, yes.

22 Q. Do you have an understanding of how
23 Garrison's filter shown in figure 34 would
24 work?

1 ATTORNEY MILLER: Objection. Vague.

2 Scope.

3 A. Part of the confusion with the
4 figure is not showing the collection and
5 retention of aspirated material.

6 BY ATTORNEY BARNES:

7 Q. Isn't the purpose of the filter to
8 collect the aspirated clot material and prevent
9 it from passing through to the check valve
10 3419?

11 A. The primary purpose is to selectively
12 trap the particulate matter which came from the
13 thrombus, yes.

14 Q. How would it do that?

15 A. As I mentioned earlier, it is a simple
16 passive screening device with opening or pore
17 sizes that freely allow fluid to go through but
18 prevent solid material from going through.

19 Q. Would that screening device be placed
20 within some sort of housing to make up the
21 filter?

22 A. It could be, yes.

23 Q. Would you agree that this filter needs
24 to have openings on either end of its housing

1 so that blood can flow through it?

2 A. Yes.

3 Q. Do you agree that this filter 3418 in
4 figure 34 is a clot canister?

5 ATTORNEY MILLER: Objection.

6 A. I would have to go to the written
7 description to confirm that.

8 BY ATTORNEY BARNES:

9 Q. What is a clot canister?

10 ATTORNEY MILLER: Objection. Scope.

11 A. As the name connotes, it is a
12 collection chamber or canister for thrombus
13 material.

14 BY ATTORNEY BARNES:

15 Q. So if aspirated thrombus material is
16 collected by the filter 3418 in figure 34,
17 wouldn't that filter be a clot canister under
18 the definition you just gave?

19 A. Well, hence my earlier comment about
20 the confusion because it is not clear where the
21 unfiltered material, in other words, the fluid
22 material goes.

23 Q. Why is that unclear in your view?

24 A. There is no depiction of a collection

1 chamber of any sort. It looks like -- it
2 appears to simply be a standalone filter in the
3 fluid path.

4 Q. Could the aspiration source 3430
5 include a collection chamber?

6 ATTORNEY MILLER: Objection. Scope.
7 Calls for speculation.

8 A. I think terminology is important.

9 The fact that is an aspiration source
10 means it is a pressure source. It is not a
11 collection chamber. Collection chamber would
12 be an incremental or separate component of a
13 package. But by definition, the aspiration
14 source is a syringe or a pump that creates the
15 negative pressure aspiration. In and of
16 itself, it doesn't collect material.

17 BY ATTORNEY BARNES:

18 Q. So starting with a syringe, if the
19 aspiration source is a syringe, doesn't a
20 syringe have a vacuum chamber that would
21 potentially collect the aspirated blood within
22 it?

23 ATTORNEY MILLER: Objection. Vague.
24 Calls for speculation and legal conclusion.

1 A. I guess, again, terminology. I am
2 trying to imagine the steps in a procedure of
3 using the syringe both as the pressure source
4 and the collection canister and then changing
5 it out regularly to enable regeneration of
6 aspiration pressure.

7 BY ATTORNEY BARNES:

8 Q. Well, let's look at figure 9C of the
9 '005 patent.

10 A. Sorry, figure what?

11 Q. Figures 9A through 9C.

12 A. Okay.

13 Q. So in these figures, 9A through 9C,
14 isn't the aspirated blood and clot material
15 being collected within the syringe that is also
16 the pressure source?

17 A. I will go back to my statement about
18 terminology.

19 It is not a discreet collection
20 chamber. It is a pressure source that is also
21 used in this particular embodiment to collect
22 the material. But it is not a separate
23 component used for the collection of that
24 material.

1 Q. Right. So if your aspiration source is
2 a syringe, you don't necessarily need a
3 separate blood collection chamber to collect
4 the aspirated blood. Correct?

5 A. It encumbers the procedure about
6 returning blood to the patient by not have a
7 discrete collection chamber. For small
8 volumes, your statement is correct. For larger
9 volumes, it would be cumbersome.

10 And I think that is the rationale in
11 the '005 for having the various embodiments.

12 Q. Are you aware of any electrical
13 aspiration pumps that included a blood
14 collection canister as part of the pump
15 assembly?

16 ATTORNEY MILLER: Objection. Vague.
17 Calls for speculation.

18 ATTORNEY BARNES: Let me rephrase the
19 question, actually.

20 BY ATTORNEY BARNES:

21 Q. Are you aware of any electric
22 aspiration pumps that were known or available
23 prior to 2018 that included a blood collection
24 canister as part of the pump assembly?

1 ATTORNEY MILLER: Objection. Scope.

2 A. It wasn't part of my assessment,
3 frankly.

4 BY ATTORNEY BARNES:

5 Q. So do you not know whether any such
6 pumps were known at the time?

7 ATTORNEY MILLER: Objection. Asked and
8 answered. Scope.

9 A. If proposed, I would do some homework
10 to discover.

11 ATTORNEY MILLER: Do you want to take
12 lunch soon to avoid food getting cold?

13 ATTORNEY BARNES: Yes, we can take a
14 break for lunch. Off the record.

15 THE VIDEOGRAPHER: The time is 12:26.
16 We are off the record.

17 (Recess taken at 12:26 p.m.)

18 (Recess ended at 1:02 p.m.)

19 THE VIDEOGRAPHER: The time is 1:02.
20 We are back on the record.

21 BY ATTORNEY BARNES:

22 Q. Welcome back, Dr. Zalesky. Did you
23 speak to anybody about the substance of your
24 testimony during the break?

1 A. No.

2 Q. Did you review any documents during the
3 break?

4 A. No.

5 Q. If you could just look again back at
6 figure 34 of Garrison. And I believe earlier
7 you testified that in figure 34, there would be
8 a flow path that extends from the aspiration
9 source to the proximal end of the aspiration
10 catheter. Is that correct?

11 ATTORNEY MILLER: Objection.

12 A. Yes.

13 BY ATTORNEY BARNES:

14 Q. In operation, would you agree that
15 Garrison's aspiration source would generate
16 vacuum pressure along that flow path?

17 ATTORNEY MILLER: Objection. Vague.
18 Calls for speculation.

19 A. In general, yes.

20 BY ATTORNEY BARNES:

21 Q. And you would agree that Garrison
22 discloses a method in which the aspiration is
23 built up while the valve 3325 is in the closed
24 position. Correct?

1 ATTORNEY MILLER: Same objection.

2 A. I didn't address that specific aspect
3 of Garrison, but it appears to be the case.

4 BY ATTORNEY BARNES:

5 Q. When the aspiration is built up while
6 the valve 3325 is in the closed position, would
7 you agree that vacuum pressure would be
8 generated in each of the components that are
9 distal to the valve, including the filter 3418
10 and the check valve 3419?

11 ATTORNEY MILLER: Objection. Vague.
12 Calls for speculation.

13 A. That appears to be the case.

14 ATTORNEY BARNES: I have no further
15 questions. Pass the witness.

16 EXAMINATION

17 BY ATTORNEY MILLER:

18 Q. Dr. Zalesky, if you turn to page 35 of
19 your supplemental declaration. That is
20 paragraph 65.

21 A. Okay.

22 Q. You were asked earlier about whether
23 the testimony here is referring to the '012
24 patent or the '005 patent.

1 Do you recall those questions?

2 A. I do.

3 Q. It is correct that you submitted this
4 supplemental declaration in the matter
5 involving the '005 patent. Correct?

6 A. Correct.

7 Q. And this testimony contained in
8 paragraph 65 and 67 pertains to the '005
9 patent. Correct?

10 A. Yes.

11 Q. And is the testimony in paragraph 65
12 accurate?

13 A. It should speak to the '005 patent.

14 Q. And same with paragraph 67?

15 A. Yes.

16 Q. Can you turn to page 54 of your
17 supplemental declaration, starting on
18 paragraph 91.

19 A. Okay.

20 Q. You were asked questions by counsel
21 about paragraphs 91 through 93 related to the
22 housing. Can you take a moment and read those
23 paragraphs for me.

24 (Pause.)

1 A. Okay.

2 Q. And can you read the first sentence of
3 paragraph 92 out loud?

4 A. "A POSITA would not have considered
5 Garrison's valve 3325 to be in the flow path
6 extending through the housing as recited in
7 claims 1 and 10."

8 Do you want me to go on?

9 Q. No. That is okay.

10 Is that your testimony that you are
11 submitting in connection with this IPR?

12 A. Yes.

13 Q. Is that testimony accurate?

14 A. Yes.

15 Q. If we turn to the patent, the '005
16 patent, in column 6, you were asked about
17 lines, I believe, 48 to 49 in part.

18 A. I have lost my copy of the '005.

19 Q. I might have stolen it.

20 A. I think you took it. Do you have your
21 own over there?

22 Q. No.

23 Oh, it is right here.

24 A. Sorry. I was looking at the wrong

1 number. Okay. There you go.

2 So redirect me.

3 Q. Column 6, and part of the way down, the
4 second-to-last paragraph, it says, on lines 48
5 to 49, "In some embodiments, one or more of the
6 components can be permanently connected and/or
7 integrally formed." Correct?

8 A. Correct.

9 Q. This sentence doesn't specify or limit
10 the components here to the tubing
11 subsystem 120. Correct?

12 A. That's correct.

13 Q. And when forming your opinions with
14 respect to whether the on-off switch could be
15 included in the housing, did you rely on, in
16 part, lines 48 to 49?

17 A. I did, as I tried to explain earlier,
18 yes.

19 Q. In considering figure 34 of Garrison,
20 in paragraphs 91 through 93, did you -- you
21 interpreted Garrison based on your
22 understanding of figure 34 and the
23 specification of Garrison. Correct?

24 ATTORNEY BARNES: Objection. Leading.

1 A. Yes.

2 BY ATTORNEY MILLER:

3 Q. And based on that understanding, you
4 believe that paragraphs 91 through 93 are
5 accurate?

6 A. I do.

7 Q. Is it your view that claims 1 and 10 of
8 the '005 patent require that the on-off control
9 be integrated into the housing?

10 ATTORNEY BARNES: Objection. Leading.

11 A. Let me just look at claim 1 one more
12 time here.

13 (Pause.)

14 A. Sorry. Repeat that, please.

15 Regarding claim 1 and 10?

16 BY ATTORNEY MILLER:

17 Q. Yes. That claim 1 requires the on-off
18 control to be in the flow path extending
19 through the housing. Correct?

20 A. Yes. That is exactly how it reads,
21 yes.

22 Q. Which, in your opinion, requires that
23 the on-off control be in the housing, correct,
24 or integrated into it?

1 ATTORNEY BARNES: Objection. Leading.

2 A. Via the interpretation of housing, yes,
3 that is what it says.

4 BY ATTORNEY MILLER:

5 Q. Earlier, you were asked about Schaffer
6 and the filament. Did you provide opinions
7 regarding why a person of ordinary skill in the
8 art would not have substituted the valve in
9 Garrison with Schaffer?

10 ATTORNEY BARNES: Objection. Beyond
11 the scope of cross.

12 A. Yes. I presented more than one
13 argument, one of which is lack of motivation
14 because of the specification feature claims in
15 the Schaffer patent and invention. Secondly,
16 the principal of operation, the mechanism of
17 closure are dramatically different between
18 Schaffer and the '012. And then, thirdly, the
19 unlikely ability to actually design and
20 manufacture using the Schaffer configuration
21 with a flexible filament.

22 BY ATTORNEY MILLER:

23 Q. You were asked about the independent
24 actuators. Would a person of ordinary skill in

1 the art have expected a hemostasis valve with
2 independent actuators and a string from Hartley
3 to have worked efficiently for sealing in a
4 hemostasis valve?

5 ATTORNEY BARNES: Objection. Beyond
6 the scope of cross.

7 A. As a POSITA, I really struggled with
8 how to enable that configuration because the
9 inherent character of a filament or string, its
10 flexibility makes it uncontrollable in open
11 space, which the Schaffer configuration
12 requires, hence the rigidity of the structures
13 in the Schaffer device.

14 BY ATTORNEY MILLER:

15 Q. You mentioned open space. I believe
16 you talked earlier about the necessary size or
17 placement of the valve and the pressure source.

18 What about the space is important here?

19 A. The fact that, with a filament in the
20 Schaffer configuration, you have no geometric
21 or location control over that filament. And so
22 it is not at all clear how you do a couple
23 things, including inserting the seal element
24 and how to control in both the constrained and

1 the flexed position of a flexible string or
2 filament.

3 Q. Why is it important to have an
4 effective seal on these devices?

5 A. Well, hemostasis is what this is all
6 about. So you are trying to prevent the escape
7 of a fluid, and that requires a very effective
8 seal.

9 Q. What could happen in a procedure if
10 that escape happened?

11 A. Significant blood loss, complications
12 to the patient.

13 Q. Could the patient die?

14 A. That is particularly applicable to
15 places like cerebral and neurovascular
16 applications and cardiac/coronary applications
17 where indeed some acute event like that could
18 be life-threatening, yes.

19 Q. How about with respect to Garrison's
20 disclosures? Is that applicable there?

21 A. Yes. That is why I mentioned the
22 neurovascular, because he is very specific to
23 that particular intended use.

24 Q. So if the wrong valve was put in -- or

1 an ineffective valve was put into Garrison's
2 disclosure or its catheter, could that result
3 in death?

4 A. It could certainly result in brain
5 damage, which, if significant enough, could be
6 life or death.

7 ATTORNEY MILLER: No furthers question.

8 ATTORNEY BARNES: I have a few
9 questions for you, Dr. Zalesky.

10 CONTINUED EXAMINATION

11 BY ATTORNEY BARNES:

12 Q. First, did you discuss any of the
13 questions Mr. Miller just asked you before he
14 asked you them?

15 A. No.

16 ATTORNEY MILLER: Objection to the
17 extent that calls for privilege.

18 A. Same answer, though.

19 BY ATTORNEY BARNES:

20 Q. The '005 patent and the '519
21 application don't say anything about how to
22 assemble the hemostasis valve that has the
23 filament. Correct?

24 A. I would have to review again, but I

1 don't recall any assembly process detail.

2 Q. Would a person of skill in the art have
3 had no idea how to assemble the valve that is
4 described in the '519 application?

5 A. I think a POSITA could look carefully
6 at the drawings and come up with an assembly
7 that would provide the features described in
8 the spec.

9 Q. How difficult would it have been for a
10 POSITA to do that?

11 A. Not trivial, but not impossible.

12 Q. Again, the '519 application itself
13 doesn't provide any guidance to the POSITA on
14 how to go about doing that. Right?

15 ATTORNEY MILLER: Objection. Vague.

16 A. As I said, I don't recall any
17 delineated fabrication or assembly methodology.

18 BY ATTORNEY BARNES:

19 Q. How does the '519 --

20 ATTORNEY MILLER: Let me rephrase.

21 BY ATTORNEY BARNES:

22 Q. How does the hemostasis valve that is
23 described in the '519 application control the
24 filament in its flexed and unflexed state?

1 A. It has a constrained internal geometry
2 that provides that garrote effect that we
3 talked about.

4 Q. When you say "constrained internal
5 geometry," what are you referring to?

6 A. The arrangement of the actuators
7 orthogonal to the seal element internally
8 assures a very controlled alignment.

9 Q. Mr. Miller asked you about Schaffer's
10 valve. Schaffer's valve also has two actuators
11 arranged orthogonally to the seal element.
12 Right?

13 A. It does, yes.

14 Q. So that would allow you to control the
15 constraint of a filament that was attached to
16 those orthogonal actuators. Right?

17 A. Only if there is significant
18 modifications to the Schaffer configuration.
19 He is very clear that rigid materials are
20 necessary for his mechanism of action, which is
21 not a garrote mechanism; it is an opposing
22 pinching action.

23 So the geometry and the materials and
24 the arrangement of those would have to be

1 significantly different.

2 Q. If you had an arrangement where you had
3 a filament going from one actuator that is
4 orthogonal to the tubular member to the other,
5 just like you have in the '519 application,
6 wouldn't that allow you to control how the
7 filament acts?

8 ATTORNEY MILLER: Objection. Vague.

9 A. Not it and of itself. You would need
10 an extra component or components to enable
11 that.

12 BY ATTORNEY MILLER:

13 Q. What extra components would be
14 necessary?

15 A. The configuration of the internal
16 surface, the bore used for the filament, and
17 related aspects.

18 Q. In the '519 application, what are the
19 aspects of the filament that are necessary to
20 provide control?

21 A. So it is the geometry of the entrance
22 and exit of the filament in the actuating
23 elements. The geometry and the material and
24 the assembly.

1 Q. Can you -- you have the '519
2 application in front of you.

3 Can you identify specifically where --
4 let's start with the geometry -- where the
5 geometry that is required to provide control is
6 disclosed in the '519 application?

7 ATTORNEY MILLER: Objection. Outside
8 the scope of redirect.

9 A. If you look at figure 5 or figure 4,
10 the filament has really minimal degrees of
11 freedom of lateral movement. I am trying to
12 see -- yes, figure 3, I guess, is better.

13 So compare figure 3 and figure 4 where
14 there is no -- in each case, because of the
15 orientation, there is no vertical displacement
16 of the filament. It remains orthogonal because
17 of its configuration with the actuators. And
18 there is sort of a fitted tubule on the
19 proximal -- on the inner aspect of the actuator
20 spring, if you see, through which the filament
21 is threaded.

22 So it is constrained around the seal
23 element.

24 BY ATTORNEY BARNES:

1 Q. And that would be the case --

2 ATTORNEY BARNES: Let me rephrase.

3 BY ATTORNEY BARNES:

4 Q. And that is the case because the two
5 actuator buttons are located on opposing sides
6 of the tubular member orthogonally. Correct?

7 A. They are directly opposing, correct.

8 Q. And in your prior answer, I believe you
9 also referred to the material and assembly of
10 the filament.

11 Can you identify the disclosure of the
12 material and assembly in the '519 application
13 that provides control of the filament?

14 A. Well, by assembly, again, referencing
15 those figures, the respective placement of the
16 components and their operation enables that
17 garrote closure effect.

18 Q. What about the materials that you
19 referenced in your prior answer?

20 A. The materials in the actuators, I
21 think, speak for themselves, that they are
22 supposed to be non-compliant structures that
23 can accommodate spring loading and the ability
24 for a biasing option.

1 But most importantly is the filament
2 itself. Its flexibility and its other
3 properties are what provide the garrote closing
4 effect.

5 Q. So as long as the filament material is
6 flexible, it could provide this control and
7 seal that is provided by the '519 hemostasis
8 valve?

9 ATTORNEY MILLER: Objection. Vague.
10 Misstates testimony.

11 A. In the appropriate geometric
12 constraint, which it shows.

13 ATTORNEY BARNES: I have no further
14 questions.

15 ATTORNEY MILLER: All good.

16 THE VIDEOGRAPHER: The time is 1:25.
17 We are off the record.

18 (Whereupon, at 1:25 p.m., the
19 deposition was adjourned.)
20
21
22
23
24

1 CERTIFICATE

2 Commonwealth of Massachusetts

3 Suffolk, ss.

4

5 I, Megan M. Castro, Registered
6 Professional Reporter and Notary Public in and for
7 the Commonwealth of Massachusetts, do hereby
8 certify:

9 That PAUL ZALESKY, Ph.D., the witness
10 whose deposition is hereinbefore set forth, was
11 duly sworn by me and that such deposition is a
12 true record of the testimony given by the said
13 witness.

14 IN WITNESS WHEREOF, I have hereunto set
15 my hand on November 11, 2025.

16 

17 Megan M. Castro
18 Registered Professional Reporter
19 Certified Shorthand Reporter No. 152614

20 My Commission expires:
21 July 22, 2027

22

23

24

1 Case: Imperative Care, Inc. vs Inari Medical Inc.

2 Witness Name: Paul Zalesky, Ph.D.

3 Deposition Date: 11/07/2025

4

5

6 Please be advised that the transcript in the above

7 referenced matter is now complete and ready for signature.

8 The deponent may come to this office to sign the transcript,

9 a copy may be purchased for the witness to review and sign,

10 or the deponent and/or counsel may waive the option of

11 signing. Please advise us of the option selected.

12 Please forward the errata sheet and the original signed

13 signature page to counsel noticing the deposition, noting the

14 applicable time period allowed for such by the governing

15 Rules of Procedure. If you have any questions, please do

16 not hesitate to call our office at (202)-232-0646.

17

18 Sincerely,

19 Digital Evidence Group

20 Copyright 2025 Digital Evidence Group

21 Copying is forbidden, including electronically, absent

22 express written consent.

23

24

25

1 Digital Evidence Group, L.L.C.

2 1730 M Street, NW, Suite 812

3 Washington, D.C. 20036

4 (202) 232-0646

5

6 SIGNATURE PAGE

7 Case: Imperative Care, Inc. vs Inari Medical Inc.

8 Witness Name: Paul Zalesky, Ph.D.

9 Deposition Date: 11/07/2025

10 I do hereby acknowledge that I have read

11 and examined the foregoing pages

12 of the transcript of my deposition and that:

13 (Check appropriate box):

14 () The same is a true, correct and

15 complete transcription of the answers given by

16 me to the questions therein recorded.

17 () Except for the changes noted in the

18 attached Errata Sheet, the same is a true,

19 correct and complete transcription of the

20 answers given by me to the questions therein

21 recorded.

22

23 _____
DATE

WITNESS SIGNATURE

24

25 _____
DATE

NOTARY

1 Errata Sheet

2 NAME OF CASE: Imperative Care, Inc. vs Inari Medical Inc.

3 DATE OF DEPOSITION: 11/07/2025

4 NAME OF WITNESS: Paul Zalesky, Ph.D.

5 Reason Codes: 1. To clarify the record.

6 2. To conform to the facts.

7 3. To correct transcription errors.

8 Page _____ Line _____ Reason _____

9 From _____ to _____

10 Page _____ Line _____ Reason _____

11 From _____ to _____

12 Page _____ Line _____ Reason _____

13 From _____ to _____

14 Page _____ Line _____ Reason _____

15 From _____ to _____

16 Page _____ Line _____ Reason _____

17 From _____ to _____

18 Page _____ Line _____ Reason _____

19 From _____ to _____

20 Page _____ Line _____ Reason _____

21 From _____ to _____

22 Page _____ Line _____ Reason _____

23 From _____ to _____

24 _____

25 PAUL ZALESKY, PH.D.

	77:13	18 46:17	1006 62:3
'	78:4, 8	47:3, 6, 11,	1007A 62:13,
	79:17	21 48:15,	16, 18
'inari'	86:15	24 49:9,	
28:10	87:19	17, 24	1011
	88:13, 20	50:12, 21	110:16, 18,
(	89:5, 8	51:3 52:4	20
(I) 77:23	90:4 91:1,	54:9, 13	1017 92:9,
	3, 13, 22	61:6, 14	11, 16
	92:1 93:3	68:3 75:15	102 46:21
0	95:22	76:12	61:10
005 6:2	96:1, 6, 17,	82:21	
12:15	23 97:13	83:4, 8, 19,	1026 63:5
18:15 19:6	103:5	23 84:3,	64:1, 3
23:3 28:11	107:21	12, 18	1040 63:15,
29:4, 18	112:5	86:1, 14	17
31:18	120:6	87:4, 11,	106 48:17,
32:4, 6, 20	125:9	18, 24	18 49:1, 4,
33:9 34:1,	126:11	88:13, 20	11, 19 50:9
20 35:8	129:24	89:8, 13	61:7, 18
39:14, 24	130:5, 8, 13	90:3 91:1,	77:24
40:7, 23	131:15, 18	2 96:23	79:17
43:14, 18	133:8	97:1, 13	
45:21, 24	137:20	98:12, 20	107 37:4
46:5, 11, 18	012 29:23	131:7	108 46:23
47:3 48:24	30:4	133:7, 11,	50:2, 8, 12,
50:4, 7	31:21, 22,	15, 17	15, 21, 24
51:11, 14	24 32:2, 7,	10 28:13, 18	52:4 53:1
57:11	13, 15, 19	82:21 83:4	77:23
61:6, 23	33:13, 19	103:15, 17	10:04 53:17,
62:6 64:7	34:2	131:7	19
66:8, 17, 23	129:23	133:7, 15	10:19 53:20,
68:4 71:20	134:18	100 79:18	21
72:16		1001 39:18,	11 8:7
73:2, 17	1	20, 23 64:8	61:23
74:4, 15		1002 62:3	62:1, 6, 12,
75:5 76:1,	1 28:13, 14,	63:18	14, 20
12, 16	18 43:15,		

63:1, 14, 20, 23 64:2 76:11, 23 77:13, 20 11, 554, 005 5:23 1102 62:4 1126 64:1 11:16 90:11, 13 11:29 90:14, 15 120 72:2 79:3, 10, 19 80:20 81:3 132:11 124 5:14 124A 77:24 126 46:20 47:13, 15, 20, 24 48:6, 24 49:3, 9, 18, 22 67:8 68:11, 16 70:7, 17 71:4, 8, 14 77:22 128 72:2 12:26 127:15, 17 13 40:4 46:16 85:22	86:14 132 19:8, 10 14 47:7 48:10 50:1 54:7, 9 65:10, 11 85:23 87:12 88:1 140 46:22 54:10, 12, 19 55:3, 7 143 34:4 35:17, 21 144 23:4, 6 15 22:2 26:10 57:9 103:15, 17 150 103:23 104:4, 14, 18, 20 108:8 150A 107:12 150B 107:12 16 58:14 60:3 61:4 16-117519 91:16 168 37:2, 6 17 61:13, 17 91:10 104:12 18 91:11 92:21, 24	19 57:11, 20, 23 58:4, 11 59:9 60:2, 11, 21 1940 57:13 1942 59:9, 12 1:02 127:18, 19 1:25 143:16, 18 2 2 27:6, 7 28:6, 7 20 12:17 22:2 69:1 101:2 2001 18:20, 24 19:2, 9, 12 20:4, 6, 15 21:2, 22 22:6, 16 24:5 2006 23:5 2018 32:2 42:8, 23 43:6 44:5 55:19 99:17, 24 100:3 103:2 126:23	2025 4:8 19:13 23:9 2026 22:21, 23 23:1, 12, 15, 22 24:1, 6 25:6, 15, 23 26:8, 15 2030 118:7, 10, 15 119:24 121:16 2045 118:19 20C 68:24 69:5, 10, 11, 14 70:5, 10 20D 70:15, 16, 24 20E 71:3 210 34:6, 7 24 71:20, 23 72:3, 8 26 39:2, 5 27 79:15 29 79:16 3 3 34:22, 24 76:11, 22 77:13, 20 141:12, 13 30 36:5, 14
---	--	---	---

31 19:12 95:15	33:11 40:4, 6, 15	132:4, 16	107:6, 9 130:16
32 44:19, 24	41:4 43:20 44:11, 13,	49 76:13 78:9, 10, 18	55 88:15 119:3, 5
33 102:8	16, 24 129:18	79:2, 22 80:19	57 95:13, 17
3325 83:9, 20 84:17, 22 88:17 121:11, 14 128:23 129:6 131:5	36 46:15, 17 47:17 65:17, 23 66:6 86:13 97:6	131:17 132:5, 16	58 98:24 99:2, 24 101:11
34 36:5, 14 44:20 85:3 113:14, 18 114:5, 9, 12, 16, 20, 23 115:2, 6 118:4, 5, 9, 13, 23 119:7, 11 120:13, 20 121:7, 10, 19, 23 123:4, 16 128:6, 7 132:19, 22	37 57:10	4A 57:15 4C 57:15	59 102:10
	38 61:5	5	6
	39 91:8, 13	5 27:5, 9 50:5 79:15 141:9	6 76:11, 12, 23 77:2, 8, 13, 20 78:7, 22 79:2, 21 111:21 131:16 132:3
	3D 64:9, 11, 14, 23 65:7 66:8, 13, 16	519 91:19, 23 92:3, 17 93:3, 10, 14 94:10, 12 103:24 104:3, 9, 24 105:3, 8, 14 106:22 107:17, 22, 24 108:7 109:2, 5, 15 110:1 137:20 138:4, 12, 19, 23 140:5, 18 141:1, 6 142:12 143:7	65 29:11, 14, 23 30:4 31:24 32:16 104:11, 13, 24 129:20 130:8, 11
	4		67 33:12, 20 130:8, 14
3418 121:20 123:3, 16 129:9	4 28:14 141:9, 13		6A 83:1
3419 117:19 122:10 129:10	40 12:23 93:1, 2		7
3430 114:13 124:4	43 50:6		7 4:8
35 29:12	45 76:13 78:9, 10, 22 79:1, 21 80:18		700 105:1
	460 57:15 58:17		
	47 50:6		
	48 103:21 131:17	53 108:5, 19 54 82:23	

108:10, 20 109:7	125:11, 13	acts 140:7	additions 24:22
702 105:4 108:11, 21 109:8	9B 67:10, 18 68:19	actual 108:6	address 5:13 73:6 129:2
	9C 66:22 67:2, 10, 19 68:22	actuating 37:8, 17, 20 38:2, 4, 7 140:22	addressed 86:18 101:18
8	125:8, 11, 13	actuator 38:12 102:18 103:6 140:3 141:19 142:5	adjourned 143:19
8 105:7, 15, 18 106:8 110:9	A	actuators 96:3 97:15 98:14, 23 134:24 135:2 139:6, 10, 16 141:17 142:20	advance 116:8, 9
86 35:19	a.m. 4:9 53:19, 20 90:13, 14	advantage 60:19	advanced 113:24 114:2
9	ability 11:8 134:19 142:23	advantages 59:24 60:9	advice 25:20
9 23:9 105:7, 16, 19 106:8 110:9	access 93:6	agree 6:1 33:6 36:22 42:21 43:3 48:23 50:6 64:2 66:16 67:9, 18 68:4, 13, 18, 21 70:5, 9, 16 71:3, 13 72:8, 15 73:1, 17 74:16 76:15 77:4, 12 78:9 79:1,	
91 119:2 130:18, 21 132:20 133:4	accommodate 142:23	acute 136:17	
92 85:10 120:15 131:3	accurate 9:21 11:5 19:21 23:18 35:5 130:12 131:13 133:5	adapter 85:19 119:17	
93 75:21, 24 76:17 130:21 132:20 133:4	accurately 87:7, 12	adaptor 118:22	
9:01 4:9	acquired 11:18 13:19	add 109:24 added 47:8	
9A 66:22 67:2, 9, 18, 22, 23 68:9, 14	action 139:20, 22	addition 117:13	
		additional 31:7 52:22 70:22	

16 85:24	27:9, 16	71:8 72:1	121:15
88:16	85:2	110:19	applies
94:12	analyze	118:12	88:13
103:23	34:10	121:21	101:17
104:3, 23	analyzed	124:2	apply 37:8
105:3	34:15	129:3, 13	58:5 99:5
110:6, 9	analyzing	applicable	approach
114:4, 8,	35:16	136:14, 20	42:5
15, 19, 22	anatomical	applicant	approximately
115:1, 5	117:16	113:9	16:7
118:5, 9,	anatomy	application	area 98:8, 9
13, 17, 21	115:12, 19,	32:2 42:6	111:11
119:15, 24	20	50:22	115:13, 21
121:9, 13,	and/or 27:14	51:23	116:18
18 122:23	80:1 132:6	82:16	117:16
123:3	Angiovac	91:15, 18,	argue 60:4
128:14, 21	42:14	19, 24	argument
129:7	117:4	92:17	134:13
agreed 80:17	annotated	93:4, 14	arm 64:19
Airport 4:11	47:3, 6, 11	94:10, 12	65:9
alignment	48:10	103:24	arms 63:8
139:8	49:24 51:2	104:4, 9, 24	116:6
all-inclusive	54:9	105:4, 8, 14	arranged
74:13 75:2	61:14, 17,	106:23	55:1
80:15	22 62:1	107:17, 24	139:11
alleged	86:1 87:3,	108:7	arrangement
85:14	11 119:6,	109:3, 6, 15	58:4 60:1,
105:15	10 120:3	110:1	10 139:6,
106:22	answers 9:20	137:21	24 140:2
allowing	apparatus	138:4, 12,	art 17:8,
84:14	60:8	23 140:5,	10, 18, 24
altitude	116:12	18 141:2, 6	18:7
75:17	appears 49:2	142:12	31:17, 19
amend 27:15	62:9 68:1	applications	82:9
analysis		136:16	
		applied	

110:20	45:21	41:18 42:4	24 15:9,
112:2	46:1, 18	assembly	11, 15, 17,
116:19	50:23	86:9	21, 23
134:8	52:3, 14, 17	126:15, 24	17:3, 9, 12,
135:1	55:4, 6, 18	138:1, 6, 17	17, 21, 23
138:2	56:16, 17	140:24	18:3, 5, 10,
arteries	57:1, 15	142:9, 12,	13, 22
46:9	58:3, 17	14	20:16, 24
artery 112:1	60:2 64:20	assessment	21:3, 8, 16,
113:24	67:4, 11	127:2	20, 23
114:1, 3	69:8 73:19	assume 10:10	22:3, 7, 13,
aspect 90:5	80:3 82:14		17, 19
94:5	86:15	assures	24:7, 9, 12,
112:11	95:20	139:8	17, 21, 23
129:2	113:21	atherectomy	25:2, 5, 16,
141:19	114:5, 9,	95:8	21, 24
aspects	12, 15, 16,	attached	26:6, 12,
140:17, 19	19, 22	50:17 61:9	13, 20, 23
aspirate	115:1, 2, 5,	62:17	27:2, 4, 23
116:9	6, 22	139:15	28:1, 19
aspirated	116:5, 20,	attempted	29:1, 6, 10
58:12, 16,	24 117:5,	106:21	30:5, 9, 13,
19 122:5, 8	17 118:5,	attempting	18, 23
123:15	10, 11, 14,	30:19	31:4, 11, 13
124:21	15 119:23	ATTORNEY	32:8, 14, 22
125:14	121:15	4:17, 20	33:5, 21
126:4	124:4, 9,	5:6 7:1, 3,	34:3
aspirating	13, 15, 19	8, 10, 14, 16	36:17, 20
40:8 42:21	125:6	8:19, 21	37:21, 23
aspiration	126:1, 13,	9:2 11:15,	38:16, 17
8:18 40:8	22 128:8,	17 12:6, 8,	40:19, 20
41:1, 7, 8,	9, 15, 22	16, 18, 22,	41:22, 23
17 42:1, 7,	129:5	24 13:5, 7,	42:11, 13,
9, 15, 18	assemble	11, 18	24 43:2, 7,
43:4 44:17	137:22	14:9, 11,	10, 21
	138:3	16, 18, 22,	44:2, 6, 8,
	assemblies		14, 15
			45:1, 9

49:5, 7, 12, 15, 20, 23 50:16, 19 51:6, 8, 17, 20 52:6 53:11, 15, 23 55:8, 13, 20, 23 56:8, 14, 19, 24 57:4, 7 58:6, 10, 22 59:3 60:12, 18, 22 61:3 63:6, 12 65:2, 5 66:1, 5, 10, 12 67:13, 17 69:6, 9, 12, 13 71:16, 19 73:23 74:3, 20 75:3, 13, 20 76:20 77:7, 11 78:14, 21, 23, 24 79:5, 8, 11, 14 80:4, 16, 21, 24 81:4, 8, 20, 24 82:5, 8 83:11, 15 84:1, 2 85:6, 9 87:9, 10,	21, 23 89:9, 12, 19 90:1, 6, 9, 10, 17 91:4, 7 93:11, 12, 17, 22 97:4, 11 99:13, 14, 18, 20 100:10, 14, 17, 22 101:3, 10 102:2, 7 103:8, 12 105:10, 12, 20, 24 106:18, 20, 24 107:2 108:2, 4 109:20 110:5, 12, 14 112:6, 13 121:3, 6 122:1, 6 123:5, 8, 10, 14 124:6, 17, 23 125:7 126:16, 18, 20 127:1, 4, 7, 11, 13, 21 128:11, 13, 17, 20 129:1, 4, 11, 14, 17 132:24 133:2, 10,	16 134:1, 4, 10, 22 135:5, 14 137:7, 8, 11, 16, 19 138:15, 18, 20, 21 140:8, 12 141:7, 24 142:2, 3 143:9, 13, 15 augment 117:11 August 6:14, 17 7:17 9:6 11:11 12:10 13:1, 10 14:5, 14, 21 15:3, 13 avoid 127:12 aware 7:5 8:20 20:3 23:24 35:15 42:19 106:15 107:24 116:19 126:12, 21 axial 65:8 86:8 88:7 axial- configured 94:2	B back 5:10 21:24 32:1 40:3 43:14 44:11 53:22, 24 54:7 65:10 74:1, 23 79:21 85:22 88:15 90:16, 18 106:10 119:21 125:17 127:20, 22 128:5 back-and-forth 20:22 background 33:4 balloons 95:9 ballpark 117:23 barbed 52:10, 16, 20 53:8 Barnes 4:17 5:6 7:3, 10, 16 8:21 11:17 12:6, 8, 18, 24 13:7, 18
---	--	---	---

14:11, 18, 24 15:11, 17, 23 17:9, 17, 23 18:5, 13, 22 20:24 21:8, 20 22:3, 13, 19 24:9, 17, 23 25:5, 21 26:6, 12, 13, 23 27:4 28:1 29:1, 10 30:9, 18 31:4, 13 32:14 33:5 34:3 36:20 37:23 38:16, 17 40:19, 20 41:22, 23 42:13 43:2, 10 44:2, 8, 14, 15 45:9 49:7, 15, 23 50:19 51:8, 20 53:11, 15, 23 55:13, 23 56:14, 24 57:7 58:10 59:3 60:18 61:3 63:12 65:5 66:5, 12 67:17 69:9, 12, 13	71:19 74:3 75:3, 20 77:11 78:21, 23, 24 79:8, 14 80:16, 24 81:8, 24 82:8 83:15 84:1, 2 85:9 87:9, 10, 23 89:12 90:1, 6, 10, 17 91:7 93:11, 12, 22 97:11 99:13, 14, 20 100:14, 22 101:10 102:7 103:12 105:12, 24 106:20 107:2 108:4 110:5, 14 112:13 121:6 122:6 123:8, 14 124:17 125:7 126:18, 20 127:4, 13, 21 128:13, 20 129:4, 14 132:24 133:10	134:1, 10 135:5 137:8, 11, 19 138:18, 21 141:24 142:2, 3 143:13 based 21:10 27:15 69:21 105:23 132:21 133:3 beginning 34:23 35:21 78:22 behalf 4:18, 21 5:17 believed 19:19 23:16 believes 30:21 beneficial 93:5 benefit 44:9 100:23 103:13 benefits 40:10 41:2, 11, 14 43:19 44:1, 4 bias 102:17	103:4 biassing 96:11, 13 98:17 142:24 billed 12:14, 20 billing 12:4, 9 bit 40:2 bites 38:20 blades 38:11 blood 8:17 40:9, 23 42:9, 15, 17, 22 43:4 46:2, 4, 10, 12 58:12, 16, 19 59:23 60:16 61:1, 8 102:12 103:18, 20 112:4 116:21 123:1 124:21 125:14 126:3, 4, 6, 13, 23 136:11 blue 47:8 87:14 88:1 board 35:23
--	---	--	--

37:7, 24	Brian 4:17	124:7, 24	113:24
board's 35:7	briefly 6:20	126:17	114:1
36:12, 23	14:23 17:7	128:18	case 7:19,
37:16	35:11, 13	129:12	20, 23, 24
Bob 4:6	112:16	137:17	8:1, 9, 17,
body 50:18	broader	canister	22 19:4
101:20	78:16	57:13, 19,	23:3 49:2
111:12	Broadly	23 58:13,	68:19, 22
116:18	39:15	21 59:10,	121:21
bore 100:16	built 128:23	17, 20	129:3, 13
102:24	129:5	60:1, 10	141:14
140:16	bump 116:24	61:2	142:1, 4
Boston 4:10,	bursts 101:7	123:4, 9,	cases 7:18
11 16:16	buttons	12, 17	Castro 4:7
bottom 27:7	37:10	125:4	catheter
61:4 64:15	142:5	126:14, 24	8:13, 14
92:21		capture	40:17
95:15	c	60:15	42:22 43:5
113:22		cardiac/	46:21
box 54:10	call 94:4	coronary	50:18
brain 111:14	called 8:12	136:16	61:10
137:4	17:13	cardiovascular	62:3, 4
branch 50:8,	28:20	8:10, 11	63:18
11	111:9	Care 4:13,	64:21
break 10:22	calls 17:4	19 5:22	79:18 94:6
11:2 53:13	18:11	6:10 7:13	101:20
54:2, 5	20:17	11:14	102:14
90:8, 20, 23	21:4, 17	12:2, 21	113:23
127:14, 24	22:8 24:13	13:4 14:3	114:2
128:3	25:17 26:1	Care's	118:6, 10,
breakfast	30:6 32:23	15:13, 19	15 119:24
16:19	45:2	carefully	121:15
breaks 10:21	89:10, 19	138:5	128:10
	91:4	carotid	137:2
	105:21	111:23	catheters
			8:16 40:22

99:5	character	78:4, 8	139:19
100:16	135:9		
101:1		citing	client's
102:16, 24	characterizati	107:19	13:15
111:13	on 31:12	claim 43:15,	close 116:9
CCA 113:23	characterizati	18 75:15	117:17, 21
	ons 31:6	83:8, 19, 23	closed
center	check 117:19	84:3, 12, 18	128:23
102:10	122:9	87:18, 24	129:6
centrifugal	129:10	88:13, 20	
55:14	choking	89:8, 13	closer 60:20
115:2	96:21	90:3 91:1	closing
		96:23	93:20
cerebral	choose 65:21	97:1, 13	106:14
100:13	chow 113:3	98:12, 20	143:3
136:15		133:11, 15,	closure
cerebrovascula	circle 120:2	17	103:11, 19
r 111:9	circled	claimed	134:17
challenging	119:12, 16	95:21, 24	142:17
29:17, 23	circular	96:6, 17	clot 8:17
30:4 33:8	94:20 98:2	claims	40:8 42:9,
45:8	circumferentia	28:11, 13,	15, 17 43:4
chamber	l 39:1	18, 24	57:13, 19,
56:13 57:2	96:21	29:3, 18	23 58:12,
123:12	97:17	31:18, 20,	13, 20, 21
124:1, 5,	106:3	23 32:6, 7,	59:1, 4, 8,
11, 20	circumferentia	12 33:24	10, 13, 17,
125:20	lly 97:7	45:20, 24	20 60:1, 10
126:3, 7		46:5, 11	64:22
	citation	82:21 83:4	82:14
chance 6:18	74:24	131:7	122:8
change 12:23	76:10 77:1	133:7	123:4, 9, 17
	118:24	134:14	125:14
changed			
12:4, 5, 10	cite 48:14	clarify 21:9	clots 40:23
24:4 28:3	76:16	69:17	42:22
changing	cited 29:15	clear 123:20	46:2, 4, 10,
125:4	35:2 61:20	135:22	13 101:23

112:4	79:2, 15, 21	compare	79:24
116:21	97:6	141:13	80:9, 10
117:9	131:16	compared	81:2, 3, 12,
Clottriever	132:3	38:11, 19	14, 19 96:5
14:7, 13, 20	combination	42:3 76:11	97:1
15:7	41:16, 24	completely	98:12, 20
Coie 4:21	82:13, 15,	86:20	120:10
cold 127:12	19 83:2	112:8	129:8
collaboration	comment	complex 7:24	132:6, 10
25:7	123:19	94:19	140:10, 13
collaborative	commented	95:4, 11, 12	142:16
20:7	117:1	compliant	composed
collect	commenting	36:8, 15	21:2
59:22	69:20	complicates	composition
122:8	common 45:8	116:15	20:21
124:16, 21	100:3, 4	complications	compressed
125:21	113:24	136:11	96:4
126:3	commonly	component	comprise
collected	43:8	47:12, 15	104:1, 14,
58:24	114:17	50:17	21
123:16	communication	56:12 63:5	comprised
125:15	46:22	80:2 96:24	104:5
collection	51:1, 16	104:20	comprises
41:20	63:18	124:12	108:9
122:4	communications	125:23	comprising
123:12, 24	20:17	140:10	57:13
124:5, 11	21:17 22:8	components	conceivably
125:4, 19,	24:13	39:16	63:11
23 126:3,	25:18 26:1	41:7, 10	101:5
7, 14, 23	32:24	43:17, 23	concentrated
column 50:5	45:3, 5	44:7 51:24	98:8
76:11, 12,	105:22	52:2 60:1,	concern 36:3
22, 23	company	5 62:2	concerns
77:2, 8, 13,	113:11	67:20	5:22
20 78:7, 22		78:19	

conclusion	123:7	35:12	continue
36:13, 23		75:10	27:11
37:17	confusing	107:3	CONTINUED
89:10, 20	84:19, 23	131:4	137:10
91:5	120:17, 23		
124:24	confusion	consistent	continuing
	122:3	68:5 82:7	27:16
conclusions	123:20	constrained	contribute
35:15		84:7	96:11
confidential	conglomerate	135:24	98:21
13:12	59:23 80:8	139:1, 4	
32:23	connected	141:22	control 41:8
	40:17, 22		42:6 46:21
configuration	49:3 56:13	constraint	47:13, 16
38:13 48:9	58:8 63:9	139:15	49:22
62:10 63:8	64:16, 18	143:12	63:21, 24
66:20	68:8 79:24	constricting	64:3
67:19	113:22	37:9 43:24	66:14, 17
82:2, 10	132:6	106:4	67:5, 7
88:11			68:10, 14
89:2, 23	connection	constriction	70:6, 9, 17
90:2 94:19	131:11	39:1 97:18	71:4, 14, 24
95:4	connector	constricts	72:9, 12,
134:20	46:23	97:7	14, 17
135:8, 11,	50:2, 12, 15	construed	73:3, 10, 21
20 139:18	52:11, 16,	62:15	74:7, 19
140:15	20, 24	construing	75:7 76:4,
141:17	53:5, 8	83:23 84:3	6, 19 77:2,
	62:14, 16,		5, 14, 21
configurations	18 81:17	contained	78:12, 20
38:24	118:11	105:19	79:9 81:16
54:21 67:7	120:11	130:7	83:7, 18
79:3 80:19			84:4, 12
81:23	connotes	contends	85:4 88:24
89:22 90:3	86:20	37:7	89:7, 14,
95:9	123:11	content	16, 23
		35:16	96:14
configures	considerations	contents	121:10, 14
49:8	34:9, 11, 16	31:9	133:8, 18,
confirm 27:3	considered		

23 135:21,	33:9 35:3	106:16, 22	22:9
24 138:23	44:17, 21	107:18	24:15, 16
139:14	46:2 47:4,	108:15, 21	25:8, 9, 18,
140:6, 20	9, 13, 17	109:12, 17,	20 26:2, 14
141:5	48:13	19 112:22	28:9 30:9,
142:13	49:1, 4, 11,	113:9	15 31:1
143:6	19 50:2, 9	114:13	33:1 34:19
controllably	54:10	117:5, 6	45:3
58:8	57:16	119:8	105:22
controlled	58:11	121:16	130:20
41:17 42:1	59:10	126:4, 8	counsel's
117:22	61:15, 19,	128:10, 24	21:10
139:8	23 62:4	130:3, 5, 6,	couple
convenience	63:15 64:4	9 132:7, 8,	135:22
44:10	65:4, 14, 19	11, 12, 23	coupled
convenient	66:14, 19,	133:19, 23	57:14 76:4
60:4	21 71:1, 2	137:23	77:18, 23
conventional	72:10, 18	142:6, 7	118:10
40:11, 14	73:4, 22	correctly	court 4:6, 23
41:3 44:4	74:19	27:18	7:22 9:7,
conversations	76:13	28:15	16, 20 13:3
17:15	77:16	29:20	cover 91:1
24:15	78:1, 5, 13	33:16	covers 88:14
30:15, 24	79:4, 10, 19	34:13	create 54:21
copy 92:16	80:20	36:10	55:11
131:18	82:21	37:14	56:6, 17
coronaries	83:4, 5, 10,	39:11	58:2 97:2,
46:7	21 84:5	40:12	8, 13 98:5,
coronary	86:5 88:3,	46:24 76:8	13
100:13	21 89:8, 18	85:20	created
correct 5:19	90:4	115:24	56:22
6:11, 24	91:16, 19	counsel 4:15	creates
18:15 19:6	93:1, 7	10:13, 16	56:12 94:5
29:5 31:21	95:22	16:6, 9	124:14
	98:17	17:15	
	104:1, 6,	20:8, 9, 18	
	15, 18, 21	21:13, 18	
	105:5		

creating	17:2 18:7	108:6	depict
54:14 56:4	19:3,5,18,	111:1,3	67:14,16
97:17,20	20,22 20:1	119:2,3,6	73:10,13
creation	21:12,15	120:14	110:2,7,11
52:23 67:5	23:2,9,17,	129:19	depicted
critical	19 24:5,6,	130:4,17	71:12 85:7
98:15	11,20 25:1	declarations	120:18
102:12	26:19,24	18:14	121:12
cross 134:11	27:1,6,12,	115:15	depicting
135:6	21 28:3,8	declared	69:7
culminated	29:4,12,	19:19	depiction
32:2	15,24	23:16	123:24
cumbersome	30:11,21	deep 45:7,	depictions
126:9	31:10	18 99:8	72:6
	32:18,20	100:8	depicts
	34:5,17,23	101:24	72:11
	35:2,3,10,	defined	deposed 6:9
D	18 37:3	105:4	7:18
damage 137:5	39:3 40:3	defines	deposition
dashed	44:12	104:24	4:12 5:21
84:20,24	45:13,17	defining	6:13,17,
85:3,11	46:16 47:7	69:18	19,23 7:7,
date 4:8	54:8 57:9	definition	17 8:2,5
8:6 27:13	60:3 61:5,	123:18	9:6,22
day 10:21	22 65:11,	124:13	10:14,19
dealing	12 66:7	degrees	11:11,19
73:16	74:9 75:8,	141:10	12:11
death 137:3,	12,22	delineated	13:1,10,20
6	82:18,24	138:17	14:5,15,21
decade	85:23	demonstrate	15:4,14,20
100:4,5	86:23	59:6	16:1,5,18,
decision	88:2,16	denote 85:12	22 17:1,20
35:7,23	91:9 92:6,	dependent	18:2,9
declaration	18,22	29:3	31:7
	95:14 97:3		143:19
	99:1 102:9		
	103:22		
	107:7		

depositions	detail 73:14	94:19, 20	disagrees
7:12	75:18	95:4, 8	31:5, 12
describe	111:4	111:12, 20	discarded
77:5, 14	112:17	115:17	59:2
120:19	117:2	136:4	disclose
describes	138:1	diagram	13:14
48:8 50:7	detailed	50:13, 14	62:7, 14, 20
77:17, 21	112:18	diameter	63:20
96:20	details	98:7	72:16
104:4	74:11	die 136:13	73:2, 19
121:14	113:13	differ 38:6	76:17
describing	determine	difference	78:10
30:24 79:2	105:18	76:2	82:20
80:8	determining	difficult	83:3, 7, 18
description	82:10	102:4	84:22
32:11	106:8	115:21	disclosed
33:24	develop	116:2, 5	34:1 75:5
51:18, 22	24:24	138:9	95:21
55:12	developed	Digital 4:7	141:6
56:10	42:18	digits 96:4	discloses
65:23	device 8:10,	dimensions	74:5 118:5
67:16 68:6	11 14:8	52:9	128:22
73:18	15:7 56:23	directed	disclosure
74:2, 11	76:4, 6	40:7	35:24
75:16 76:1	77:22	direction	107:16
92:2 97:9	78:20	63:5	137:2
105:23	81:16 82:7	directions	142:11
106:1, 7, 12	88:24	97:17	disclosures
112:10	94:5, 7	directly	136:20
119:18	122:16, 19	142:7	discover
123:7	135:13	disagree	127:10
descriptor	devices	36:12, 22	discreet
86:8, 10	14:14, 20	37:16, 22	44:7 70:4
design	39:15		125:19
134:19	41:20		discrete

50:17	78:15	drawings	129:22
126:7	79:6, 12	138:6	132:17
discuss	81:21	drawn 58:20	134:5
26:15	83:12	68:16 71:7	135:16
34:20	89:10	drink 11:7	early 22:1
44:13, 21	92:10	Drive 5:15	easily 96:3
90:19	110:17	driver's 5:4	102:19
137:12	documents	drivers	103:6
discussion	16:24	98:22	East 5:15
44:24	18:9, 17		23:13
dislodge	54:4 90:22	dual 63:7	easy 95:18
101:7	128:2	duly 5:4	96:1, 7, 12, 15
102:6	dots 84:24	DVT 44:17, 21, 23	eating 16:20
displacement	85:4	45:16, 22	edge 118:2
141:15	draft 20:6	dynamic	effect 139:2
distal 64:19	25:6, 14	106:14	142:17
86:4 129:9	drafted		143:4
distance	21:12	E	effective
117:23	drafting		100:21
distinction	20:14	e.g 46:20	136:4, 7
76:3	21:22	76:5	effectively
district	drafts 20:17	earlier	8:13
7:22 8:1	21:14, 17	48:12 56:3	102:19
13:3	25:18, 22	72:5 75:1	103:7
divided 98:9	26:1 32:24	80:17	efficiently
doc 116:6	dramatically	86:18 87:1	135:3
document	38:10, 14,	98:18	effort 20:7
18:19, 21	18, 21	100:12	electric
19:16	134:17	111:3	126:21
22:22	drawbacks	112:18	electrical
39:19	93:7	117:1, 3, 12	126:12
73:24	94:14, 16,	120:22	element
74:21	23 103:1	122:15	
76:21	drawing 76:2	123:19	
		128:6	

68:16	enable 51:14	128:9	106:9, 16
135:23	71:10 96:7	ended 53:20	escape
139:7, 11	125:5	90:14	136:6, 10
141:23	135:8	127:18	escaping
elements	140:10	ends 86:4	20:11
38:12	enables	energized	essentially
41:9, 16, 24	60:15	116:2	60:16
72:2	96:13	energy-driven	93:20
140:23	142:16	56:23	estimate
Eller 17:24	enclosed	engines	12:17
29:17 33:8	94:6 96:21	55:11	evaluate
embodiment	enclosure	ensure 103:5	68:7
70:13, 21	95:12	ensures	evaluated
74:24 75:4	encompass	102:18	35:1
76:17	46:1, 5, 11	enter 58:12	event 136:17
78:2, 3	encompassed	entire 61:1	evidence 4:7
125:21	8:4 82:3	67:16 86:9	34:10, 15
embodiments	90:3	88:7	exact 117:20
36:4	encompasses	entirety	examination
74:12, 14,	61:1	87:20	5:6 129:16
17 75:2	107:23	entrance	137:10
76:3, 6	encumbers	140:21	examples
79:23	126:5	equivalent	43:13
80:14	end 19:9	59:15 67:3	73:19 74:5
104:13	23:4 28:7	errata 6:22	95:3
108:8, 16	34:4 43:15	7:5	excerpted
126:11	61:9	error 106:22	92:14
132:5	85:13, 18	110:11	exclude 77:2
embolism	105:1, 5	errors 6:22	exert 56:7
45:14 99:8	106:5	7:4, 6 20:3	exerting
100:8	107:12, 13	23:24	54:14 56:5
embolisms	108:10, 11,	105:9, 14,	exhibit
101:24	20, 21, 24	15, 19	
employed	109:7, 10,		
33:15	17 122:24		

18:20, 24	exposure	28:20, 21	feature
19:2, 9, 12	115:16	30:6, 7, 14	134:14
20:4, 6, 15	expressly	31:2 32:23	features
21:2, 22	107:10	45:2, 4	36:4 97:19
22:6, 16,	109:16	105:21	102:17
21, 23		137:17	103:4
23:1, 5, 12,	extend 87:19	extra 103:15	138:7
15 24:1, 5,	118:22	140:10, 13	field 39:8,
6 25:6, 15,	extending	extremely	13
23 26:8, 15	46:19 47:9	36:8, 15	figure 46:17
36:3	62:21, 24		47:3, 6, 11,
39:18, 20,	65:18 66:9	F	21 48:10,
23 64:8	85:5, 15, 17		15, 24
92:9, 11, 16	86:16	fabrication	49:9, 17, 24
110:16, 18,	87:13 88:3	138:17	50:12, 21
20	131:6	fact 32:12	51:3 52:4
exhibits	133:18	88:17	54:9, 13
35:2	extends	89:15	57:11, 20,
exit 140:22	47:20	102:22	23 58:4, 11
exiting	49:10, 18	124:9	59:9 60:2,
64:21	63:3 64:24	135:19	11, 21
expected	65:7, 13, 15	factor	61:6, 14, 23
135:1	85:13 86:3	103:14	62:1, 6, 12,
expert 5:17	119:22	fair 10:5,	14, 20
explain	120:1	11 11:2	63:1, 2, 14,
35:13	128:8	18:18	20, 23
47:19	extension	familiar	64:2, 5, 9,
54:24	8:12, 16	42:14, 17,	10, 13, 23
64:13 67:1	extent 13:12	19 112:24	65:7 66:8,
69:4 93:23	17:4, 5, 13,	113:11	13, 16
97:23	14 18:11	116:22, 23	67:22, 23
101:15	20:17, 19	117:4	68:3, 9, 14,
132:17	21:4, 17	family	16, 19, 22
explains	22:8, 10	93:18, 21,	69:10, 11,
93:4	24:13, 14	24	14 70:5,
	25:17		10, 15, 16,
	26:1, 3		24 71:3, 4,

7, 12, 20, 23	18 106:8	6:10 7:12	134:21
72:3, 8, 11	110:2, 6, 9,	11:13	136:1
76:12, 17	10 125:11,	12:1, 21	143:6
84:19, 24	13 142:15	14:2	flow 46:19,
85:3 86:1,	filament	filter 41:19	20 47:8,
14 87:3, 4,	38:10	59:7, 9, 12,	16, 20, 24
5, 7, 11	97:6, 12,	14, 18, 21	48:7
91:2	16, 19	60:10, 14,	49:10, 18
113:14, 18	98:5, 7, 11,	20 81:15	51:1, 16
114:5, 9,	23 103:23	121:19, 23	58:9, 13
12, 16, 20,	104:4, 14,	122:7, 21,	59:16
23 115:2, 6	18 105:5	23 123:3,	62:20, 23
118:4, 5, 9,	106:5	16, 17	63:3, 21
13, 20, 23	108:8, 20,	124:2	64:24
119:7, 11	23 109:7,	129:9	65:6, 12, 18
120:3, 13,	12, 14, 16	filtered	66:9, 14
20, 23	110:3	58:24 59:4	67:4 71:11
121:7, 10,	134:6, 21	finance	83:7, 18
19, 23	135:9, 19,	113:5	84:9, 17, 23
122:4	21 136:2	find 111:6	85:5, 13,
123:4, 16	137:23	fine 13:16	15, 17
125:8, 10	138:24	17:6	86:2, 8, 16
128:6, 7	139:15	finish 10:1,	87:8, 13,
132:19, 22	140:3, 7,	4 11:1	16, 19
141:9, 12,	16, 19, 22	92:22	88:1, 2, 7,
13	141:10, 16,	fitted	10 118:14,
figures 17:7	20 142:10,	141:18	17, 21
36:5, 14, 19	13 143:1, 5	flexed 136:1	119:22
37:1 57:15	filaments	138:24	120:1, 11
59:6 66:22	104:1, 5,	flexibility	123:1
67:2, 9, 18	14, 21	97:22	128:8, 16
68:24	107:12	135:10	131:5
69:5, 17, 21	108:1, 9,	143:2	133:18
71:9	10, 15, 17	flexible	flowing 61:8
72:16, 19	109:9		flows 42:6
73:2, 6, 9,	110:7, 11		Flowtriever
15 85:8	filed 5:22		14:8, 14, 20
105:7, 15,			

15:7	formed 27:13	furtheres 136:19	
fluid 41:19	78:18	137:7	137:1
42:6 46:22	80:1, 2, 7		garrote
57:14	81:2 132:7	G	95:19
63:17	forming 35:9		96:19 97:9
76:4, 6	74:7 75:11	ganged	99:3 100:6
77:19, 21	107:4	54:20, 23	106:14
82:16	132:13	Garrison	139:2, 21
122:17	found 38:1	17:18	142:17
123:21	111:5	82:20	143:3
124:3	frankly 74:1	83:2, 6, 17	garroting
136:7	75:17	84:21	106:2
fluid/gas	84:19	110:19, 23	gastrointestin
36:2	120:17	111:2, 4, 6,	al 46:7
fluidly	127:3	8, 15	
57:13 76:4	freedom	112:9, 15,	gave 123:18
77:17, 22	141:11	20 113:2,	gears 40:2
118:10	freely	8, 15, 18	gelatinous
flutters	122:17	114:5, 9	36:8, 16
94:3	French 101:2	119:7	general
focal 98:10	111:21	120:21	40:16
focus 28:17	front 92:13	121:1, 13	57:21
44:23	141:2	128:6, 21	93:18
focusing	full 5:12	129:3	128:19
41:12	fully 24:18	132:19, 21,	generality
follow 25:20	function	23 134:9	111:18
food 11:7	37:13, 19	Garrison's	generally
127:12	38:3, 6	83:8, 19	13:16 43:1
foot 118:1	59:20	84:17 85:3	67:19, 21
force 37:9	102:19	88:17	68:2
98:8, 9, 14,	103:6	89:15	106:19
16, 19	functionally	117:18	generate
forget 8:6	82:6	119:16	128:15
		120:13	generated
		121:9, 23	57:3
		128:15	
		131:5	

101:21	guess 69:16	happened	83:10, 21
129:8	92:15	136:10	88:19
geometric	125:1	hard 68:6	89:1, 6, 14,
135:20	141:12	harder 102:5	17, 24
143:11	guesstimate	Hartley	93:5, 10,
geometry	26:10	17:16	14, 16, 24
52:8 95:12	guesstimating	29:16 33:7	94:8, 9, 13,
97:22, 24	22:1	135:2	17 96:16
116:15	guidance	hearing 9:7	100:24
139:1, 5, 23	138:13	heart-related	102:15, 23
140:21, 23	guide 8:12,	46:6	103:5
141:4, 5	14, 16	helpful 9:11	111:18
Giannini 4:6		104:8	112:11
Gilbert 5:14	H	helps 98:5	119:17
give 117:23	half 16:8	hemostasis	135:1, 4
gloved 116:7	Hamilton	8:22 9:1	136:5
good 4:3	20:10	33:13, 19	137:22
5:8, 9	22:4, 14	41:10	138:22
143:15	25:9	43:24	143:7
gradient	hand 18:19	48:19, 20	hesitating
52:22 95:1	22:20	61:7, 19	100:1
101:6	39:17 92:8	62:3, 7	hexagons
granting	96:4	64:4, 20	98:2
35:8	110:15	66:18	high 75:17
great 117:2	handing	67:23	94:21
greatly 93:5	18:21	68:15	higher 28:6
Greenwich	22:22	69:15, 19	98:10
5:15 23:13	39:19	70:2, 11, 18	Hilton 4:10
ground 9:13	92:10	71:6, 15	home 5:13
grounds	110:17	72:4, 10, 18	19:17
28:14	hands 94:22	73:4, 21	23:13
Group 4:7	116:7	74:6, 18	homework
	happen 136:9	75:6 76:19	127:9
		77:6, 15	honestly
		78:12	75:9 107:1

hour 10:20	80:12	120:2	importance
16:7 53:12	82:21	121:11, 19	28:23
90:7	83:3, 9, 20,	identifies	important
hours 12:13,	24 84:4,	113:8	96:9 124:8
19, 23	10, 13, 15	identify	135:18
16:23 22:2	85:5, 14, 18	48:11, 15	136:3
26:10	86:3, 5, 16	50:1	importantly
housing	87:13, 17,	62:11, 23	143:1
43:22 44:3	20 88:3, 8,	63:23 75:4	impossible
46:20	9, 18	95:3 96:24	138:11
47:9, 21	118:23	106:6	in-flow
48:11, 16,	120:1, 4, 8,	141:3	60:21
18, 21	14, 16, 18,	142:11	inaccurate
49:1, 4, 10,	19 122:20,	illustrate	65:24 66:3
19 62:7, 8,	24 130:22	47:8 67:10	Inari 4:14,
11, 18, 21,	131:6	illustrated	21 5:18
24 63:4	132:15	58:14	11:12, 18,
64:4, 6, 19,	133:9, 19,	65:12 86:2	21, 24
21 65:1, 3,	23 134:2	88:1	12:14, 20
4, 7, 14, 16,	housing. '	illustration	13:2, 3
19 66:9, 18	85:16	85:17	19:4 28:9
67:23	I	imagine	34:19
68:3, 8, 15,	i.e 61:7	113:4	106:21
17 69:11,	idea 107:1	125:2	Inari's 14:7
14, 15, 20	138:3	impact 92:4	Inches
70:3, 4, 10,	identified	impacted	117:24
14, 18	5:3 6:22	27:22	include 35:2
71:5, 14	7:5 41:13	Imperative	48:18
72:3, 9, 13,	47:12 51:2	4:13, 19	54:20
14, 17, 23	61:18 62:2	5:22 6:10	59:17
73:3, 11,	63:14	7:13 11:14	64:24 66:8
15, 20	68:10 70:6	12:2, 21	67:23
74:6, 18	105:15	13:4 14:3	69:11, 14
75:6, 19	114:13	15:13, 19	71:23 72:3
76:5, 7, 18	118:6, 18	19:4	108:16
77:3, 6, 15			
78:11, 20			

110:10	107:22	18:11 21:5	35:8, 23
124:5	incorporates	27:16	instruct
included	91:14	28:20, 22	21:6 25:19
7:24 43:5	incorporation	30:6, 8	instruction
46:14	93:3	32:23 33:3	21:10
89:11 94:8	102:17	45:2	instructions
119:8	incorrect	105:22	9:10
126:13, 23	38:5	inherent	instructs
132:15	incremental	97:22	10:17
includes	41:11	135:9	integral
36:6 42:5	124:12	inherited	70:3
43:22	incrementally	32:3	integrally
66:13	100:19	inhibit 11:8	78:18
68:10	independent	inhibits	80:1, 6
70:6, 18	28:13, 18,	61:8	81:2 132:7
71:5, 15	24 31:18	initial 15:8	integrate
72:4, 10	134:23	inserted	32:12
73:20	135:2	113:23	integrated
74:6, 18	individual	inserting	41:6, 8, 14
75:5 76:18	80:9	135:23	42:5, 8
78:11 85:4	107:11	insertion	43:23 68:7
92:2 106:2	108:1, 15,	111:23	72:12, 21
114:9	20, 23	inside 114:2	77:2 81:13
119:16	109:6, 12,	inspect	89:1, 15, 16
121:10, 19	14, 16	14:7, 13	133:9, 24
including	110:3	inspected	integrates
73:18	individuals	14:19	44:7
100:12	112:21	15:6, 12, 18	integration
129:9	113:1	instant	59:7 60:5
135:23	ineffective	103:19	69:19
incorporate	137:1	instantly	78:19
32:6 34:1	information	103:10	80:10 89:6
39:16	13:13, 15	institution	120:9
91:22	17:4, 13		intended
incorporated			
48:22			

82:7,13	interventional	12:14	June 112:19
136:23	8:14 95:7	13:23	
inter 5:18	111:20	18:15,20	K
6:4	intracerebral	22:21 23:3	
interesting	111:19	24:4,11,19	key 46:8
16:15	intravascular	25:1 26:18	79:13
interfere	93:6 112:4	32:19	81:22
52:18,20	introduce	34:20 35:8	86:19
53:1	4:15	39:18 92:9	kind 8:6
internal	invalidity	110:16	55:6
114:1	89:18	131:11	Knobbe 4:18
139:1,4	invention	IPRS 6:9	L
140:15	39:10 92:2	7:12 11:13	
internally	134:15	12:1,5,10,	L.A. 6:16
139:7	inventive	20 13:8	labeled
interpret	92:2	14:2	47:12
78:16 81:6	112:11	irrelevant	54:10 64:1
interpretation	inventors	111:5,7,16	67:8
67:3 77:1	112:21	112:4,8	120:17
79:22	involve 8:24	Island 5:15	lack 134:13
82:1,12	30:24	19:17	language
86:12	involved	23:14	109:2,5,23
87:18,22	100:16	issue 6:2	large 94:19
88:6,8,12,	101:19	8:8,17	100:2
14 92:1	involves	32:3	101:6,9,18
109:18	8:22 30:14	issues 24:4	102:14
134:2	41:7 65:4	IV 117:15	large-bore
interpretation	involving	J	99:5
s 72:6 80:6	12:15 13:3	James 4:20	102:16
interpreted	130:5	jerry-rigged	largely 27:3
81:11 88:5	IPR 5:22	42:4	111:5,7,15
89:5	6:5,11,14	Joe 20:10	larger
132:21	7:22 8:1,	John 5:14	100:21
interpreting	3,4 11:22		101:19,20
81:9			

102:24	lines 50:6	longer	manifolds
126:8	76:13, 22	116:14	41:18
late 100:4	77:13, 20	looked	manual 40:24
lateral	78:9, 10	75:15, 17	56:23
141:11	79:1, 15, 21	85:7 117:2	manufacture
Leading	80:18	loss 102:12	134:20
132:24	87:14	103:18, 20	March 19:12
133:10	131:17	136:11	marked 18:20
134:1	132:4, 16	lost 18:16	22:21
left 63:2	liquid 59:16	131:18	39:18 92:9
65:9 71:11	listed 98:20	lot 9:10	110:16
legal 26:14	lists 112:21	117:15	Martens 4:18
34:19	litigation	loud 131:3	mask
89:10, 20	13:3	luer 53:3	117:12, 13
91:5	loading	lumen 40:16,	Massachusetts
124:24	142:23	21 97:7	4:12
length 88:7	located 4:11	lunch	material
111:22	64:3 66:18	127:12, 14	27:11
116:14	68:14		30:11
lets 59:16	70:10, 17		32:12 34:1
letters 69:1	71:5, 14		36:9, 16
license 5:4	72:9, 17		40:9
life 137:6	73:3 77:19	made 80:7	58:12, 20
life-	83:9, 20	107:20	59:1, 5, 8,
threatening	88:18	make 9:14	16 60:15
136:18	142:5	10:13	61:2 82:14
limit 132:9	location	106:13	122:5, 8, 18
limitations	111:24	111:15	123:13, 15,
115:18	135:21	115:21	21, 22
limited	locking	116:1	124:16
45:21	114:23	120:16	125:14, 22,
limiting	Logan 4:11	122:20	24 140:23
112:9	long 16:21	makes 97:20	142:9, 12
	143:5	116:4	143:5
		135:10	materials

27:10, 17, 20 35:1 36:1 52:9 59:23 139:19, 23 142:18, 20	4:14, 21 5:18 28:9 39:15 113:9 115:16 medication 11:8 meet 16:4, 6 meeting 16:12, 14, 17 Megan 4:6 member 36:7 140:4 142:6 members 37:8, 11, 18, 20 38:2, 4, 7 mentioned 72:5 112:17 122:15 135:15 136:21 method 128:22 methodology 138:17 mid-cerebral 112:1 114:3 middle 10:24 97:5 107:9	Miller 4:20 7:1, 8, 14 8:19 9:2 11:15 12:16, 22 13:5, 11 14:9, 16, 22 15:9, 15, 21 16:10, 18 17:3, 12, 21 18:3, 10 20:16 21:3, 16, 23 22:7, 17 24:7, 12, 21 25:2, 16, 24 26:20 27:2, 23 28:19 29:6 30:5, 13, 23 31:11 32:8, 22 33:21 36:17 37:21 42:11, 24 43:7, 21 44:6 45:1 49:5, 12, 20 50:16 51:6, 17 52:6 55:8, 20 56:8, 19 57:4 58:6, 22 60:12, 22 63:6 65:2 66:1, 10 67:13	69:6 71:16 73:23 74:20 75:13 76:20 77:7 78:14 79:5, 11 80:4, 21 81:4, 20 82:5 83:11 85:6 87:21 89:9, 19 90:9 91:4 93:17 97:4 99:18 100:10, 17 101:3 102:2 103:8 105:10, 20 106:18, 24 108:2 109:20 110:12 112:6 121:3 122:1 123:5, 10 124:6, 23 126:16 127:1, 7, 11 128:11, 17 129:1, 11, 17 133:2, 16 134:4, 22 135:14 137:7, 13, 16 138:15,
Matt 20:10, 12, 13 matter 4:13 27:10 89:17 91:15, 23 122:12 130:4 matters 98:1 mature 102:4 MCA 114:3 means 54:14 56:4 82:2 91:22 103:9, 16 124:10 meant 101:15 mechanical 39:16 mechanism 33:12, 14 38:9 43:24 96:20 103:9 106:2, 4 134:16 139:20, 21 medical			

20 139:9	modifications	57:6 126:2	118:6, 19
140:8, 12	139:18	neck 111:11	121:11, 20
141:7	modify 115:9	115:13, 20	132:1
143:9, 15	module 36:1,	116:7	
mind 53:3	6, 15 37:9	negative	0
56:1	moment	47:22	oath 5:5
minimal	130:22	50:22	9:16
73:16	months 15:2	54:15, 22	objection
141:10	21:24	55:11	7:1, 8, 14
minimally	morning 4:3	56:5, 7, 12,	8:19 9:2
58:18	5:8, 9 73:6	17 57:3	11:15
minimizing	motivation	58:2, 5	12:16, 22
103:20	134:13	82:15	13:5, 11
minor 24:22	motors 54:21	124:15	14:9, 16, 22
minute 75:18	55:10	neurovascular	15:9, 15, 21
misheard	movement	46:10, 12	17:3, 12, 21
108:22	141:11	111:20	18:3, 10
misstatements	multiple	116:21	20:16
20:4 24:1	41:7	117:9	21:3, 13,
Misstates	104:1, 5,	136:15, 22	16, 23
32:8	14, 21	non-compliant	22:7, 17
49:12, 20	106:11	142:22	24:7, 12, 21
66:2 73:24	108:9, 10,	nonobviousness	25:2, 16, 24
74:20, 21	17 109:9	34:9	26:20
76:21	110:7, 11	Notary 5:5	27:2, 23
78:14		November 4:8	28:19 29:6
79:6, 12	N	number 5:23	30:5 32:8,
80:21	nature 36:3	47:13	22 33:21
81:4, 21	navigate	50:2, 8	36:17
83:11	116:8	61:18	37:21
89:9, 20	navigating	68:11 70:7	42:11, 24
112:6	111:22	71:9 91:16	43:7, 21
121:4	necessarily	105:1, 4	44:6 45:1
143:10		114:13	49:5, 12, 20
		117:20	50:16
			51:6, 17
			52:6 55:8,

9, 20, 21	129:1, 11	14, 17, 20,	142:16
56:8, 19, 20	132:24	22 73:2,	operator
57:4 58:6,	133:10	10, 21	44:10
22 60:12,	134:1, 10	74:7, 19	96:14
22 63:6	135:5	75:7 76:19	
65:2 66:1,	137:16	77:5, 14	opine 28:10
10 67:13	138:15	78:12 79:9	31:18
69:6 71:16	140:8	81:16	opining
73:23	141:7	83:7, 18	82:19
74:20	143:9	84:4, 11	opinion 27:3
75:13	objections	85:4 89:7,	45:20
76:20 77:7	10:13	14, 15, 23	49:9, 17
78:14		121:10	83:2, 6, 17
79:5, 11	obligated	132:14	84:11, 21
80:4, 21	9:17	133:8, 17,	100:6
81:4, 20	observation	23	105:7
82:5 83:11	85:1	one-handed	112:2
85:6 87:21	occur 101:8	95:18	133:22
89:9, 19	occurs 106:4	96:1, 7, 12,	opinions
91:4 93:17	offers 40:10	15	24:3, 19, 24
97:4 99:18	office 19:17	ongoing	26:17, 21
100:10, 17	20:11	27:11	27:13, 15,
101:3	23:13	open	22 28:2, 17
102:2	106:17	135:10, 15	29:2 31:10
103:8		opening	34:8 35:9
105:10, 20	older 102:4	122:16	39:6 74:8
106:18, 24	on-off 46:21	openings	75:11 92:5
108:2	47:13, 16	122:24	107:4
109:20	63:20, 24	operate 39:1	110:24
110:12	64:3, 17	94:22	120:12
112:6	66:13, 17	operation	132:13
121:3	67:7	38:9, 14, 18	134:6
122:1	68:10, 14	95:18	opportunity
123:5, 10	70:6, 9, 17,	96:2, 8, 12,	14:6, 12
124:6, 23	23 71:4,	15 128:14	opposed 65:9
126:16	13, 23	134:16	86:20
127:1, 7	72:9, 11,		111:17
128:11, 17			

opposing	142:6	44:11, 13,	51:7, 13
37:10		16 46:15,	57:10
38:11 96:3	outflow	17 47:17	67:14
97:16	60:20	48:12	68:17
139:21	Outline	57:10 61:5	70:22 76:7
142:5, 7	20:21	65:17, 23	79:9, 17
option 54:17	owner 5:17	66:6	85:1 87:17
55:22	30:18, 21	75:21, 24	88:9 110:3
70:2, 4	31:8, 11	85:10	122:3
84:6 89:4	owner' 28:10	86:13	126:14, 24
142:24	owner's 31:5	91:8, 13	127:2
optional	oxygen	93:1, 2	131:17
36:4, 7	117:13	95:13, 17	132:3, 16
89:21		97:5 98:24	partes 5:18
options	P	99:2, 24	6:4
54:18, 20		101:11	partially
69:24	p.m.	102:10	86:21
84:8, 14	127:17, 18	103:21	98:18
order 53:1	143:18	104:11, 13,	particulate
59:18	package	24 107:6, 9	122:12
ordinary	124:13	108:5, 19	Pass 129:15
39:8	paging 92:20	119:2	passing
134:7, 24	paragraph	120:15	122:9
organs 46:8	27:5, 9	129:20	passive
orientation	28:7	130:8, 11,	59:14 94:8
141:15	29:11, 14,	14, 18	119:19
original	23 30:4	131:3	122:16
111:3	31:20, 24	132:4	patent 5:17,
orthogonal	32:16	paragraphs	23 6:1, 2
139:7, 16	33:12, 20	44:19, 20,	7:20 12:15
140:4	34:6, 7, 22,	24 130:21,	18:15 19:6
141:16	24 35:17,	23 132:20	20:8 23:3
orthogonally	21 37:2, 6	133:4	25:7
139:11	39:2, 5	parallel	28:10, 11
	40:4, 6, 15	55:2 72:14	29:4, 19, 23
	41:4 43:20	part 16:24	
		22:1 44:1	

30:4, 18, 21	24 97:13	12, 18	Paul 4:13
31:5, 8, 11,	106:17	66:9, 14	5:2, 14
21, 24	109:18	77:19	Pause 73:8
32:4, 6, 7,	110:19, 23	82:16	76:24
15, 19, 21	111:2, 4, 6,	83:8, 18	130:24
33:9, 14, 19	8 112:5	84:9, 17, 23	133:13
34:20 35:8	125:9	85:5, 13,	PE 44:17,
39:9, 14, 24	129:24	15, 17	21, 23
40:7, 23	130:5, 9, 13	86:2, 16	45:12, 22
43:14, 16,	131:15, 16	87:8, 13,	pentagons
18 45:21,	133:8	16, 19	98:2
24 46:5,	134:15	88:1, 2, 10	Penumbra
11, 18 47:4	137:20	118:14, 17,	42:18
48:8, 24	patent's	21 119:22	116:23
50:4, 7	103:5	120:1, 11	perform 13:2
51:11, 14	patentability	124:3	performed
57:11	28:11, 12	128:8, 16	11:12 13:9
61:6, 23	29:18 33:9	131:5	peripheral
62:6 64:7	39:7	133:18	46:9
66:8, 17, 23	patentee	pathology	100:13
68:4 71:21	106:15	115:19	peristaltic
72:16	patents	paths 67:4	55:16
73:2, 17	17:8, 10	pathways	115:6, 22
74:5, 15	106:16, 23	41:19	Perkins 4:21
75:5 76:1,	path 46:19,	patient	permanently
12, 16	20 47:8,	60:17	79:24
77:14	16, 20, 22	102:12	132:6
78:5, 8	48:1, 7	115:13, 21	person 16:12
79:17	49:10, 18	116:16	39:8 82:9
86:15	51:2, 16	126:6	113:3, 5, 6
87:19	57:14	136:12, 13	134:7, 24
88:13, 20	58:9, 13	patient's	138:2
89:5, 8	62:20, 23	40:9	personal
90:4 91:1,	63:3, 21	patients	85:2
3, 14, 15, 22	64:24	117:12	
93:3, 10	65:6, 8, 9,		
95:22			
96:1, 6, 17,			

personally	56:21	53:1	31:7 46:6
9:9 20:6		60:20, 21	60:24
21:12 25:6	pinching	62:17 63:4	80:11
112:24	139:22	65:13, 15	124:21
	piston 58:1	77:23	
perspective	67:5		practicality
41:12		portion	118:3
75:18	place 16:14	78:4, 8	Practically
	50:24	80:18	115:11
perspectives	51:15	82:17	
41:5	placement	106:6	precise 66:4
pertains	135:17	119:11, 15	87:2, 16
130:8	142:15	120:13	88:22, 23
			109:22
petition	places	portions	
29:17, 22	136:15	21:11	precisely
30:3 33:8		25:14 36:1	32:10
35:3	placing	106:11	preferred
110:21	60:19	120:24	98:3
119:8	plasma 59:1,		
	5, 13	POSITA 85:16	preparation
petitioner		99:2, 12,	17:1, 19
4:18 29:15	plate 53:7	15, 22	18:1 22:6
31:5 33:6	play 20:14	115:15	
85:12		131:4	prepare
PH.D. 5:2	point 10:22	135:7	15:24
	80:7, 13	138:5, 10,	16:4, 18
phrase 78:17	98:10	13	18:9 24:10
86:11	111:23		
108:15	pointed	POSITAS 88:6	prepared
	81:10		6:21 18:14
phrasing	120:10	position	86:2 87:12
86:13		128:24	
		129:6	preparing
physical	points 67:11	136:1	16:22 26:8
116:17	poorly 71:7		110:24
		positioned	
physically	pore 122:16	116:13	present 29:2
14:7, 13			33:13
15:12	port 50:8,	positions	95:11
115:10	12, 15, 21,	67:6	120:12
	24 51:15		
physics	52:4, 10, 17	potentially	presented

74:8 75:11	101:22	99:16, 24	101:23
92:5	pretty 55:12	100:3	102:13, 16
134:12	56:21	103:2	115:17
pressure	prevent	110:20	117:8
46:22	30:19	112:2, 18	proceed
47:23	122:8, 18	116:19	28:22
50:22	136:6	119:21	proceeding
51:1, 15,	preventing	126:23	5:19
23, 24	31:8	142:8, 19	process
52:19, 21,	103:19	privilege	20:15
22 53:2	prevents	33:22	51:19, 21
54:10, 12,	61:8	137:17	52:2 69:8
15, 19, 22	previous	privileged	100:12
55:3, 7	42:3 43:9	17:4, 13	138:1
56:4, 5, 6,	69:17	18:11 21:4	produced
7, 12, 16, 18	70:20	24:13	27:10
57:3, 12,	71:17 95:5	30:6, 12, 22	production
19, 22	previously	31:1 45:2	5:3
58:2, 5	6:9 70:12	105:21	products
63:7, 9, 10,	Primarily	privileges	15:13, 19
13, 14, 17	28:23	28:20	proper 85:17
64:16 67:5	44:10	procedure	properties
82:15	primary	60:6, 7	143:3
94:21	122:11	67:12	proposed
95:1, 2	principal	111:10, 11	127:9
98:9, 10	134:16	116:8	provide 11:4
99:6	principle	125:2	36:2
101:6, 7,	93:20	126:5	37:12, 19
12, 16, 20	prior 6:9	136:9	38:3
124:10, 15	7:7, 12	procedures	41:11, 17
125:3, 6,	17:8, 10,	8:15, 18	42:1 43:19
16, 20	18, 24 18:7	9:5 42:3	44:3, 9
128:16	31:17, 19	43:9 95:7,	47:2
129:7	40:23 42:8	8 99:5, 7	61:14, 22
135:17		100:3, 8,	
pressures		11, 15	
42:7 55:11			

96:1, 7, 17	pump	55:4,	10 30:1, 14	rationale
100:23		6, 14, 16, 22	31:15, 16	126:10
108:7		56:16, 17	48:2 69:16	read 27:18
134:6		114:16	70:21	28:15
138:7, 13		115:3, 7, 22	72:24	29:20
140:20		116:2, 5	101:17	33:16
141:5		117:5	104:7	34:13
143:3, 6		124:14	119:21	36:10
		126:14, 24	126:19	37:14
provided			137:7	39:11
27:12, 17	pumps	55:19		40:12
41:14		57:1	questioning	46:24
98:16		116:20	45:11	57:16
143:7		117:8	questions	61:11 76:8
		126:13, 22	10:9	85:20
providing		127:6	129:15	86:17 99:9
83:1			130:1, 20	102:20
proximal	purported		137:9, 13	107:14
61:9 85:19		85:12	143:14	108:12
86:4	purpose			120:15
118:22		50:20	quick 102:11	130:22
119:17		122:7, 11	quickly	131:2
128:9	purposes		102:18	
141:19		88:19	103:6	reads 79:20
		89:17	quote 35:24	133:20
proximity	put	30:20	108:6	ready-to-use
46:8		32:10	109:2	60:8
Public 5:5		136:24	quoted	reason 11:4
pull 50:4		137:1	108:18	71:8 100:1
97:16			109:2, 5	reasonable
pullback			quoting	82:15
56:11			107:16	reasoning
pulled 37:10	qualify			31:9
		73:12		reasons
pulmonary	question			30:22, 24
45:7, 14		10:1, 4, 11,	rapidly 40:8	recall 7:9
99:7 100:8		16 11:1	rate 12:4, 9	
101:24		12:7 21:4,		

8:5 14:8,	9:12, 21	61:18	51:10
10 15:1	10:23 31:4	68:11 70:7	69:24
17:10	53:16, 18,	81:18	80:2, 19
19:15 20:9	22 90:12,	91:14, 23	93:15
21:1, 11,	16 127:14,	105:1, 4	94:10 95:5
14, 21	16, 20	106:13	99:16, 23
23:11	143:17	107:20, 21	104:17
25:22 26:7	red 84:24	112:21	129:23
31:16	85:4, 11	113:8, 15	139:5
36:22	red-lines	114:13	refers 31:20
74:22 75:9	20:23	118:6, 19	108:16
105:17	redirect	119:22	reflects
121:5	132:2	120:16	76:2
130:1	141:8	121:11, 20	refresher
138:1, 16	reds 84:20	referenced	9:12
recent 6:13	reduce	39:24	refusing
recess	102:12	142:19	21:9
53:19, 20	reduced 98:8	references	regard 71:18
90:13, 14	refer 6:1, 5	18:7 29:16	regeneration
127:17, 18	16:9 44:16	93:15	125:5
recited	45:12, 13,	110:21	regularly
43:18	16, 17 51:9	112:3	125:5
83:8, 19	54:23	113:12	relate 6:10
84:12, 18	55:10 81:2	referencing	112:3
87:24	91:18	31:23	related 6:14
97:1, 12	93:24	33:18	7:12 8:3
98:12	97:2, 24	142:14	11:13 13:2
131:6	101:12	referred	106:23
recognize	108:14	48:12	112:11
18:23	109:11	92:17	130:21
22:23	reference	142:9	140:17
39:20	17:19 18:1	referring	relating
92:11	29:22 30:3	16:10	5:23
110:18	32:15	40:15 41:4	release
record 4:4,	50:1, 7	42:2 43:20	
16 5:13		48:16	

103:10	38:7	76:22	retrospect
relevant	replacing	rereview	65:20
17:8 26:21	37:11, 17	111:4	87:1, 15
88:19, 22	38:1	reserve	returned
relied 106:7	reporter	27:14	60:17
110:21	4:6, 23	34:10	returning
rely 132:15	9:21	reserves	126:6
relying 33:7	represents	31:6	reveal 30:16
remains	27:12	respect	revealing
141:16	reproduced	28:13	17:15
remind 36:18	119:6	31:18 98:4	20:19
rendered	Requested	132:14	22:11
34:8	24:16	136:19	24:15 26:4
repeat 30:1	require	respective	28:22 30:8
31:14	36:6, 14	142:15	33:2 45:5
49:14	83:24 84:3	response	review 5:18
72:24	89:13	16:3	6:4, 18
83:13	94:22	restate	16:2, 24
99:19	116:13	93:11	17:18, 24
133:14	133:8	restaurant	18:8 31:17
rephase	required	16:15	54:4 90:22
126:18	13:14	restrictive	92:23
rephrase	89:7, 11	81:7	108:3
12:6 26:12	141:5	115:12, 20	109:22
38:16	requirement	116:3, 4	110:23
40:19	52:15	result	112:18
41:22	requirements	137:2, 4	128:2
44:14 56:2	115:18	results	137:24
69:12	requires	103:17	reviewed
78:23 84:1	13:12	retained	17:7, 11
87:9 99:13	133:17, 22	5:16	18:8 21:15
138:20	135:12	retention	25:23
142:2	136:7	122:5	27:20
replaced	rereading		72:20
			74:10
			75:16

111:2	5:3	124:6	seconds
112:15, 16	satisfy	127:1, 8	103:15, 17
121:2	52:14, 17	134:11	section
revise 27:14	scenarios	135:6	77:8, 24
Rhode 5:15	45:7 94:21	141:8	82:18, 24
19:17	Schaffer	screen 59:15	83:1
23:14	17:16	screening	sections
rigid 139:19	29:16	122:16, 19	21:1 76:16
rigidity	33:7, 15	screwing	seek 31:7
135:12	38:12	94:4	106:15
Road 113:9	82:20 83:3	seal 36:1,	segments
robust 97:10	134:5, 9,	2, 6, 7, 14	20:22
102:11	15, 18, 20	37:9 94:18	segregated
role 20:14	135:11, 13,	95:19	89:24
Roller 55:22	20 139:18	96:18	segregation
rotated	Schaffer's	97:2, 8, 9,	60:14 90:5
71:10	35:24	14, 21	select 80:10
rotating	36:5, 13	98:6, 13, 21	selected
102:14, 23	37:8, 17	102:11, 15,	74:12
rotation	38:1	24 119:20	80:14
94:5	139:9, 10	135:23	81:12
roughly	scope 7:1, 8,	136:4, 8	110:2
10:20 26:7	14 8:19	139:7, 11	selectively
rule 70:21	11:15	141:22	122:11
72:13 98:1	12:16, 22	143:7	self-closing
rules 9:13	13:5, 11	sealing	36:3, 9, 16
run 118:18	14:9, 16, 22	33:12, 14	102:11
runs 118:14	15:9, 15, 21	94:6 96:20	sentence
	44:6 55:8,	135:3	34:24 37:6
	20 56:9, 20	Seattle	39:5 40:6
	57:5 58:7,	20:11	75:24
	23 60:13,	second-to-last	76:11
	23 101:4	132:4	85:11 93:2
s	106:18, 24	secondary	95:17 99:1
	122:2	34:8, 11, 16	
satisfactorily	123:10		

101:11	57:15, 20,	15, 18	60:5
104:12	23 60:2, 11	25:23 26:8	simplify
107:17	62:12	28:4	60:7
109:24	64:13, 23	significance	simply 40:24
131:2	67:1 68:3	43:19	59:14, 22
132:9	69:4 70:24	significant	85:7 124:2
separate	87:14 91:2	40:10	single
63:9 70:13	113:18	41:2, 13	37:11, 18
124:12	114:4	44:4 99:6	38:2, 19
125:22	118:23	101:12, 16,	40:16, 21
126:3	121:23	22 102:13	73:20
September	shows 46:18	103:18	74:5, 17
8:7 23:9	57:11 59:9	136:11	75:6 76:18
serve 5:16	61:6 70:16	137:5	78:11 80:2
set 24:18	86:15	139:17	singular
26:18 28:2	87:16	significantly	104:5, 18,
31:10	143:12	100:21	20
107:10	side 50:8,	116:11	sitting
110:24	12, 15, 20,	140:1	36:21
sheet 6:22	24 51:15	signing 25:1	size 98:1,
7:5	52:4, 10,	27:21	4, 5 111:21
short 10:13	17, 24	34:16	135:16
111:22	62:17	silicone	sized 116:11
shorthand	63:4, 8	94:3	sizes 101:1
6:2 91:19	64:18	silk 113:8	122:17
show 62:10	65:9, 13, 15	similarly	skill 39:8
67:19	77:23	6:4	82:9
72:20	sides 142:5	simple	134:7, 24
87:7, 12	sign 19:12	40:16, 21	138:2
115:14	23:8	53:3	slightly
showing 67:7	signature	122:15	65:21
122:4	19:10 23:5	simplest	small 8:13
shown 48:20	signed	56:10	101:8, 18
54:13	19:15, 18,	simplifies	111:12, 13
	21 21:15,		
	22 23:12,		

113:23	124:4, 9,	109:1	97:15
114:1	10, 14, 19	141:3	98:19
126:7	125:3, 16,	specification	103:9
smaller 98:7	20 126:1	51:7, 9, 11,	springs
100:16, 20	128:9, 15	14 80:18	102:17
smoothly	135:17	107:11, 19	103:4
9:14	sources	110:4	stage 34:11
soft 36:8,	63:10, 13	132:23	stand 7:11
15	space 116:3,	134:14	standalone
solid 59:15	4, 12, 17	specificity	124:2
122:18	135:11, 15,	111:17	start 10:2
Sonsie 16:16	18	specifics	69:10
sort 122:20	speak 22:15	113:13	95:15
124:1	54:1	speculation	141:4
141:18	127:23	124:7, 24	starting
sound 6:15	130:13	126:17	124:18
source 46:22	142:21	128:18	130:17
47:23	speaking 4:5	129:12	state 5:12
51:1, 15, 23	spec 138:8	spell 72:1	27:9 29:15
52:1	specific	spelling	33:12 34:7
54:10, 12,	12:14	113:4	35:22 39:6
19 55:3, 7	20:22 21:1	spend 16:21	46:17
56:4, 6, 16	25:14 29:3	spent 21:21	57:11 61:6
57:12, 14,	36:19 52:5	26:8	76:1 91:13
19, 22	74:23	spoken	93:2 95:18
58:3, 17	77:10 78:2	11:21, 24	99:2
60:2 63:7,	89:23	13:22 14:1	102:11
10, 15, 17	111:8, 19,	spring	107:10
64:16	22 129:2	141:20	108:19
114:10, 12,	136:22	142:23	109:6
15, 19, 22	specifically		138:24
115:1, 5, 23	8:3 10:16	spring-	stated 27:15
117:17	34:5 48:14	actuated	28:8 35:23
118:11, 14	50:5 64:8	37:10	47:15 68:9
119:23	77:12	spring-loaded	statement

19:21	38:2, 7, 11,	substantially	14, 24
23:18 35:5	15, 19	37:12, 19	32:20
47:2 79:23	135:2, 9	38:3, 23	34:5, 17, 23
81:1, 18	136:1	substituted	35:10, 18
82:2, 3, 11	strong 95:19	134:8	37:3 39:3
94:13	96:17	subsystem	40:3 44:12
104:17	97:2, 13, 21	79:3, 10,	45:13, 17
108:14, 18	98:5, 13, 21	18, 19	46:16 47:7
125:17	structure	80:20 81:3	54:8 57:9
126:8	52:5 96:22	132:11	60:3 61:5,
statements			21 65:11
19:20 20:1	structures	sudden 101:7	66:7 74:8
23:17, 22	135:12	suggest	75:7, 12, 22
30:20	142:22	50:14	82:17, 24
states 34:24	struggle	suggested	85:23
37:7 40:7	94:21	78:17	88:2, 16
79:17	struggled	suggesting	91:9 92:6,
108:7	135:7	30:10	22 95:14
stating	Stryker	suggests	98:24
83:22	13:9, 19, 22	50:13 65:8	102:9
stent 95:9	14:1	78:18 86:8	103:22
steps 69:8	Stuart 5:14	suitable	107:7
125:2	subassembly	81:23	108:6
stock 11:18	80:11	supersede	111:1
13:19	81:13	27:1	119:3, 5
stolen	subject	supplement	120:14
131:19	91:15, 23	27:14	129:19
stopcock	submitted	supplemental	130:4, 17
42:5 43:4,	32:19	16:2 17:2	supplements
8 77:17, 22	130:3	18:6 23:2,	18:17
stopcocks	submitting	8 24:6, 10	supplied
41:18	131:11	26:19, 24	101:6
string	substance	27:6, 21	support 35:1
37:12, 18	54:1 90:19	28:3, 8	supported
	127:23	29:4, 12,	97:8
		supposed	

142:22	98:17	telling	115:23
surface	113:22	30:17	121:4
140:16	114:4, 6, 8	template	127:24
swear 4:23	117:18	32:19 33:4	129:23
switch 40:1	119:11, 16	term 65:21	130:7, 11
64:17	121:18	108:1	131:10, 13
73:10	systems 40:8	terminology	143:10
132:14	42:9 45:22	120:5	text 74:2
sworn 5:4	46:1, 12	124:8	therapeutic
syringe	95:21	125:1, 18	95:6
40:17, 22	100:24	terms 69:18	thing 10:23
42:22 43:5	116:20	101:18	things
54:16	T	115:10	103:14
56:11, 22	tactile	terribly	135:23
57:2, 24	96:13	69:18	third-hand
64:15 67:4	Taking	testified	113:12
114:20, 23	103:15	5:5 14:6	thirdly
124:14, 18,	talk 13:15	56:3 117:3	134:18
19, 20	talked	128:7	thought
125:3, 15	135:16	testify 9:17	94:20
126:2	139:3	11:9 30:10	threaded
syringes	talking 6:6	testifying	141:21
41:18	77:9	30:20 31:9	thrombectomy
54:20, 23	talks 97:9	testimony	99:4, 7
55:1	107:21	7:6, 11 9:7	100:2, 7
system 41:6,	target 47:23	11:5 32:9	101:23
9, 15	52:1 64:22	49:13, 21	thrombosis
42:15, 18	technically	54:2 66:2	45:7, 18
43:4 46:19	31:2	73:24	99:8 100:9
54:13	technology	74:21	102:1
56:7, 18	8:8 39:9,	80:22	thrombus
58:5 64:23	13	81:5, 21	52:1 59:23
67:10		87:4 89:20	60:14, 15
73:19 80:3		90:19	101:8
86:15 91:2		112:7	
96:11, 13			

102:4, 5	101:20	116:15	141:18
111:24	tough 101:7	treatment	Tuohy-borst
122:13	tougher	44:21	9:3 93:18,
123:12, 15	102:5	treatments	19, 21, 24
thrombus-free	track 18:16	40:11, 14	103:16
60:16	tracks 85:14	41:3 44:5	119:19
tight 36:2	traditional	trial 9:7	turn 19:8
time 4:8	93:4, 15	trivial	23:4 27:5
9:24 10:7,	94:9, 13,	138:11	29:11
14 16:7	16, 18	true 19:20	34:4, 22
21:21 26:7	100:24	20:1	35:17 37:2
34:9 39:9	102:14, 22	23:17, 22	39:2 40:1,
53:17, 21	103:16	43:1	3 43:14
88:4	traditionally	truthful	46:15 50:5
90:11, 15	9:4	11:5	54:7 57:8
95:11	transcarotid	truthfully	64:7, 9, 18
103:14	111:10	9:17 11:9	65:10
112:14	transcript	tube 40:17	66:22
127:6, 15,	6:18, 23	94:6	68:24
19 133:12	transfer	117:15	70:15
143:16	52:19, 21	tubing 49:4	71:20
today 6:2	53:2	64:17 68:8	75:21
9:13 11:5	trap 59:7	76:5 77:24	85:22
today's 4:7	122:12	79:3, 10, 18	88:15 91:8
5:21 6:10	traps 59:15	80:20 81:3	95:13
9:22 10:14	treat 40:22	113:22	102:8
16:1, 5, 18,	45:22	116:14	103:21
22 17:1, 19	46:1, 12	117:13	104:9
18:1, 9	99:7 100:8	118:18	107:6
Tony 113:3	116:21	132:10	113:14
tools 95:6	117:9	tubular	119:1
top 97:5	treating	140:4	129:18
total 12:13,	112:3	142:6	130:16
19, 23	tubule		131:15
16:21			turns
			102:15, 23

type 8:8, 11	understanding	20, 22	110:12
52:5, 24	32:1, 5	114:5	112:7
53:5	33:10 45:6	124:20	121:3
types 46:2, 4	52:19	128:16	122:1
55:18	53:10	129:7	124:23
93:10, 14	57:18 69:7	Vague 21:23	126:16
typically	91:21 92:4	24:7, 21	128:17
55:1	93:9, 13	25:3 26:20	129:11
111:21	99:11, 16,	27:2, 23	138:15
typo 32:16	23 110:22	29:6 36:17	140:8
typographical	113:17, 20	37:21	143:9
105:8, 19	114:7	42:11, 24	valve 9:3
106:9	121:22	43:7, 21	33:13, 19
110:11	132:22	49:5 50:16	36:5, 13
	133:3	51:6, 17	37:9 38:9,
	understood	52:6 55:9,	14, 18
u	10:11	21 56:8, 19	41:10
U.S. 5:23	18:18	57:4 58:6,	46:20
91:15	104:7	22 60:12,	47:20, 24
unclear	113:7	22 63:6	48:6, 19,
123:23	unfiltered	65:2 66:1,	20, 24
	123:21	10 67:13	49:3, 9, 18
uncontrollable	unflexed	69:6 71:16	50:9 61:7,
135:10	138:24	73:23	9, 19 62:3,
understand	useable	76:20 77:7	7 64:4, 20
5:21 6:6,	115:11	78:15	66:18
8, 21 9:15,	utilizes	79:5, 11	67:24
19 10:8,	111:12	80:4 81:5,	68:15
10, 17, 18		20 82:5	69:15, 19
35:22 37:7		85:6 87:21	70:3, 11,
39:6 48:2,	v	93:17 97:4	19, 23
3 85:16	vacuum 40:7	100:10, 17	71:6, 15
99:3	46:18	101:3	72:4, 10,
115:17, 23	86:15	102:2	18, 20, 23
120:20	95:20 99:6	103:8	73:4, 21
121:1	101:12, 16,	105:10, 20	74:6, 18
		108:2	75:6 76:5,
		109:20	7, 19 77:6,

15, 23	variations	video 4:12	25:10
78:12	93:19	view 123:23	26:11
79:17	vasculature	133:7	wire 37:12,
83:9, 10,	111:13	viewpoint	18 38:2, 8
19, 21	vein 45:7,	39:7	withdraw
84:17, 22	18 99:8	virtually	116:8, 9
88:17, 19	100:9	14:19	withdrawal
89:1, 7, 14,	101:24	15:6, 18	40:24 58:1
16, 17, 24	verbal 9:20	visit 15:8	word 32:3
94:2	verify 92:19	volume 61:1	79:13
95:19, 24	version 8:13	101:19	86:19
96:6, 16	47:3, 6, 11	volumes	96:19
99:3 100:7	49:24 51:3	126:8, 9	109:13
102:12	54:9		words 86:22,
103:5	61:14, 17,		24 106:3
112:12	22 62:1	W	123:21
117:19	86:1 87:4,	wait 10:1, 3	work 11:12
119:17, 20	11 113:21	walks 51:18	12:5, 9
121:10, 14	119:7, 10	wanted	13:2, 8, 9
122:9	120:3	109:24	22:5 57:23
128:23	versus 4:14	wash 52:1	59:12, 18
129:6, 9, 10	19:4 56:23	ways 81:12	121:24
131:5	59:1, 5, 13	88:6	worked 135:3
134:8	60:20	website 15:8	works 57:20
135:1, 4, 17	101:18	websites	worse 100:18
136:24	vertical	14:23	written
137:1, 22	141:15	week 112:17	32:11
138:3, 22	vessel 40:9	wheres 56:15	33:24
139:10	111:23	wide 55:12	51:18, 22
143:8	vessels 46:8	Williams	68:6 73:18
valves 8:23	101:8, 9	20:12, 13	74:2, 11
9:1 93:5,	VI.A 82:18	22:5, 15	75:16 97:8
10, 14, 16	vicinity		105:23
94:1, 3, 8,	48:17		106:1, 7, 12
9, 13, 17, 18			
100:24			
102:15, 23			
103:1			

119:18

123:6

wrong 37:24

86:7 87:5

131:24

136:24

Y

year 6:14

22:1 111:3

112:19

yellow

119:12, 16

120:2

Z

Zalesky 4:13

5:2, 8, 14

18:23

30:10, 19

31:8, 15

39:21

53:24

90:18

127:22

129:18

137:9